var title_f38_35_39472="Psoriatic arthritis hand";
var content_f38_35_39472=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Psoriatic arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph of the hand of a patient with psoriatic arthritis shows characteristic early nail separation (onycholysis), swelling and erythema of the index and little finger distal interphalangeal joints.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Daniel Z Sands, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_35_39472=[""].join("\n");
var outline_f38_35_39472=null;
var title_f38_35_39473="Febrile seizures";
var content_f38_35_39473=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Febrile seizures (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/35/39473/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39473/contributors\" id=\"au4408\">",
"       Marvin A Fishman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/35/39473/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39473/contributors\" id=\"se1864\">",
"       Douglas R Nordli, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/35/39473/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39473/contributors\" id=\"de8764\">",
"       April F Eichler, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/35/39473?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      FEBRILE SEIZURE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Febrile seizures are convulsions that occur in a child who is between six months and six years of age and has a temperature greater than 100.4&ordm;F (38&ordm;C). The majority of febrile seizures occur in children between 12 and 18 months of age.",
"    </p>",
"    <p>",
"     Febrile seizures occur in 2 to 4 percent of children younger than five years old. They can be frightening to watch, but do not cause brain damage or affect intelligence. Having a febrile seizure does not mean that a child has epilepsy; epilepsy is defined as having two or more seizures without fever present.",
"    </p>",
"    <p>",
"     Seizures in children not related to fever are discussed in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/26/419?source=see_link\">",
"      \"Patient information: Seizures in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/5/19540?source=see_link\">",
"      \"Patient information: Treatment of seizures in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CAUSES OF FEBRILE SEIZURES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;Febrile seizures can occur as a result of the fever that accompanies bacterial or viral infections, especially human herpesvirus-6 (also called roseola or sixth disease).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Immunizations",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fever can occur as a side effect of certain vaccines, particularly after measles mumps rubella (MMR) vaccination. The fever typically occurs 8 to 14 days after the injection [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/35/39473/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Risk factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;A family history of febrile seizures increases a child's risk of febrile seizures.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      FEBRILE SEIZURE SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Febrile seizures usually occur on the first day of illness, and in some cases, the seizure is the first clue that the child is ill. Most seizures occur when the temperature is higher than 102.2&ordm;F (39&ordm;C). The table describes how to take a child's temperature (",
"     <a class=\"graphic graphic_table graphicRef57109 \" href=\"mobipreview.htm?7/6/7277\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Febrile seizures are classified as being simple or complex.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Simple",
"     </span>",
"     &nbsp;&mdash;&nbsp;Simple febrile seizures are the most common. Typically, the child loses consciousness and has a convulsion or rhythmic twitching of the arms or legs. Most seizures do not last more than one to two minutes, although they can last up to 15 minutes. After the seizure, the child may be confused or sleepy, but does not have arm or leg weakness.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Complex",
"     </span>",
"     &nbsp;&mdash;&nbsp;Complex febrile seizures are less common and can last more than 15 minutes (or 30 minutes if in a series). The child may have temporary weakness of an arm or a leg after the seizure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      FEBRILE SEIZURE EVALUATION AND TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     A child who has a febrile seizure should be seen by a healthcare provider as soon as possible (in an emergency department or provider's office) to determine the cause of the fever. Some children, particularly those less than 12 months of age, may require testing to ensure that the fever is not related to meningitis, a serious infection of the lining of the brain. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/48/1796?source=see_link\">",
"      \"Patient information: Meningitis in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The best test for meningitis is a lumbar puncture (also known as a spinal tap), which involves inserting a needle into the low back to remove a small amount of fluid (cerebrospinal fluid or CSF) from around the spinal cord. Other tests may also be recommended.",
"    </p>",
"    <p>",
"     Treatment for prolonged seizures usually involves giving an antiseizure medication and monitoring the child's heart rate, blood pressure, and breathing. If the seizure stops on its own, antiseizure medication is not required. After a simple febrile seizure, most children do not need to stay in the hospital unless the seizure was caused by a serious infection requiring treatment in the hospital.",
"    </p>",
"    <p>",
"     After the seizure has stopped, treatment for the fever is started, usually by giving oral or rectal acetaminophen or ibuprofen and sometimes by sponging with room temperature (not cold) water.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      RECURRENT FEBRILE SEIZURE",
"     </span>",
"    </p>",
"    <p>",
"     Children who have a febrile seizure are at risk for having another febrile seizure; this occurs in approximately 30 to 35 percent of cases. Recurrent febrile seizures do not necessarily occur at the same temperature as the first episode, and do not occur every time the child has a fever. Most recurrences occur within one year of the initial seizure and almost all occur within two years.",
"    </p>",
"    <p>",
"     The risk of recurrent febrile seizures is higher for children who:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Are young (less than 15 months)",
"      </li>",
"      <li>",
"       Have frequent fevers",
"      </li>",
"      <li>",
"       Have a parent or sibling who had febrile seizures or epilepsy",
"      </li>",
"      <li>",
"       Have a short time between the onset of fever and the seizure",
"      </li>",
"      <li>",
"       Had a low degree of fever before their seizure",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Home treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Parents who witness their child's febrile seizure should take a number of steps to prevent the child from harming him or herself.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Place the child on their side but do not try to stop their movement or convulsions. Do not put anything in the child's mouth.",
"      </li>",
"      <li>",
"       Keep an eye on a clock or watch. Seizures that last for more than five minutes require immediate treatment. One parent should stay with the child while another parent calls for emergency medical assistance, available by dialing 911 in most areas of the United States.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Parents of a child who is at risk of having a recurrent febrile seizure can be taught to give treatment at home for seizures that last longer than five minutes. Treatment usually involves giving one dose of diazepam gel (Diastat&reg;) into the rectum. One dose is generally all that is required to stop a seizure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Preventive treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;In most cases, treatment to prevent future seizures is not recommended; the risks and potential side effects of daily antiseizure medications outweigh their benefit. In addition, giving medication (eg, acetaminophen or ibuprofen) to",
"     <strong>",
"      prevent",
"     </strong>",
"     fever is not recommended in a child without fever (eg, if the child has a cold but no fever) because it does not appear to reduce the risk of future febrile seizures.",
"    </p>",
"    <p>",
"     Treatment for fever (temperature greater than 100.4&ordm;F or 38&ordm;C) is acceptable but not always required; parents should speak with their healthcare provider for help in deciding when to treat a child's fever. A detailed discussion of fever in children is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/23/37235?source=see_link\">",
"      \"Patient information: Fever in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      FOLLOW-UP",
"     </span>",
"    </p>",
"    <p>",
"     Intelligence and other aspects of brain development do not appear to be affected by a febrile seizure, whether the seizure was simple, complex, or recurrent or whether it occurred in the setting of infection or after immunization.",
"    </p>",
"    <p>",
"     Epilepsy occurs more frequently in children who have had febrile seizures. However, the risk that a child will develop epilepsy after a single, simple febrile seizure is only slightly higher than that of a child who never has a febrile seizure. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/26/419?source=see_link\">",
"      \"Patient information: Seizures in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Febrile seizures are convulsions that occur in a child who is between six months and six years of age and has a temperature greater than 100.4&ordm; F (38&ordm; C). The majority of febrile seizures occur in children between 12 and 18 months of age.",
"      </li>",
"      <li>",
"       Febrile seizures can be frightening to watch. However, they do not cause lasting harm. Intelligence and other aspects of brain development do not appear to be affected by a febrile seizure, and having a febrile seizure does not mean that a child has epilepsy.",
"      </li>",
"      <li>",
"       Febrile seizure can occur with infections or after immunizations that cause fever.",
"      </li>",
"      <li>",
"       Febrile seizures usually occur on the first day of illness, and in some cases, the seizure is the first clue that the child is ill. Most febrile seizures occur when the temperature is greater than 102.2 &ordm;F (39&ordm;C).",
"      </li>",
"      <li>",
"       Most febrile seizures cause convulsions or rhythmic twitching or movement in the face, arms, or legs that lasts less than one to two minutes. Less commonly, the convulsion lasts 15 minutes or more.",
"      </li>",
"      <li>",
"       A child who has a febrile seizure should be seen by a healthcare provider as soon as possible to determine the cause of the fever. Some children, particularly those less than 12 months of age, may undergo testing to ensure that the fever is not related to meningitis, a serious infection of the lining of the brain.",
"      </li>",
"      <li>",
"       Children who have a febrile seizure are at risk for having another febrile seizure; the recurrence rate is approximately 30 to 35 percent. Recurrent febrile seizures do not necessarily occur at the same temperature as the first episode, and do not occur every time the child has a fever. Most recurrences occur within one year of the initial seizure and almost all occur within two years.",
"      </li>",
"      <li>",
"       Epilepsy occurs more frequently in children who have had febrile seizures. However, the risk that a child will develop epilepsy after a single, simple febrile seizure is only slightly higher than that of a child who never has a febrile seizure.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498690712\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18221252\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/20/11586?source=see_link\">",
"      Patient information: Febrile seizures (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=see_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18221278\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/26/419?source=see_link\">",
"      Patient information: Seizures in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/5/19540?source=see_link\">",
"      Patient information: Treatment of seizures in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/48/1796?source=see_link\">",
"      Patient information: Meningitis in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/23/37235?source=see_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/9/3226?source=see_link\">",
"      Febrile seizures",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31577?source=see_link\">",
"      Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18570?source=see_link\">",
"      Pathophysiology and management of fever in infants and children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28982?source=see_link\">",
"      Roseola infantum (exanthem subitum)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39818?source=see_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Neurological Disorders and Stroke",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.ninds.nih.gov/\">",
"      www.ninds.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Epilepsy Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;1-800-332-1000",
"     <br/>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.epilepsyfoundation.org/\">",
"      www.epilepsyfoundation.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Family Physicians",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://familydoctor.org/066.xml\">",
"      file://familydoctor.org/066.xml",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/35/39473/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/35/39473?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39473/abstract/1\">",
"      Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001; 345:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39473/abstract/2\">",
"      Practice parameter: the neurodiagnostic evaluation of the child with a first simple febrile seizure. American Academy of Pediatrics. Provisional Committee on Quality Improvement, Subcommittee on Febrile Seizures. Pediatrics 1996; 97:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39473/abstract/3\">",
"      Practice parameter: long-term treatment of the child with simple febrile seizures. American Academy of Pediatrics. Committee on Quality Improvement, Subcommittee on Febrile Seizures. Pediatrics 1999; 103:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39473/abstract/4\">",
"      Berg AT, Shinnar S, Darefsky AS, et al. Predictors of recurrent febrile seizures. A prospective cohort study. Arch Pediatr Adolesc Med 1997; 151:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39473/abstract/5\">",
"      Verity CM, Greenwood R, Golding J. Long-term intellectual and behavioral outcomes of children with febrile convulsions. N Engl J Med 1998; 338:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39473/abstract/6\">",
"      Berg AT, Shinnar S, Levy SR, Testa FM. Childhood-onset epilepsy with and without preceding febrile seizures. Neurology 1999; 53:1742.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f38_35_39473=[""].join("\n");
var outline_f38_35_39473=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           FEBRILE SEIZURE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CAUSES OF FEBRILE SEIZURES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           FEBRILE SEIZURE SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           FEBRILE SEIZURE EVALUATION AND TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           RECURRENT FEBRILE SEIZURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           FOLLOW-UP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/6/7277\" title=\"table 1\">",
"           Measuring temperature PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f38_35_39474="Straddle injury";
var content_f38_35_39474=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prepubertal child with laceration from straddle injury, note extensive bleeding and difficulty in assessing extent of injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 504px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH4AVQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDrtEUvoum4GcWkX/oAqdsgkc57+1JoDbdE0wrj/j0hz/3wKmC+bI2TtHU+9fmVZLnfe7/M+/oy9xX7IqSMF+70prfd3g8HjpS3GFAXIJ9fWqkjkKRnGPSuSba3OyEbodcSEkAHjvUWTwajLnk8mmqzEcdRwc1lqdCjZCySfN15pYXYgbvvdRmo5PTp9KVDlu1MppWGXDl5DwSR3HSqc/8AdJFWjgFsfrVSUBmzjJrSG5tBETZMZHG088VWuF2rgYPGaskcHHGKqyMNjNwcDHFbw3NjEuImWcTMuFZevY/StKyT5V4681mM4mvBGGZtvBGelbNplMr944rrrNqKQRW5dkZkVeBg8U5W45zn3qDeZH+bOV4+lWA2cAVxNDtoOTJyDxWnZMig70yD3qpHGVh8xvXGKuQPxhVGMd6zTszmqvmVkJOqvIwA4A4qgRzjpg4+tTuSrHnPtSECQ/dAbGeO9K92EPdRDdfdQgcGoZ9rYZeB/WpXYA7Sfp7VBIoBHTNXE2hoWLaSP+z5o5GG8MCgoul2/LgA7arQIpmTfj7w5q7qUbJcsx+7jirlrqZySVSy6lDUVUPH5BwSPmz61GgzuJ5GOoqO5DHcSCcd/So7efaCevBBFWo3idcYPl0Nmxcf8I7eqyFv3ww3Zayxv2HB/CrVi8qaPfsRuhZlB9j61SjkJjAyM/TrVyvZGNONpT9f0RYtiA/Tr7VfQ5wfw5qlboWOc8+lXYRgEniuaoFTQcMltp4Bq3EQgAJPJ7VVTLHBq3CcsAeawkc0y7C2Tg01gQ+QTTocbPr1xU6gHPHQVrujjcrMhUBiM5yKmEI6ZPNLtXdn9DT3IHOeaqNlqQ5PoRCLkgfU5pyoSRtPepNpZQc1JHHtPyjBq0rslzJ7fCxjGSWp5IyBxSyKoUBT9ajZgnvWz0OZa6lotsjxmqbMWfgGrFviY4diFqRgqMdgBX+VPV+hCai7HmnxIY/2za7hz9lX/wBDeinfEtt2t2pK/wDLqv8A6G9FfTYP+BDXoebVfvs6zQT/AMSbTgva0i/9AFWM7WYDgmquhsF0TTSDz9lh/wDQBVq7+XnPavl63xy9X+bPYpaxivIpON8mCefWoZYiGPJ+tSzONwK/SoGkPRuvpXFJrqd0bkbEKMU3juePQUr8ntnt6UgPTd9TUGy2EcZz6+1JHIVBzgNjuKtZQKDxzVMj95x+H1pji+bcZLhjz07VWdfnweatS8JgH5h71WbOc+lXE3gRSYGGX7o7VSkHysp5zU80mDjGaimG5GOOe1dENDW1kY9hGVnmkJG4t2HatBZCuAp5NQIrRqwYYIJGMdKfbsX+Y8101HzO7KgrotSyeUu7OSasWu5kBI5qlISSC3r1rQtSNmM1zT0iVPRF0MzBQ+NueKvIMRjaFDdTmqEa4ZSTn9atyK+Qo5PrXP5nBUVyG52+blcEVAJNsmeo9KluIwANpO7FVQDu/WhamsEmixLGPJWQYO79KrgAspYblBxipIcZZWbAx0qu5+bA4q0VFPVEtlth1WLcNyB8la1NdukuJyVi2AcAVi3LBLlHVs4wTV7UiTKsoXCOufqa2u+SxnOmnUjJ9ioyh7SdSw6g4rFhYFHbHfFXZHJLYOAaqCJ0tt7qQrklTnrirpqyO6C5E7vc0JLloYPsattgkAdhjkmqAl2qUxhiRg1PeyLHdNJJGCBGABnkHFVHlDJGCuX3cGrSbRFNde5pWuc571fiJAPJqhZktk1eU4HPauWpuTUWpMmTyMVYi4YDjBqvDk9+vIqxGRxk89Qa55bnJMvwnKjpUqjk5zVeHgnvVmPkYOM1adjjnoIm4nHepOmM80kQ+YZ/WpMBny3A9u9VujOTH7RxipEzu3HtUTbdwx0NTNjbjqK1izKQkjZYEE1Np8YubmOI/LuOM1VfJ4TpUluXjlR1bG05zVRXvJy2Jkvdstze1bShpyoQwKsPWs3zd7AEcY/Op76/mvCnmsSBwAO1RRhVYc8/SuqrKEpv2WiOKkpxp/vXdnnnxO/5DdptAx9kX/0N6KPidn+3LbDDH2Ve3+29FfQ4Zr2UfQ86r8bN3RsDRtObn/j1hwP+ACrsoLr0P41S0cZ0TT8H/l2h/wDQBWj8xj2kdu9fKV7qpJeb/Nn0NPSMX/XQqGNSucYIFU5Rh8AH3Jq/wrEHOKr3UYC7gM5rlktLnVTeupTYHuce9IPlYE9KeqFs5NKUwPb+VQdF0Eu1grdx0FQA/OW7dhUkhCj5BxVbd83PFNalQiPcng46e1VJiTkD61afBKjPHWq8mAGzyT7VcTaBRcbn59KR1D7Ru2k8AngCpmKsWPTHTiq+oEfZyARnGK6Y6tI1lsVb4n5lLqzA4LA9aWFgFQY5FU2YYjGcEck0/wAza5HQGulw0sXT2LE0ys6p3PStW3ARM1hQsjXankmt22JOUwccc+vtWFZWSQ6uxehxmP1rWdVyrP8Acxg4rLs/3bbm7dAa1mYPblsZzzn0rKnHRs8uu9UY90VVz5f3agdtqjsx/SrN2F4wOTVPOR06VnY6qa0BzlajYDHXJNKTlcetQq5VgKtI2URXAYDn5+9XbwvJZQSOCoUFQMcEVUdgW3Y47gVceQz6NGAeI26E1otmZzveL8zHk4dge44pk14JrKC1CbRCeo6nJqSVSQ7Y4Ud6q26K/P3SOCa1htc67Rau+hY1dIEST97JFhRsHUsfSoBtK2yhgzbSWA9aseKbfyLiKMHIwpBJ7GqbQIoSRJMsfvD0NaJWirmVFpxTTNTT2GGBGB25q+q5Xr9cVnWYwRxWiuCAK4qu5FVWZMoBIHbHap4xjGM4qupO+p42IOcZwa55HLMuIgABOaliAycEYJqJHAXHenI+JAF6GhtHK0WwjEZGcVJhgoBHNJExK+1OZ8rjnIrboc73IxhWHODSmU9O1IV3DnIyKiEZbnJI/KhNpjsnubElsIrdJd2Q3WogDu6Y9KBdb7YRnkCoCzZ+TmuqUo3vE5oxfUtqOOv4VKhG0EioY0ymTyaTeVbaopXa1JkrnA/Exg2t2pBH/Hqv/ob0VZ+JNsi6vZfNy1opP/fb0V9RhYS9jH0PFqzjzs2tEGNB0/ufs0P/AKAKvlyI+g545rJ0R8aNp43f8usXB/3BWgH5AOcV8pUl+8l6v82fRU4+4vQgZSJDnoaddAeWCRz7ipHOG5x+NMu2DoAPyrBx0ZsndoohjtyB+dQ72L7QCOe1S7sZHbvzSLgtntnP0rA6loQT8cDNV1zk55qe4IMmFPtUajC4PX6Va2No6K40tlc+naq7twcj8amlBX5R37ioZB8vynk9a0ibQ0KnIySetVr9s2754461df5lORxnFZmst/orBO/FdVLWSRoyiSv2UuOQOaWxzKGkJwBwBVETH7N5fPoM961bX5LQKRg12TTihwCPbvDcZHWty1fOOgz1ya55n2uDnitWzfcAw5rlrR0uazV42NuMFioHUc/StCFwunsWYbicYFY8cgxySB/jUqTEfKcEZrlg+VnnVKTkPmIPH5+9UXYI3Oammk+c4qpKwbOeooijopxdiRSCcheaY4I5PUc1FA++TbnnP51bKBc5q37rNH7rIWIC8DHHJxU1sIxpsjEZl3Y5NVnfAYZx71CrfusAnJNUkDhzIsshNhJJkAZxXPCcpIykn5m7VvSORp2SeS2Ntc+FD3hGORzXRQS1NKezudN4oKslqykMfJXnp0rCiDsVk/5ZE4z71b8SNIkKKzggRr0rMgmZEjj42khvoa0SbTZnQjamkjctflYjrWiv3cn16VRtEZgTiruc4+XGK4Km5NTVk6fO+PWp0IUkYH+NRQDDAk1LsDZxXPI5ZbkysGxjt+dTwggZPJ+nWoIlyduORV5YyqggZGahK7Oao0ie12umGwCD0pxUbufrSqoC5Xt6UoOc/nXVbSxyvcXcpyKRSAcZBPelCEDAFO8sbOeDRZ7kt2JpZYyqqi846ioVJHGeTVdAQ4z681bijV5PvYqrubE4qBNGhjTDHOR+VTYA54NJZwtc3PlKchepqzcWvkSbec45z2roUG1e2hyymlKz3PMPiW0n9t2vJ/49V7/7b0U/4mqBrdqP+nVf/Q3or6bCfwY+h5lW3O9Db0jD6Np56YtYf/QFq9GwVvc+1UtEwdE04Y/5dov/AEAVdEZQZB4PrXyNb+JJ+b/M+gpfAl5IgnlJY8Ej1PrSxqxC5OB71KwVxwARUcZGc8gdqxW92bp6aEF2BtKDrVYZPQ4rRlijdWZ+3Q+tZ0qEZI4z1qZxszWlK6sV5T8x7+uKcNu1dx5JxmmHpjv7UAYwMDmg6WtBsrDceePpULdsAZA4FTSEDPBFVWb0q4mkFoVmy27t3yKqXib4CC341fbCIzN24rPv1ypKg9K6qbuzW9zmZJT5mG5INa9uxMIOe3QVzzy/6VKo6g8Vu6Ywns41H3s9AK9KvG0UxRY9sgq1atkB5fy9D0qhLGdwXdn61csGITa/DKfXrXHU1jobN6GmSdo56ehoV24NQFwWI5HbOOtPGQw6CuOxnYdJxn8+KgYnZyPmNTS8nIqNsDG4d+tUhor7WjkDEck1YR2C85J75plxJuTCDntioo3OzBJyO1XbmV2V8Q664RiGznpmmptEQAJz61BcygKAAc5p8OwKBKWDdgpqlG0SkmkWLlNtpGVfLPnj0pfB2jtrHiAQAjYi73J6YFVbmcBApPCjFa/wx1T7NrtzCI8m5Xy/MHb2rpw0bvXY5sW6lPDzcNyp48aI6vcrbgeUpCDb04Fc/A5klAIC7fStfxNBJFqNxH1kE5OKhvbWKNLGWIjdLHubHXdVNrUKElGnCKfQv2jcjDZzV5AduOSap6emYwSRn0q+oBzwB6GvMqNXHUavoSIBt44qeH5uTwPWoVznsDjrU6kAYHB9K52c09SaD5ZOO/NXYtwHXIB4AqvDgjoNw5471KrjJwfwpo5J6l2PjIxTTkY9KZE5wc9afgsOuc+9b7o59mTQSAH5+3rT/N8wgZGAarMMn69fapYVG3GapS0sRKK3J5IgQCvemMgRQaXzdozjimNKWP3etDcfmSlIt2EzW0u6M89Oat3c7TOGI69RVTT0Ryd55qVGBkZT2reMpcvKc01Fzb6o85+JbH+2rT/r1X/0N6Kl+JuBrdpg/wDLqv8A6G9FfTYXSjFW6HmVJe+zW0ggaNp47fZocY/3BWhvyuCORVDSnX+w9OIx/wAe0P8A6AKtc7fl6+3Svka38SS82fQ0VeEf66IUPwQcDPpUJiKkYOR1p+0jk9aY7ttOe1ZO3U6F5EZnYo0YHHrVefO0k9KkTJByPzqG4ywAU8fzqHK+5tFJMrxrznPNSMNpJHJ7ClK7Sf8AOaVYyybsYH1obNXK+5XmztB5qDPHSrU4+Uk1Uc46dSK0jqbU9iG5Bycd6oXD7YHXAJIq+wYAkn/9dZt/HtiLYzXTSs2kbROKuv3d+QnO7mtvQpmjdkfncdwArJ1EbLksflBartmximjlP3QcHHpXs1Vz07GO0mbspLDr9adp8oM22TtwPU1HuDAE5z/OmvH5cizKM5PI9K8+2lmbJ6G05IAIHA71GZQzYK8e1QJNmMA8gc4oG1jx1GPaufltuJFovu78CoS4PyDBYmgjggNxT7YDdnrU2SKuOdD5LBG+bocCshpDEzAsRz0NdEgVVkGM5rn9bVBLHyEU8Z9K0oPmlysmMtSISB5STnitKO1MrRhsRrjduzxisqyi/chjjJ5BqZ5JIQMtkN2Braau7I3UXJWTLGqyqX+QIFVdowOvvWv4H03UrLUNOuJQkVteTeZESAS2B19q5a9fZExdgWwTXYeHra50u68ODVJ3dGy0cW/d5YPQj862pRUY/ccWYNwpezT3v89DJ8XGWfW7ySY5fzTkD61m2rLM6cYIyDzW14yUw65ellyPM3n0NYGkTxsLhpFUSMw2YOMfSpldpsrDv93BrsjobVFVDkkNngVcTgD3qjanfgnI71dj6YHbtivMqblVNGWOAVHrU0a5654qNV5+bBPbjpU0agY755rnbOWRZjHzBc8YqUKFIznn0psKlgeD8tTqQyDgcD1q1GyOWUhw5AK9atDGAfXrUCADGDkdqmY4GSee1aR2uc8tRqr8xqUcEGkjxJIFPFLONjYByv0q7aXIe9h21M8kZpGVeo64pgYHrUqt0AAqX7wmmiazm8lw23I6VpMECvNIu1SPTpWSxBI28ACtBdQH2EwMvJFdVGaSak9jlrQbacUeZ/E+VG162K9Psq/+hvRUPxHQ/wBsWvb/AEVev++9FfS4Nt0IO3Q8+pyqbR0GijOi2APOLaLp/uCrybVTIOKp6HhtF04Y5NrF/wCgCrLqQOeg6V8fW/iSa7v8z6ClrCK8iVJECEuKpt8zEDoacmM7T1xzSyAKcrwfWs3JyVzaMeVkZUqcAZFQSDb1wT/KrAmJbGAM9ahmAzkHrUOxrG99SFgAmTnnmk8zI2cbadn5eRnHTimHIPrmg2SvuV7h9y+mKixuXFOl5fNI2Rjk1qtjoirIhcg8Y6Vk6rIclUyF961ZFBccHNZOoqWXAXgGuqglzGqOX1mNn3FcNx2q3pyCexjODyvPrTnOIJlCBiRy3cVN4YI+ySpwWRv0NepObVL0MKis7hBIyTiBnBAPWtmRBtA3Y5z9aoQwCHVA0ija+eo71du1Gxc5PG04rkqtOSsVF2ILi7hiG2SUDn8qrRakJL1SqsbfG3JHU+tQXlhmPzACQOue1XdK0z7ShRDg4yMVdqcY3ZTdtzUjZSAF5z0+lXo4URFK8nB5xWZZrIjCGT76nGfQVuJFthY7mY+gFcM9GRN2sR277WIbk4P1rnfEMRMsUaZxkn3rdk3lvl4bpn0rn9fMqXMQk6gckVeG+NFQj71yzYwosZycFV4BqpcqXddvJXkACp7BSQp3NgjJwM0sOJNUdZz5QACg9Rj1rZaSbOhPluxdD0KXxLqDWvmCILGZGbHQCtvQyt14ptoZ3DxoRGncYX0qjLrcej6DNYWMateXrFZLlTyqeg+ta3gq3eC/g8qJZJdnylv4fc1vde6efiJTaqTlolpHv6lr4gaW02q3UsMU2DFkEDOSPX2rgIoWgC7xgbq9h8c3EsPhyKcFDdco7L6GvHYZnkJViGKnrWlaHJNpbGWU1ZVKK5umn3HSWz5wV6elX48HPHas2xU7eB37GtNMfLwCa8arud1XckVjnIGT0q1GTjA6/lUacA9BT0UuPlOcelczZySZdj4GFODU0eQpB71BGCcZ/DNW0Cqpz1rVI456CxjkAnI7YqVhkCo4sHkcj+dDuQ2QBjpVXSRk9x3CZYt81O3NIRwaiZhkcip43QoDjBFC1Jemo0KAccVMsbqoLqQD+VCnHIx+VWJZWmjVSowK0io2bM5SehGMYGKmitmK+aMbRyRiowUVOx96Yblw+1T8p4OKtKKepm1J7HB/EuQHWrXA6Wqj/wAfeio/iQh/tm06f8eq/wDob0V9VhZP2MfQ8qqlzs6HQnI0fTv+vWP/ANAFWZXycMPlxVLSMjQtPIB4toucf7Aq4LgGEocEN3r5Gs/fkvN/mfQUvgjbyG20QeUIOppJ1aKRo25YflSQlEcEnJHcUsuWZpCcgj1rG65TbXm8isVAJOcZ55pMcHHTsKdng54Ud6a7ZAAPHasjZELNtBIFRueBjNK+SQPbmmuNoye/NWkbRsV5CS3HJpshI6Z64NSnIINR3BAGR1rRGyIJWwR1JPX2rNvgMYIPWr8hLFTjtVGYhrpS2Sm4ZGa6aW5sl1MeeEgPtyC/GKsaHps0TyzuymHcEYKckHGRV67iQ34x/q8nAFdB4Xtbe703WYCSt0I0niJ4XKHnP1rtjNzXJ3ObFVPZ0+e3b8zI1JUdrZPLZWUlmOOtRNlyckHbg/WrUymeVAJGcqT8rds1GsHluRxnFcrmtDSnHTUSWGKa0lySkmMkDofrVKwbyzhWIYccVpqgWORWXOV65rNhiP2hgFOD0NODvFopRvoatqNrrNjP6cVuOFSHdG2UIyBWVZ2ctxAy5UsgztpYkZQBLkD371jeyZhUSk99UK4O4lup7iqN7YSXsyeXIv7sF9r8ZA9PetmzsjdvuQ4285PtVTUomWUhMGQchif0op3g1IcanvckXqjEj/dRsUzleGA9KxzdywX0825gcHbuFbEuoLBazxBVy3O4iuUvZ2nnDMTkDHWvQw8HJttHdBb3RpeHojLqUbt85Dbua9V8ELE1zK5ybrOVUdAPevNvDC7ZWYBThDnNdR4Yujb61FJuKIVIJUUpT/fpvocmZUnVpSjHSyNLx9NPHLJE7MEc/u0xww9K89itpbW9aCeNkl4LAmvRviPbX99BBdQES2xXIdOoxXnFvMXkV5HJkJwSec1pNNSkc2WP91Fr5nT2vyduKtxEghuc1QtT+dacfHXv+leRU0Z2VSaLlSOg75q3Bhe2KqoMYBHynrVuBRu564rn6nDULQA2jnFSKGIwB371GgAOBjFTDdtAGBWj1OWRIinoOCKa2SuCMHNJGS2T15/OjBzTuZ21FVM9smrEQTsBnoabtG3rSKSr/L09qa0Jk7lgrheBz7UDOeM0sTZXLA81IWAwR93vWiS6mLdiFgCOc561LAitzg9ajZcknJIOMDFPRzGSBjH0qk9dRO7WhwnxKA/tm0wBj7Kv/ob0UnxHkY6xafL/AMuq/wDob0V9XhdaMbdjxaqfOzX0e4caDYIAD/o0XOP9gUrnB9TTdIRjpOm5z/x7Rf8AoAqe6VUbavXrxXxte/PL1f5n0+Hsoxt2HW0eVz+NNkIZcgMRzwaTzdkeM80iuNpLHnHAFZN6WRtZt3IieNo496Y33jx2qcAFN2efyxUbgY4z6VJomRN97AGQfaoXGOTz7VIvXBJA/nTZCC3PJz1qloaxK7E889aZKMgKOuKmk5BNQck/yrVG0SEoDkjoOtZ9yhAB7Zq+77Q4NUpTkYXoO1dFO9zeCY4DcpJB+UVULyeZIYycA49+lXccdeK2ND0SO80K/wBRWYm5gfesQ/iUYzW9NOV7GWIqwox5p7bfeZkUbLOuB06n1q+YwyKcfMOTT9LjEpkebAyMdOtaTRRphiPlC4xXK02Y1K1nbsYDghHwM5qCzGCRgA5zW1dQRpATkgsMnPesaE5yBzz601omjalLnizs9J09FkilEo+de3QmsO/ic3DqXyVbaPpV9nkttOtpkLYA7elUbgrKV/eAu3J/+vVTklFRsefQUudzbN7w3bx2dm88yEswOMmud1WTzJ2Zseo4xWtb3vmaJJAwxJG3Bz1rEkRppMA5bB69KqpNOMYoeGg1UnUmYGtQjyhK6BfMGRnv6muPbH2kgdM123iC6jbTjbSkpLGw28dfX8K4iMZuDgdD1r0sJ8LZ61GTaVzpfDRzfLEScFTjHrXZeHYopbpzcJhI+c1w2iSmDVLdxxlutdn9pKaiHhCxKWwRnr71z1bRqKTM8bGTvGPVHdeKoP8Ail2Fo22JYiVxzjivBtOcvOFbgK2K9st9UFzoN5GWMf2eMqDJxu+teM6awa/fIHLc8cV21pxlHmj2PJyiMqfPCXRnW2QGFzV8HdjHf1rPtj82R09qvpwVGMjtivAqbnp1dyzGS3y49gasxK2D61XUbucEfhVmFmXrz26VgtzimWUTJycn0Gal42nP1zUaH0696eCTjp06VocrJY+AKcAAQ2Qc+opsbEDHJ96TceeOKdtCGrk2N4OOKIQS3zVGjkdSMVIjchu38qa3IaZaYHYMcelMUnnHSkd/3fGTTEJ7Vb3M0tCyqrgkk5pTt28VFHuyBipNuSRzVRb7EPRnnnxHOdZtef8Al1H/AKG9FTfEiIf2xZn1tFP/AI+9FfWYRtUYryPGrSXOzc0khdE05jxm1i/9AFNOWkJHSk0vaNF0z5v+XWLI/wCACjLM52D5RXx+Jf7yXq/zPpsMv3a9CadUKqfveoqvGm8YxzzinNGQhLH5jyBT4fkc5JGawerNk7LRiTIFKr0OOSKYQoQgj5j0qSRt7E5+hqvISoP6UupUdURlDzk89elRsmT64qZVKrknmomf5/lUfjTRtFshGFJzUUuS3yD6c1LL8wJ/CmMwwBWi7m0SlMoOfmGapYPJznnpV6VSWbtxmqkEbSvtXr3zXVB6HVFpK4y6kEUJPtk12ngi1nltbqaKJvshgeJ3HQHGf6Vw+qctFERnLDPPpXXaNrVzY+HmsreR0R2O5VXhhit4cqSlK/XY4syjOdFRp2u2tyKyAVDxv+o71ekQs4O3tz9Kp2n3QuRwM471aVlkk+8RtHX1rjizmmne5la1NsiYZ4UZNYWgz/aoGJ5IYipvF9wY7aQZ+9wSOlcz4LvT/aFzBn5RgjNdlOi50JTPQpe7TSfU9YZJrzw15wC7bb5SB1xWFblwyMyKQTjmtrwy880d5bxOqoyZYetVbuH94sT/ACqvqMcelYVVeMZHnUpunOdJ9yO1iL3r23yAsflwc/rUcLi1v9jkHJ2896Ij9nuPMGWKng9sUt0q3F8m3kk5x61mrWujbW7T2aMn4hWsVu8cpAJOQStedpIFkAz9412Pix5HuZDOxYfwjPFcMQVuM44znrXtYS0oXO6gpU6cb6nQacN11ED03dTXfpp4WdY5lZwwzwOfrXnunMBNGTnqK9AtnvHmgud5ZSQpC+nSuTEJc6uPHXsmnbct6RAsnm2lwZQJFMTuRkc/dNefC1ax1aaAnPluVJ9cV63JZ2cWrq19cGGzlgzuBwNwHT6151r09nca1JJYEGJgCWx1Ira3JDlPNwFX2lZ22smXbRz5IG7r2rUtynlHd17Vj2g+Xk5FasIwR1xivJq7ndWSLsWcfT3qeNhkn8z6VWTnipowB044HWudHDNF1WO/BA+oqQKNpb8KhTDfQVYibC4JJJFXHzOWSsGcYwaIyAeRxTRwCOTTAW3YHeht3FYtBoye3HalV1A7ZzVcA07jocU07EuJeDKflPWow2W+UGq5c7h6U4ORjBH41pKSZnyWL0LmME4HrzU8au/7xkIXPU1TjyV5OR7Vpx3TPF5ZGOMcVvTtLRnNVunojzr4nEf23aY/59F/9DeiofiYpGuW3X/j1Xv/ALb0V9Nhm/ZR9Dx6sVzvU0tJjL6LY89LaIf+OCrgOzCnrVXQyW0ewAOB9miP/jgq86A8tjHvXx9dfvJW7v8AM+opP3EvJfkRSsQFzg/XtSFizDcR/hTZjyQOTUZXnnPpxWLep0KJPI24gLngVF0IJOTSKdoO4jPQAUNxjbznnrSeoJW0GSMHJ4yahYgFRgj3qQ4GPr3qNwM8dehqkbRKzt97HrTZhsjQ/wARFEgxntmopHBIznAGK2ijoS1ViO4bIJIqtb5UEr61Yl+ZBjPvSwxbvl6e/pWqdkbJpRKk8a+bG5BJHtXXR3kC+F4Le0d1uHc+eMcMO1Ysdqs9zDBE33yqlz0BNbGs6fJpNxFYvMJfL+YMvQE1onJQcktNjz8VOFWUKcnruUYUkJkaM42+lE7yJCcqFz3p1pMIpZC6Z3cDI6VHrE4wqbQCBk+1c6j1KV3Pla0ON8W3IMJXdlhya47w5qX2HWhI33JDsb6GtzxWQqbh/ESK4lnw2QeR0r6XBUVKi4vqbYqfJKNuh774XvGtdTikjAbJwRnqK6fXvstyzugy33jk15f4ZvRc6ZbzbiWACsfcV6d4Uit7zTrnzhmbacFj2ryYxlzOg/M4cfCNOSxSOW3FSwZsL1pn2lhPHICN3GG71e1O3WFynPGc+lZUK5kKnA4rhtyvU7KfLUjzGV44+aZJCoXeDk1xkiZIPfNdn4siUwIxY71PBPeuSKkk5r2MHK9O53UIfu0ixZcFR716bYm50yeyW6QZdR8inOVNeYQNsYZ6dcV38d59pu4GjYpAYlCeacj3xWeJWqZnjYuaS6anSeJIhdaHcLAGbblsE/dNeaWCDzMsB0rv1uo1jaG6wUuV2n61xE9ubW+kh3ZCng+o7UpzUrtHHl0XBOm/U1rTaxzwB6elaMeARz83QVk6eAW46VqqxABzj615lVanTWWpYU4wCef51KOB0x9KqliGyO1XYtuMgjHWudxOOehYiBKZJwB3qdDx9DioSwEfqOKdj5CAcE007HK9SQNlyOgxim+Zhh3pC2FPY+1Qlg+BnmiUgUbk6y5PUfgKnRldjyM4/GqybR0yKsBF+8o5x1qo3ZEkhzYIHXr1oQYI+tMLHjd36U8A5XOdtUnqQzoXgUWMcix4zjtUKjgnGKtXt6r2EEMfGOtVCT5fGcjrXozST0PMhzW97uedfEo51q1P/Tqv/ob0Uz4ky7dZtR/06r/6G9Fe/hdaMX5Hn1V77NTRWKaNYMOv2aLj/gAq40pERKrls96p6Syf2PYAnpbRZ/74WrakfMS3y9q+PrStVl6s+mor3I37Iibh8E8kc0xTtYZyTTpDhefvYpFKr6HisDqS0Fc8ZI5NJG2xPuk+9A2thhjA7Uky7gdg4FAeRBMRvGDgmmv6ZHHNLKh254qMdskGrWxurEbt87bumKrvyB0zU02NmQBnuKYUxFv7VrE2joMKgxngmn2yNuCjOX4FNUjaM5o3Ey8ZA6AVQ5XaaHF/Jljb0bPrmtS/upr69aWRVWRgCcDGOKqpCvDNjJHrTrlmR0yc/KD7mk2+WxzSjGU0+pNG+50EgwG4yO1Y+uTqrSNyVAx9atDeR8mc9uawdfkIXyjksx6VpRXNJRN6FNKdzi/EdyZFIIwo+7XJs4LVv+Jn2EqRjFcur5ORX1+EhamedmVZKpyna+BdRMdxJaEna/K+xr1jw/qE0YMaglT1we3evAdIuWtdQhlBxhq9h0y5UojhyNw4IryM1o+zqKcep1Ya2Iw7g+h2mpxbQZFTfARkZPINc/Gx80YHcj6e9dbaAXvhpdkYYo20ux6n2rn72yFpc5wc4zxXmV6e01s0c+Eqr3oPdOxznisn7MncbsZrlSvXJrr/ABWjvYrIY9qBxg+tciTg9MGuvCfwz3cLrBFjTLKXUNQt7O3UGaZwiA8DJ9a3PEenzeHrmKylnSfbnLICMEHkc1zkE8kM6Tws0ciHcrKcEEdxXUXFrrfie3/tPUZwY48RLLJhQ3sMVvU5FG8jOtKUKsZyklC2vq9jfuLQy6LBOoJygOR2965l0L3LGQknHJrT0vxKdNt30vUUA8gbVPXPtWTJeJPcFouI85x3rklCzvExwsKkW1JadGXbJgcgdBxWghLAAms22+ViQMA1qxKpGScGuOroy6ujFLhM7hnNXbeT7o7H1qrtDnJ7VYT2rnkzkqJNFxXbPtTkfLc9c96hiJznAAxU6EZyAKzRyyViQuFPt703y9xb1pzkMoNNXIyQc84607XZAqNsznnHrVtTlSRj2qkw3dsmrUfyxjPX3qop7ETJAQQCQMj86jefyzjjkdKmCB0DA89hiqcikMTjkVUm42Igk9DUtJTKg56DgnmrasPLJ644rIhbEYxwPap4ZMAgnrW0KtlZmE6WuhwnxJYHW7bn/l2X/wBDeio/iKP+Jxbc4/0Yf+hvRX1WC/gQ9DyaqXOza0ld+k6fgf8ALvEP/HBV8puYLk4qLw9CJNIsPmwfs0f/AKAKmfAYjk4PWvj66/eSb7s+goyvFJdkVXJLFfQ9KEIY9OcUoYCU8Z7mjkHOOM1kzrJVPyqFHOfSop3CEAnr74qZG+UYBOe4qpcxB2HoD60K19SYq7sx0rFu4AA4FQsQTjtip2CFCBndioSuWwRyKqJrFpELsMYOMdKi6jaeg7E1PKoBwOgFRMudx9s1qjeLVhjY4HbvUtvC7uCqk/NjPbNQDoODmr0SNHCsh+6WwvPem9BVJcqI7pjHLgHIz25xVi9Uh0LQ+UDGDtznI9aq7TJIqYLMx4FTXL52hmYuBt5PT2ourGLWsRYpRCjMF3sVwCTjFctfkT3bbiQqjOQO9bl5N5URJ4rnbpyLKV8kOxrowye510KdryPPPFT/ADNgjk1zsZIxW14ob98FFZMa8DIr7LDq1JHzeYNzxT8iVG6HuK9L8LXn2iwiYcsoANeZ7GxwOK6bwbemGV4Hzh+lcuPpe0pXXQ7ctrOFXll1PdfBGp7lNlK5VSdyKO7elal7BHcRu4B3Z/I+leeaZJtDSiXY8eGQDua6/R9RE1nN5kgV85HNeDGorezkaYrC8lR1aZy3i8EaeAZMEPgp61x5Iwe+BXV+N3LRwFT8u/kVx+c9sCtsMvc0PawmlNChu2a6mw8X3lvoCaX5MEkMb+ZGzryrVz11ZpBYWtwJQ7zlsoP4QPWq4J4yeK1lCM1qOdOniFaauk7/ADLNxO9xcSzStudzuJx3pLd/LcMDwOuaiApy46ihrSx0JWVkdVYuGg3cYI4rRRjtGf5Vi6TKPs6jOSK37FowrmVc5XA9q8msrNnFiPd1LEYyvP8ALNDMQMLUcJwBjnHpUowT3AFcb0ZyPcnt/mGGqwgCgg9T3NV4gvb6VICSB8uRmpvqc8iZSFI54p3JYY4WmbSTz0p77lA7n8qRkxwJTJB4HPNSB94+bGPaoxlk+Y8+lLGwXpj/AAq00S9S3anywV9ahuP9f83SnJJuPAGaZNHtfce+M1b1joZpWldhznKt8uMYqRXwCrd+nFQ+WJCQTkYqdegB6/SkgkcJ8Qmzq9rjB/0Zf/Q3opvxCwNXtv8Ar2H/AKG9FfYYH/d4eh4lZr2jOg0U7dGsATki3iwf+ACpmcs2D1qvo+Bo9gM/8u8X/oAqyw3HIyMdxXx1f+JL1Z9DQ0gvRDhEoXJ69aaoUrzwM9qeMlBg59fek2gAj8cVizTUZKQrEr92mph4SQeewqeHyljkEqksfu+lNACjjj2NN6IFLotyowIk9xTh1HPSj7spypAxxSISRyTnPNWbbq4TDAbg81UI6qO/FaJwc8cfXtWbJ/rWJ6AVUNdCqbvoRT/JIFA5FSxudvBPHbPFV2JZiTyexpTlB71tY6HG6VyXzGEysN3HpRLLh265J5pkancrZIxz1q3aJ59wwRAQACSRwKRE2o6szrlzMPLzmsjUYisDKQQvXHeuru7WOIAhBkDr0zWFqq742bHPY1vRnaSSNqFVT2PI/ERAviByBT73SbnS5IUvkVHljWZQrBvlYcHio9dz/aEueuazZ7kpHjNfY0otwikfOYuahWlJlln2HBGM8inQXXkTrIjAMpzkViTX7ysN7FsDA+npURmY966Pq91qea80ipXh0PYtFvBeWySRH689637a4Cp85XAzyDzXkHg7VWhvPId/kf3rv/tRVhg7l6+tfOY3BOnUceh9ZgcbHGUVP7/Ut6zfrLbFG+9urDj5HWrOosbjaMZOeCP5VWhXt+FFKChCyPQg+g4HIGalUDAznmmKOe9SA8DA71TNoi46Dr6U5VJYBQdx9KQg5pRnrnBHNQyumhu2EElsximUpKp5U9RW9CQsWeOlZsUCJJGY7r7TuQMX9Ce1aGB5ZBryq75mcNSXOkWYFwpK85qwiZHXpVO3k6DPAFWkJPA4FcctzkmmmSJ7VImQxI696hTgZPJqZG4wv6VBlJEwy3Pp6U9SXAAyOeaSEls8cVMqEHg4powkwMZPfpUSLkkDIqwWyNp7dacgjC8cE0WM1JohTdGN2e/Wo5rnewBHA71ZYFl27Rg9/SqE8LK3Azk05aKyKgk3qWLZ8ttJ/GtHA4Ix+dZ9qgwMcGrigjaSc1VN6XMqyVzg/iHn+2LfP/PuP/Q3opvxDAOs25Of+Pcf+hvRX1+Cf+zw9D5/EP8AeyOg04qdKsMDg20P57BV9z8m3aenX0rP0dQdGsCP+feLv/sCr2HKE4OCOK+Prv8Aey9WfR0vgj6L8iBcn6mhiScDBUU4qBzx+PFCnkg4rI6LjVOGJHpzSowY5xwKVkIBKn5e9MOMfXoaNwsmRTEO2fwNIQAMAZxxUvlnywc/mKidlCsvO7PBqkaJ9ENuDtAAJJ96qOQ4btj0q3P88YGAuP1qoQApA+taQNoWSFjhPlZPrzT4VCPk5wKkBJiK/wAJpXj2Jhxhscim3fcTm9mX9QtIE0a2lSBluZpCSS3RR2x/Wl0eEJaluFZ2xnPas5g0su9QflHAzmuhhijiijRR/Dls9c966FJSehwVL04crd76mdqmzGD0Uce5rntT/wCPc+vXpW/eAFpPQD0rC1dT9lcZ7detRF3qHdhNLI8R8RyFZp5O4c1yl1dlzjOa6fxQdq3WP71cWDX6FgoJ00z4jiCvKOI5U9yYS4x60/zfkqGFfMlVemSB0zXqXir4aabp/gm517Q9dlv/ALDJFFexT2b2+GfpsLdcGumcowaT6nhQnJrQ840+4MV7Ex9etesadN5sSg8lRxXjqnbID6GvW/C6i7tI8nkjINeXm0EoqR9bwpXd50/RmmCcDPBXJ5qqh3A8AZq1cRtEDuOSKqxDmvEjsfc09yQHuOtPUdsfiaAOmFp+B/8AXpNm41ec49e9Tx2s8kTSpG7RryXCHA/Gul+Hfhd/E/iCO1ckWyfvJ2HZfT8a9M+Leo2PhvQLfQ9JhjhllwcKo+RBjk/WtFRk6bq7Jfizx8VmqpYqGCpx5pvfXZHlGhAiPIznNbiAlGLHiqGn3RvnMjqqvjHyDA471oBSpwfyrw67993OirJuWujCOMY4qyrbV5HSoQCBwcUISSN2etc71MZe8W0+dcqcZ6U9cqf8imxEIAc8fyqRyG9fxrFnOSREhsnBFWfMO3nk1WGCmAMmlIK8gk+1F7bGLV2To3PJH+NSBdzEg81nrIxIH61o2h9cHHeqi7uzJnHl1JQpYfNkEcVWdGlfA6Z71YaUhjjGD6UkbjzBg9KuXYyTa1GLEUPSrOSE5HsKbM4fkHmkjLMdvJ7dKcdNiHdq7OE+IZU6xbHaf+PYd/8AbeinfESPy9YtQQc/ZlP/AI+9FfX4JuOHgrdDxK3Lzs3dEUHSbDPT7PFz/wAAFaEhLKuG+X+VUdHAXRbEsM/6NFj/AL4FWwTjnPNfHV378vVnv0leCfkvyIwePu89zSFdzgZA71KwL4xTdu04z83rWFzfmQwg469KCi+WNvOKk2gZBHOKCuAAvHeqQKWoxziPA6+lUGQiXc3T0FX5ACByM/WqqMFDbsn0BqouxrTdthMqjjdyMcCq6kBzu6HNTYViMn86hcc49KtGsULEcjA6A0+VjPLtYnd0P0qJMgEkEfSrcSRi3LEhZPSn1FO0XcZbl4bpljy38IyK33QqGO7JC+n6VkQhojbyHLyHhuMADPH41rTn/Rwyg7geQtb07JM4a0uaSaMuUEsRjnmsXWATbyZ9K2i+OAdzc1ia84S1IHU1lSd5o7sLdTR4h4piMkV1gY+Y1wx616brcIkjusD1NeZyjbIwPUGv0XLp81Ox8XxRR5K8Z90IjMjBlJBByCK6jxL4+8T+J7C3sdc1e4u7SDBSNsAZAwCcDk47muWo6V3uKerPmE2hc816p4DkJsoTnkHivKxXqPw/wLGMkdTXmZt/APqOFG/rUl5HZarbgW/mqM8c1jRc4FdTPHutyAMqR61zJQJOycdeK+Xw8rxaP0anuO6Adafwev500cjBFL1H41qdB3Hw68bx+EI7/wD0I3EtwBsYMBgj19q5zX9Zu9d1WW+vn3SynkdlHYCsvd047VYsI2kuFwuVHJzTlUfJyt6I44YKhSrSxMV78t3/AJHRaUqw7fLLYrWBJYbhkmqdrHsAyMemK0nK+SAR81eFWleVznryXNoMlK59qb5ZYcA468VJGu5zu7ClQFXYHnNZX7GPNYcikrgnIHvUoAUHHJ6UkYXJz1FPUZbGKzbMmyREJz7jrUhTbGBxwOc0zLK2BT1bjB9OaRkyNkXYCOo9KtWiEjCnn3qJV3YA4zVmDKnAOAO9XFdzOb0sOKBcg0CMbgT0ofJORye2acgwvf8AOq3ZlrYkEanoQKmgXaQwIqvEp7HNWI85xnNaQsZT2scF8SpWbW7bK9LVR/4+9FJ8R8/21bcf8uy/+hvRX12Dd6EPQ8Wqlzs3dDYNo9jkEL9mi+n3BVnc2WwAAOgqno4xo2nnt9mi4H+4KubsYyOh6da+NxH8SS82fQ0fgT8kOhZlzgdaVlABOfm9KU/Lxnj1oxtfGRg9KxfY06jFUnJY7T0pZCDjt+PWpCRtK5PtTCFJwe1PTYV7kKxjczZJBHFVpdoYL2J49aukYHAJNULnKtkinHc2p6simGDgHPpSQbTIBIeM8n0pcAfM/Q0yUBWyvStF2Ohaqw6UKZDs6dMCnpHwAcH2qMKWIbt/OrECnzDnhcZFJkydlYvtIDAsKgD5ucmr04AtiOQWHUVlq7GUbcbAf51q3ZBsnA+8AMcdT6V009Ys8+quVoxvl2YPOB1I61g679wknt3roEj/AHZYnJPYVg66uI+Dlsc1lQ+NHp4R/vLHm93HvkmQcivLdVi8q/nX0Y161NH/AKc6gYJrzvxbZmHU5TtwH+avuMsqWk490eFxXh3OiproznaTBNS7CO1AGDyK9y58DyCIhZgB3r1rwXbeXaIh/wAmvN9Gt2ub6NVXK9TxXrXhaAhenG70rxc4q2p8p9pwnhdZVn6HWQxjyVzzjtXOapD5d3nbhT6V1cSELjGKx9dhIj8wcgV8rh6lp27n2sHqYvXHajkHtQB8o9aXHzHHNdx1oAOMV0ugxAWYOBuJzXNquR7mur0uMpapu44rlxUvcsYVvhNgoqxqFoVSTk9KhBJKjtVtEKoMk7TXky0PNlpuwymAQckelKz7mAwOuc1CVKscDBqSMjHP41FiOXqTDnpnBqaMdTioowDkmpM/IexpbGTfQeB3zSg/KRio1PcmlXB7dalsloerkfUVMH6GolXGTxmrEKEhf1xVRuZyaHI3OeSKlX5z81GVAxgUsXPAFWlZ6mDZPGoQdR9afj94SDwPSqx3A4BFPUuOwq076GTj1OD+I+TrVscf8uw/9DeimfERh/bNtnkm2HX/AH3or63Bf7vD0PIqx99nR6QP+JHY+1tFz/wAVZjBJHPFV9J50ew/69of/QBV6VBEAT39K+Qrq9WT82e7RdqcV5L8hAm859O9IqbiMjJFIrnHrUnKA46mslrqaO6GNEXOePTFRruG5TjHrT1ZiWIzx3q+J7WPTDEvzXLtycdBVRgpXd7ESlKFtLmfg4U5BOe1UNQY8DritGRCTjqDVW9h+QZyPUmklZ3N6ckpK5SbdsA6jFDMhj2nr61JG68kDPaoJkKLle/pVLXQ6VvZlm1K7MYB4qSFCSw6nNYkMk320RYOwck101nbs4HHI6UTg07dyK69nq2T6fHCmS43Pnj2q6sfysQeNp4NUHzA53A9Qa0IXV4ztyMj05rqpNfCedV35jnkViWBFZmr8jkAjpxW2VCu6KDkdc1jamvyYbrXPTfvI9TDy99M88vhsvdw9awfGOmteW6zxjLp1HtXTarGBMGX1qMxeZAV65HevpaFZ03Ga6Hbi8LHEU5U57M8h8k916UsNo80qoiEsTXYX2hSNdN9mTIc5x6V0Phvw8luBJKmZe5NezVzGFOHN1PjaXDtSpV5ZaJdTJ0DQv7PtTNKP3hHPHSuz8MwholJGPem6lB5do/BAPAFX9Ai2pGMcAfrXz+KxMq0HN9T7HD4aGFp8lNWSRvRqPqMVS1aINZS9uDgVoxr+75FQX0e+1kHYjp6V40JWkiIS944g5xjOTQRx1pzDBIFIBk17R6ZNYpvuI17A5NdbEPkGOK5/SrZvMWTHUV09pH8wH868/FzTZy4mVgTIXpVtJmYBDjgVHJ8hwMegp0URPOOT3FcDaepwyaauyclNg7UwZBBxzU0IQDDEfjUZOR04HSszFPWw9Dx0AFOJPGT35qMNuwvoaXayuC2TzSJaJEBIOeQPanA/MAeBT0BwT1ApypuRnHWhJshsQFRn1x61PFKV9PrVYA9COD1qRgUI4xQtyGk9CwBJJnnBzT0k2nB60kTBhkHkjFPVMsWOK0MG+jJY3LuMgU8dePrSIvU01XIY46n1qloZNdjhfiKudYtv+vYdv8Abeio/iIT/bFt15th/wChvRX1+C/3eHoePV+NnV6FGZNCsiBgC2i5P+4KsFTMTnoOlVdAZv7F085+X7NFx/wAVqIVY5GK+QrRTqS9WezSk1Fei/Ip7GVhnopokOee/SrEq5Bxmq6owPI5HpWLVtEbqV9SFCVOAc59aG24ySQ3tVnBC9Poagn+6eBj1pWVilK7FjbBAySexpLx98RHfvimWknzEd/enXgIjYkdOetWn7o7WkUQhY4GM9qcSyoy7RnoaIX5Unr6Ur/M5JHXn6VNzoe+oWxRcttBNadmxYbu/XmsxVO4A9zwRV+3bYHGauL1MayuXBZNdK7FiR1PtipoEIHJz2PvTbN8QScgADJz0PtTVlKDIbP16V1RtGzOFuTbRmXCCO5dAGCg/eNZ+pJviYAjOTWrdOGH3SWzktWLfFlLEfjXPtKyPRw920zi9TiKyNxwKi062lu50gt0aSWQ7VRe5rQ1Jf3hJpvhmc2us2UqEgrMoyO2a9iM/wB3c92o3Gm5rezIYbcJOwlTbIh2sCOhFaqxAKCgAXvSeJA0WsyzYx5x8w+57/rmoFuwYcc+wrGTc0pIiDdSnGa6oo61IZJY4hwM5Na2kDbGMevpWCzeZdFm/Kuj0pCBk9zTr+7TUR1UowZsQAyZXPUdRVbU5FgtZCR0X9avQgAHJx7gVi+J51W2WJTlnPzD0rgpR5ppHn0lzVEjlT9/pyfWremWhu7kIBwOTiqrDPqK6Hwx+6DuAPSvUrT5INo9WtNwg2i/BZ+XtVR04rQji2DOB6U62AaTLnB65q7IE4ZSNo/WvHlJyPGq1m3ZmZKvI9qnEnygD6VLMyOMqAD71HFGWIBI56VLZPNdajokLjr0pcHoOKl24zz0pGGAT36cVDI5iPy8NtU+9PYnIDc4pAGUAjqaQqT35NAXuORyScEipow4ViCfeqsY2yHmp1JCnBPPWjqKa7EqnC0hcsPn6elEYyBjrUhUAZPNFmZ6IWAMFzkbanVsjJNRRjoMmpWHRecE5zVJGMndiGR174NIHYKrdcmnlUxjnpSwlAGXqPenFWe4rqxwvjyQvqlsWHP2cf8Aob0U74iD/icW3A/49l6D/beivscApPDw16HgV0nUk/M63RYd2i6fzgfZYs4/3Fq0pQAjPfFQaNMYtCsQOXNrDx/wAVIy+3U18niLKcvVns0LuCv5fkiXd0A5HWmBlJPHNNRSv+NKQw2kEYB5rFPS5tawFlBwx4FROuRgHjtT5BuKsOfSm7euclv5VO+5S0K5G35+v9KglnaQjcOOlXWQdDxk46VBJAFY7ce5FK1jaEo31IigUA5wD0FS25VWywppTce5xUMjFVIH6UIr4tCZmDP1I59KvRPE0a5HJ74rNi+ZgB365NaAR0AHVe5q4XTMqqWxZuJEW0KR9G6iks180fMQR0NFpGJJ1RwcA85rQutiTHyAMJxwK64R5ldnJKah7q3M3UwEiUFdpBwKxrzoSBk4rb1X51hkYcE4JrKuQpBH5VlVXvnVhpaI4nWAfMbjA65qja/uisvo4OO5xWtrYw5BHNY5yOMZ+telRd4I+mp+/TVztPiPbQ2/9lPEwLTwtIcdgxyP5muOVvl68+1FzeT3Jj+0ytJ5ahF3HOAO1A4i96qMeSKRlg6MsPQVKTu0Q25zKc9M9a6fT/ljGK520jPmf410lmn7oA+tY4pq1h4j4bGkk2AQq5PbFcprocaidx6jNddaBGDqBg9a57xTHiSKTbjOa58K0qljjwskqtl1K3hyxgv7+SK681kWJ3Cx/eYgcAVe0OJlgwAwIYg54NUfC19NpviKxurfZvWYcN0IJwc12N8umxa9qaWEskmZCTuXAUk8ge1dmK/h3ROLrThW5LaNJ/c7fLcrxcADJzipTvjADd+cUAbTkLgD8ankxKegAA7V5DOSUtStjJzUqjaGxUkYAG44I7UiKJWI6Y9akTlfcdHuZxyDmpXT+E9KSOMrkr26E9aA2c565zQkZehG33to9OtLuA9zjrTsHJzyfam4wSTkexqWURBeTTl5U0MT17Up4Zc9KCh8bjoFHGB1qVnyAQAQewqAggZGNv61PDhgCevpmmm9jOXclRWK7hmnIWP1qVmVFGO9VpXwdw7VctDJXkT7WPfFRlCJgQetRpckoDz6VYikD5OPpQuWTFJSicP8Qf8AkL22SP8Aj2HX/feik+IZ/wCJvbf9ew/9DeivssF/u8PQ+er05OpJrudpoyq+h6ec4/0WH8PkWp5NgAAPNQaIudD04A9baI/+OCpowFdt/NfJ4hfvJLzf5nsULci+X5IapJ4HPpUZ3r83b1qYgfwjn6UwB1ynXnvXP5HQmN3kAZAIx1oZ9zE9Cf0pCCpKkAd+KQqUBf8ApSXYpWHLtweOR0qIKTkdvengNkkNTnRv4f8A9VMa0IUbZu4yD71XZct8ozipW3KSOh/nRCf3wDDtU63NFpqRptR84wT0rRjmDw7QOfeq1zEDIFQDB7ilRcLgVcLpmcrTSZOZPLgTOd2entWrPEhjjfdneM4A6VnRx7guRnHerLSsY1Hcda7afmctRXasVNSSQRDBJQHPtmseeXeHUjGOT6V0l05ksWVUyD94g9K567Ro4/mXHPJrKtGzTOnCu+j3uczq6A89u9YEvLnjiui1ZsoUwNpPauemUhyOcV3YZ+6fTYdvkGZ+YelSLy34VADVmPG0HvXRLQ6EWrBB5obtiugs4wo4rL0uAOM456Vu267HSPu3FediJ3djzsVUs7Fu3iCgsD7Vl+JIFksyR1Ukg1teUUXaCCuOn9KyddcJpsrY56YrGndSXc4KEm6iZx8chilSQdVYNx7c16b4ws7X7XY6lprxqtzboZ4s4bcRndivLs9q7G4uNLvdG0ieO4l/tmIC3lg2/LsGcNn8q9aetOSOrMKcnVpTje2qdvNdfLQ1lGVzjPvT1UDI7jvUVsNmxT93vViVlbIUYXpg14mh58m72IC2COw/nUiqAwz1xSwhej4AHSnL1C9cmpE3qTIflAwKYF3HqABT0TBweB2pzxErnNFupldJkRYID3qIODJuPT6VKI92ecAHrUckYyB2HWpZat1IZTzlPWlAAAznPXrTztVRj+VIxz0oLTJozlCM9s0kfDEmkQ4BXbg1IycAjrQQxkrnaMn/AOtQj70G41LIm7APSo4yplCHPHai2thJ6AsJ3E4GDUsQ8jBAyO9DMUOF6Z9KePnH07mqSV7IiTdtTiPH7F9VtWz/AMuw7f7b0Uzx6rDVbbB/5dx/6G9FfZ4Bv6tD0PAxGlWVn1O40WUjRtOHQ/Zoh/44KnuMc4OTUGkKDoWn+v2WH/0AVYwM+tfJ103Ul6v8z1KFlFP+tkMiY8MBnjrS9cHODT2JH3AMDvTS2RnPTrisUrG+5HtOehOe9KASerEZzz29qcfmBxz7U/GV64x2o0C4xgFCnigyqhJOCaGBx14x1qEgKw4JJ70N2eg0rjZVy24DPsKJYTsBUlWBycU5twUsAaYkpxg4Cipe92aK/QfbLuYbiD6Vee2ATzOPpVWAYDY79KtMx27QeK2p2tdmFRu+hNbw+ay4yBU92kaABMlh1JplsR5ZwdmOc0x0ZNjuS27pXXDY5W7y3GFNsciKADKOhPU1mX8MzxoJEAJ79gK2nj3oVAPTt2qneRSzQ7EZl2jqaJw5omtKfLK5wWrGOOZkLg46VhTYZeOT1rb1vTZpmkmhRpBH95gOAK1Phz4Yi8RPe/amZEhT5fdj0rWhZQTR9N9bpYXDurN6I4ZVwe3FWrVC7AdcU7UIHtrua3YYaJyhyPTirumwEDcQTWtSdo3O32icOddTW0u3KIH6YrXtrfe3msdrKcniqlorOqBQcDn2ra4hhwRhiOTmvLd5SuzwsTUbl5lS/byggU8setcv4muMhLcHoctUmt6u32wLHgqh6+tYuoXX2qYybccYrqo0ZcymzuweGcWpSKgGWODg1p6FAZL5SBwnJrNX26mux8P2Qigz0JHJPeujEVOWFu52YqqqdN+ZqIp2j5qWMMzYC5ozyVAwKnhOBhuB/OvJaPCb0AIR94Z/pU0KjPIz+NDum0H07UqblA+YY+lFlcxbbQowc8Yz6mnFtw5J4HQfzpFIyRg0jYLcZ6U9tiCErjgZNP2Ej1qQIWJ6AdKRiw6dOgqOW25V7kLRDGetRLESxByKnXcSTzjtUhOFJxyPXvRZPUrmaGImDzjPepsAA7v/AK1MP3Mmk5bAOcU72Ieo3zAzlMDGak8jB3Z/GmBCCSBzU8YJU/pRa+4pO2wiryBgEDnOabL8iZUfhTgxXK45p+0lOc5FUl2IuecePJidVt9xwfs46/77UVL4+t8atb5xzbg8/wC+1FfX4D/doeh4+It7WVu53ulKRoOnEDP+iw/+gCrEZ3J6Go9FCnQtOLf8+kOP++BUzoQcjOOvFfK1k/ayfmd9B3gv66IQoAmScUkcaksUyD0NO24XJ/IGo8NuBXueh7VkzZDgMOeCcClfBGDy3rTyvyMTkZ9+tRcAZ6mhrlBakRPzHnk9utO2kjOM1KpQncyjNNRwTkA4z0xSSV7lXImfBPXn16Cq+3957Z5q26rgE9CaiiUkkEY79amS1sXGSSJIwSRg4x1qx5Rdcr1BzUfAcYP6VchYJ1GR1raC6GM5PoMiJXCSDBPINT7i7YJFNuJRJtJGOcc0+BDvz1HrXVBHO3pdixMUuNpJOR19KmdPllyMgrjpT3jEfz7s8cAilhdpQwI3LjBAH610Q7GMpX95HNWtveLLc6XZmP8A0vAJdc4+npT9KtxaeJrbStImZ4baXzbiVeA7Dr+AroLDUtM0XWi17F5ZePaGHO0+v41i3WpadpNteDSQXubtjukP8Kn3rm5YwW+t38v+HOhVKtWTgoO0krdm+79EcBrmLzXr2VRgPMzfqat2kB2KoHPoKYluGuSe3rWnEgFxtB7cVFWpdJI+klUUKagnsi3YHyl2bQd3bHNQ67epa2YJbL4wB71pQIFwSpZz29K5fxkGDx5BC+o6ZqaUOZpM48OlWrpM5mVzJKzHqTnpUZznjmnHn6U+2t5Lm4ighRnmkbYirySTXqI+ilJQi30Rb0ezNzOHK5RTk129tEEjwcYquBL5ojubFLOeJFidF7sB1q4ifKeOK83Ezbm/I8GvXdZX/W5MfLcZjXnHWowCQS3FJFmPh/vHoB6VPFtOQa5ranJ8JHDGXOTx71MEwNp+6PShGw2OMVKvzEnHNNIiUncbtzwOBim4Uck8Y9alI4OefakVADgDp3NFtSLjA2DgZpkhAzx1qYlVzjBaoiNy1LKQxW+QZ4qVVyMgfrTUjIwOtTDG7GRtPoaUV3CTIwD0xwaVSVzleKkAAHT6ZqPB5yD7VdhJ3JUZScY5+lK7BcDGKhPyHgc0MHY5HWi5PLd3Hqvz7jkmpVJ2HdxnpTYAQPmOanOMcCqiupEpHnnxCLDV7buPswxjP996Kd8Qx/xN7XH/AD7D/wBDeivrMF/u8PQ8et/EZ3Ohup0HTh3FrD/6AtXTtbcDxx61n6OoOhabt6/ZYeP+ACrjRkqOetfMVm+eS8zvpJcq/rsR5POMEU4HaeRQi8YCkH3oIDMBzj1Fc6ubiSfMmRyPWoUkCZBHWnSKQTyce3SmJEu0k5/Gpd2y42tqLw2eevNIdy5UjipcbeRgVCSzkg59cjkUPTYaZG0mTgjGaTBXIXuKnWEMg/rUbnargjPb3NJaFcy6DUc7wSTj0q+Hwnuar+XmPcDzjpSxMQvPJ960g7EStIsKNxAz71ZRthHc56CqanzGOzqOCSM1Mjlcq23Oa66ctTCavoWZmaUgKevQZxmtW2ubfRtMurmVlLCP5WLdSe2KwrjEULOzhQq8e5riPEWqO0Ji3cVoqrhL3dWwpYB4xqmnZdSO91M6lfyXNwRlzwOwqeIpIoGOtcgsp8zknAq/FqDLjHFRUw7ex9W8HyxUYdDrdBs7a71y3gupfJt2PzMDjHtW5caXaW+wwCQXHmMrCUjO0dCPY15xPqp42feHenWPiK+tpvMZzJ8u3EhzgURoStqjz8RluIqS9pGWi6HojxiNVA/i6VyfjS8h8hLVDmQNkn0rPufFV84KxmOIdiBmsCaV5ZGeVi7MckmtoUmnrobYPL6kJqpV6Da634aIg1+S6cjfa28ksa8cvjAx9OtcjjFTW8nlTxsueGHGevtXQpcruj0cZRdehOkna6PQIp/td401xI0m7+L1PrVp9oZQucdciqdoAYQwULnpgUluZ2vZFb/Vj7tePKTbufPuCW2iRe+XdyM4prFuuAPankY5xjJz60si859RUMzvqPjjLvhep70oDpIwJ4A60QI4bIyOKeOc4O4VottjNvUaC+Pl79qeSNnJ59KaW/ugU0ZbPpUXAAO7dPWn7VAHTIqJh8ygmpVUFc56cZpLyBjAwEoAOSRTGcCQL6cc0rfK+Bg560w8kZBNQ2Ul1Jlbux5+lBfIGP1qJvlBOevTNSRgEVSYrdQZs8jr09aWMkkegqRIwR36U6OPDcdKpJvUlyQ+LkZqTYSOKcVGzHekQ7QQOBWuxi3c89+IwYazbAAY+zL/AOhvRTviKD/bNtg8fZh/6G9FfV4L/d4eh5dV++zttBOdD03AyfssXP8AwAVbAZhtzxVPQ/8AkC6aB/z6Q8j/AHBWhnP0H518tW1nK/dndTdoIiIIGFJzUIyG7+5q2WBAyM+pquRgkevSsJLsbRdxHIx83FMRiOgJ469acNp/1hxg9xSrGN59v1pa7juhFkG3B5Y1LEfLgn4UluBk81E6YVj3xSRYYgc496aeomkwlUhMk/hUGSRlhhT7Vank4CAd+tV8Eqc9/Spa1NIPTUa0mNncZ5xQ8gXHpTGAJK5yc1NDamWJiT09aEncpuMdWSJP5SgoOT3psm7fv6nGSPeoplyuM4xzmprRvl3u2M8ciuiLb0IaSV0UdYvGAMZ/hXOPQ153fyM8zZJPNdvrylHmPTP61wd1xKRW2G1k2e/lMEoXRD9KNxP4Ud/amjjr6122PWD8KU4xTV6DJzT1UsQFBLHgAU2K66jSPajr6D3rprTwbqMyQCeSC2nnIEMEjfvH/wCA9qqad4av7/UrmzhWMG2J86Z2xHGAeSTSjJSdkcf1/DO7U1puYe4A89f0qzYyJHdRvIu5Qeh/nXTeIfA91o+kQait5aXlvKcL5BOT9M9a523sp3YEIdufSnUSjpLQdDGUcVTcqcrrY7uwkWSDjk9c1pRkBeFBrH0fBhCr1Uc8VfR+MtkHpj0rxXozwa0VzNIsgFoxxhvemFfpSF1UDJwMelNMuWAXIX1pXV7GKT6C+ayvtXjjpmnrJu+ZTgE80FV35HLevtUiKAVGeKE3sDsNAznp708bdvGRjvTiAQeMilUgLjPJq0iGyMDcBkfhTthC4GMUtx8oXFOAygI4FK1noK/UrsoOcZNRj/WbSankZVJ7ntUbZADDj8KhxWxonoMmjMhGQOPelRDGRyeBQmVYbSePWpshmPHIHJxSSvqDb2JY0461JGQPTNV0Jz3P0qeNc53da1izKSFLEtxnOfwpwB25IwetImMnsBUoVW6DpVxVzNs85+IZb+17bJ/5dh/6G9FP+JGBrVsCD/x7L/6G9FfVYJfuIeh5VV++zv8ARERfDGnB/vNaREH/AIAKau4HCtkdKb4fVrjRtNxk7bSIf+OCrdxbrFKhU59R718ziFzTk1smdtBqMUnuQZYHBHFI6ggHJqZvujjP1qthi/y9K52dC1HEZYADj1p8K/gO/vTWbCgqAPWmLkDDcDFINWiQtt+TtUajdJgcY708KXb5ASO57CmSLsIAwSaGrjVtiFwQxyTT+gAPGeaiU4ds9P51qXD2tzp0bQwmOdPlfnOfeqpwUk3cdSXI0rbmZIqiUFcBe9TeYFiwvHfFQKvOG6n9angTccNgClBa6FySSI0GV3TY5qZFUR44z24p9+kaoNhwBjrTkiACknJx+lbRTi7GXPdXMbxBA0kZYnoOleeX6FJTmvXLiIOuNgIIxzXnniq08idiAB3wPStKL5J27ntZTiNfZnOHFNIyKUn0pO/HJrvR74bS2AOhr0nwz4al0bQm1q8szLqEi4s4GHCZ/jIqH4V+F4dRuG1TU9q2FsflD9Hb/CrfxK8cLeSHTdHYC2j+V5VH3j6D2qZ6x0ep81j8XVxeJWBwyulrN9PS5hzamNEuJrmWf7Zrsq48zOUt8+nq1Y+kalqQimsrWQGG4kWWcMM7iD3Pp7VkRI0sqqMl2OOT1rv9F0dbO1AOC7D5jWM5+yWm7OyvSo4aDU/ek/u029LdCWFbm7fz7qYvKqbFUjCovoB2qQW6KdoUAHoanlGxCEGDjGRRa+YeTnHauCUnJ+9qzzE7K8dEOt1W3GxFAz1zSONowQST1xUsobbkZNIj7SCw47jrUvTQzv1ApG9tGZSrFz0zTXVd2O9K6jaSowc+mKVPlJ3YPHWpbu7gtBQTgkdQOlKpB55AHvSAB+f61G5AOB9M0PQErllG461IvXJxVeInYGGMU4Sc9PypqVkQ0Okk+YgjmkyTnccD2pZMNjNNA9O9IFsNYnJGAcUshCJvOSOOlPHIxgkU2QjZkggDnFNLQd2JtJGRzQgK596Fk+oJqWMA9MZ9qIq4NtDIhk+1WY8EDrmkIGc05eM4/OtVEyk7iFvmYHmkEhUnrS4wd3UUKoxnHWnr0FoeffEWQtrNsf8Ap2X/ANDeij4ix/8AE5tsdPsy/wDob0V9Tgk/YQ9Dy6vLzs9E0WQpoOlpGdubOHJHX7i1M4IIOc1R0ORRoemYP/LpD/6AKtck53ZFfM15XqS9X+Z10YWin5DZM+tNHzZAz+FKTz7UE+h/SsbnQHyIMN0qNwG+vpTiCw/2emaQsFByPypNjRJbyPEcKy/MOciq8zDeVDDjnimEkDHzYx1pUXL57VDlfQagk+YjWIhzzV1X8uFlUcHrnuac2DAV4BHtzVcIfL6tgcYrRrl2E3z7kYKl9x6g8cdKmhb95z25OKI4wQM8ZqxLHGEUocHFOC0CUlsRSRkneclPU07G7aPuqO1Tq3mREHtUDhuCFwo4xVWs7mabejEuZ1t0JBHIrzjxJeNdXLljnHArtdTlhgmhE4Yx5ycVheJ9Ms5rZLvT2bLtho9vT3zVU5/vLvY9XLpwpVE5LfqcO3P1oHHWnyLsYqeoNLBC88ojQAMRnk9K9G+lz6ZvlVzfvvE1wdCtdKsWMVrGvz7eC59656MNI4CjLMePrT7q2ktZvLm4bqD2IPcVb0BVbVLZXI2lxUJKEbxOanTpUKblSXd/M6PQtBnf7P5iIPKO48cn611/kMirnqOoq1albfcQORRO2/Jrlav7z3Pla2KnWnrsUnhywOOPrTyojXb0PamGXZJGuPvnA4qxLzgnqOPpWS6kOT2KrMwOcZHTpUEjBf7pP16VZkU+W+F3EDI55rE+xTvIpbci5+YZ5rCbZtTUZat2NRTvUN1ApcE7vl4HtUjLhRgDgAUwZBYgn0x2od7CT0IIp0LMoBOB1ph5fJ6VIzKpyRUKyZbAx+IrNuys2apdUW1ICAA8elMHI6EAHqTSjaFHP6VKo/dAAhsc1UdjPYYuSOfwp23HXpRjgHGMc8VIGwuBVJIlsRFy2fwNVbmURHnoD+VWQSDkD2qK4iEq7SMjqTRLVaDjvqJEPMjDjnPSpVBRuDwait1aJCqdB0FTKCw54+goigkSK2DwaElZSFA/GonbDqvpVgx/IGz+ArSL6EOy3JPv9acVwOMYxTYuwpZCV78VojJ72PPPiLn+2LX/AK9l/wDQ3oo+IrD+2LXA/wCXVf8A0N6K+pwf8CHoeVVXvs7bRU/4kumjBB+yQn/xwVbYFZOTlQOlV9EY/wBjabuI/wCPOH/0WKsHJPTI6V8tW0qS9X+Z6NG/Ir9hCF2ZyKTJ7DC/nmgqysGPT0qQOpAHHWsUrmjI2IHTrUbMQMg55q5JFGUUKcknJPpVdwvmbcE03GwRkmQSnc44H4GpowDg0LAqkjvnPNSuAiZzk+1JR6luXRDGIHfPrSrnAUDj1pijcOauR7VGH6VpGNyJOwxEwvX6U5oSU27gfXFO2jP7s1YWDEeeCa0UeljGU+pTVQjLtH41eWKMoOMk9aqy/MQvQg1ZVJlVMY59a0ho9iZyvYhubGGSQK6gx/SpZbO1ktJINoCEYUYpkcreaN67lB5BrF1nWoVkmFudvYkHoalyjBXtuOnTq1ZKEXsec+IrYWuoSIhBAY07wmkU2v28Nx/q58xn2yMVV1i5+03TPyeaf4fie51yzSMhD5incTgAA9a6Ev3Xvdj7SrFrDNSetv0Oj+JWkPpMmlwyjLi32FsYzg1zOiuE1GBhjIYda9T+IcFn4ss1n0S4Fze2OUkhHVl7kfTFeQLlWGchgfoatRjy8sWcOTVnXwnJP4ldO/z6fM9njEbxfKQ2RnGaWTqo4z2rhPDpube9j8m7ExYjMYyeK7y5ikdlYHafcVyvZpHjYih7Cpy3uPtIldWZxyORTpEUSHketLFkIR0x1rnPEWqNaqI4+JHPFS/cWi3MaVOdWpyxNOeeOKQ/MOnIqONvNjEgJw3qK5RPtIkVpg/z/wAQ5zXUxBzBDkc46HsK5tea2511aCpW1uSsoMYJb5hxVG+lWK3LtnAP51pIg2n5gfpVchJN0bKCPpTktjKnKzOYk1MySiNOvsK00JZExgZ7mrY06ANvEYzSTwbFHl1jUj2R2Tq05WUVYTcSpU9/QdKdCzEFR+BqeGEhAW61KY1UEqPrSjB7s53UjsNRSqjfSYzwpOetJIz8HOQOtPDdCB09+taK2xD2HbGCH5c0jIcdz9aQN79+lTA7kGRVKzI1QyNMp0xSP8jED0p4POB0qnqkjrZSeUPm7U5NJDinKSREJ0e6wDk1fic5A/hrz/RNQlXU3S4JyTjk9K7y1PmKOASKbpunPlZ1YvDujuXSFxkdSKgcnYcHmnx8scscYxtI6UpC5GOnNaWujgTseZfECRzrEGe1uB/481FXPiKgGsW2B/y7L/6G9FfT4JP6vD0POqzjzvQ7PQxnRNPzkf6LD/6AK0du0Absj1rL0JW/sbTskgG1h7/9MxWiqkknPPqa+ZqfHLTqdtP4V/XRD++WHPvQFVm6daGB7fSgjy2wRz61KLFyuBt6UwZJ5xS7gxO0EUqncTnjFC1BaIacFjzg+tNCE4LZ47etOJUHPFSNwu8nA9KOW4XsNQArz68cU9izAAgYNCAKNz9etNWUNMwyFAH600rbkvXUlRSu0jirUcihx7jrVUTEhQQcdKnt4w7EjrWsLJ6GU1pdkgjWSUuQAAeKsTuUwOMY6mo4hggEEZPHFPMe49mPetuVbdznb11Oa1jUJoNwgXhuC/auVvYS1o7dWbqfeum8UWM7ypLE3yA4KiqP2ONtNVmnUyOcGLuK4aikpvyPdwtSFKCkup5xNw2PQ88Vo+GHtxrUCXpIglPlswPQHjNJrdmbeZjg4rKGV5B6da9GLVSHqfSyiq9Kye6O48MaVcaV43miuLhoLW0VpJZVOAYwOOffiuT1WaK51O4mt02QvIxQegJrU1nT9UstHsb68mBt75cKA5LYHTNYABz+NNRkneRx4Onzzdfn5nZR08tzrPh44i1fLDPBHSvULkfulx1Nch4FtUh0ndJF++ZtxJ9K6ydGEKug5Has43fM7Hz2aVVVxLkumhCI9qDnJJrjvG9lNdTW62sTO5OPl611+nx3VzbyTXSiJAxVQOpqdUEbbtoJxwSKzUb2kYUMS6FTnWrRg6Dp8ttZJ9pQlwOjc4q7KmAStSPdPErGfGD0Iqv9qikGEbPPOKwcoxVnuXec25tFLUIbhoALYgN3zxUlnbvAMSPvY8k1ccg4weDSKi+YpJIHoKhRV9ClUajYCDvwegprxlpMDp6EVacIGPPJphxgNnvmm423IUiu7LEQnJ9hTd3mdM4z1pb2PkNxzzwabygA7elZNO5cbNXH7V2kEZ9hTSoLYHFSYULnJzTDjdjNV0GhMBeTz9KmJ+TpknoKjbjGDTyflGRk9qEKRHJxhsYqGXD5XkjuKnmJKnv7VCdoG4Z4qepUWcZ4nsktZ0u4AQR1rQ8PeIYtqrKQH96n8SxiTT5OM8V5/HlZEIJ6110YKrCzeqPdoUliqHLPdHryT+Zh1OM81YVs8Hk1laYrNZQtuzla1oeRhhisYX6nhVYqLsee/EU51m2xnAth/wChvRUnxHTGs23PH2Zf/Q3or6vB/wACHoeLVkudnXaIwOkaaQP+XWH8fkFaZbLEjAyOBis3SIyuh6aD/wA+kJH/AHwKtxuc85zmvlqzaqS9WelTjeCa7Fgngeo5zikClmyx60wScfKCeecU9XGwjpSVtmNqwNGFywPFG/C4C5pZOoJ6+3alCjae/pT9Av3IcbmywAIxxUhbJAYfSmiIggnoKeFXeDu6c0WG2ibAAPIz/tVSZSs25e5xVh+SMHkn1p6MGYKcEg5zVcvMyYu2oojaUAgFQDVuA7OO3rUbSopKgdR1qOIsZc9VrWKUdjJ3kjSdQy5U4/Gq8cqx7/MYdfWgs6RMSR1rMmhaVizgkHjFaSlrojOFNS0bNZAlwS3ykVR1TSobiLdF8ko7irtra4tlRBjFTEukfKqwX071rycy95EKo6crwex5v4k0xwoWQDLDg4rhbiJopGUjBHFe3arax3kJ3AAdee1eWeKLbybjjGenFYU17KXL0Z9ZlOMdVcj3IdIhudevrPT5rlhGoITcchAB2FQ6tp4066XZJ50JJ2NjGcVRtbiS2mSWGRo5V5DDjFT3V9JfTq95ISq+grVxlzXWx6Xs5xqXi/ctt5npHhPXra7t0jZlilXgr610wnSVsLIrY9O1eIzoLXy2tpwxYZ+U8iup8D6qBO8FwxJbG0k1m24RutjwsblUVGVem/kehSSPjajcZzUU9wka5llAPcE09CCpKAf4Vz2t6Pe30/mQyhVI5BNRVv0PJowhKVpuyJdQu1uLdo7VWkYHnaM4rKt7G9/1pRwnbPFdNoUR06x8qYBZl4JA+/8AWrLyiRQFww9M1jKimryep0RxLptwgrruZ1skzW4Ew2gnIHepw2dwK7Qo61ZdhhUHJ9fSqlwFw645INS4csdDJS5nqZ51GJpgpfcRxx61cDh+lcrc6RcpOZICcZ6ZrobBpvIVJ1AcY59ayT7O9zsr04QipQdy+3MeCM0wJ5jqvfNTkKQvzcUyE+Xcgjscg1qo6q5x3snYbNHsJUqQw55qCSPBUjvV+9m8+bfIBuA7VAWBQj8qUlG+gQlKyuQbSRxTg3ryaOeecCkQgkbulRsaPUJsEcflTNu5RgHBp88iIcsy7arre27f8tF69qV0nqVFO2iKWrW3m2kkYBy3SvNry2e0utso716hdTqsRYcgdK42azl1bVOYiqA4z0rbC1OST10PXy+q4RalsdToJL6fHnkAdDWxGSeM/iazNGhMKGB8jb0JrYWMAd/qKmGuq7nlYmS53Y8/+IpP9s22c/8AHsO3+29FL8RjjWLUZPFqv/ob0V9Zg/4EPQ8OrfnZ3OjDdoWmMcZ+yQj/AMcFTS444FVtHf8A4kWmYHH2SH/0AVbh+ZiGAx0FfNVbOcvV/mz0KWkEMV1Qhiqk+1KzMXyqgCmyxdSMbu1JC5BIOPc+9ZeTNbdSTna+Qc0+MkL835Us7qwAjzx1quWJYLzknvTejElzImL5JHTOaib5MvjORipo4QhOecipraFGB+0AmM9TVqLk0iXJR1KcascOP5dKR3KS8Y2+laVneWNr50U6koTlT6iszU9juDanKnnd6VE0oxundhTm5Ss42Qt4J/ISTGFPQjrTLa4mjI3AkZwPeovOleFYHcke/SrUERKDLZAOKiN5O6NWuWNpFwuZeQeM0/flwT24qKH9zksPcVAZYvNBdxsPzda7Iu25zct3obSzOq4Bwv0qeSeKC0Esk65zyhrKadSgwwAxxz2rm/EWo5CwJKCCckitJ4j2a7kUsG601FFrW9cRhIsAG09SO1ec65c+dLgHpXSXfiJNP0wW0dnEZmIzITnIrkNXvPttyZRGsYYZwOlY01KclN6n1OWYV0m/dsu99yivHJ7/AK1p6bpE9/Z3FxHhY4iMkmssEBe+K1IprZNAIS4lS+aXmMcKy10zUre6elXnKKShu2ulx76NNAbaScqLaWQIZVOduTXb+M9D0bQoVawDwTIqtFNu3ece9cfLcRSeFbWBLljc+ed0BHbsat6poGrxadby38oKgZSF3+ZRU+05Y8tS2rPMqqVSrB1KnKk2rbXO60C/+2aZA+fnIw31rTjnAk2HnPQmuN8FXtounLHJIElUngnrXUwXMbYZSCB71zqVnZvY8TFUOSpJJaFm6UH6ntSWZji4JG3uajubyMosp+VcHmsC1nn1i8uE0/B8kZYMcceoqXK8/cVzKnScoNy0SOklkTcTwB2NMUeeMryR7Vw2o+IZLW4kti29kO3I9a6Lwvqt2kZhuYNqOu9WYc4pOT3mrI3q4KpSp85qGPa3OKjkQthYlJC9TUF9dlUZk+Y1Not+BZyBkBZx970rPmi58rehi4zjHnsSx4MeM8jqB3pr4PAHPWp0XC5AGCP1qBie/FDVkStWMRTtOTuPrTHJzk59atqnyAqBg9arvFkn69+1KSdtC4y1JbeFHzvICnqaqTpskZVbKDhaswqGUqTg98VG8QQHH1okrxCLtK9zC8SpM1iTDwVHaqPh/Tma1Ek4Jbqc11DIJAUYZFOjtwibUHArNJ25TrjinCl7NFI2iNgdPYVYW3jiXCgZ/lV20hWSbEnAqC9QRzkJkjOBVqmoLmOf2rlLluUElJ1HbxjH51qqwDFQQTjJ9azIID9qL5B9hWmnAzjn1oo+Yq1nax598SB/xObXkf8AHqv/AKG9FJ8SQTrVqR/z6r/6G9FfV4N2oQ9Dx6vxs7PRDnQtMwOPssWf++Fq/wAou4jgd6KK+drL3pM74P3UiFpOScZ706E7wcjn1oorCMnqdEkkhGkVB1yDxTMHOePrRRU3vYdrFmIqwJJNK7kptydvpRRW3QyaVylewqYg7ZyeMmoY0IhHGAO1FFZuK5jeMnyE8YUIS/P1qaBwU5PGaKKd+XYmUboNUuo1hEcbZpr2ME/2SOzk/ey8MD2PeiirU+dvmJlD2dNSi+5Un0yTzZIIroicEjYRx+dcjclhO0coO5WwfrRRWPKkzvy2pKcnGXZP7zD1ty1woB6Csybgj0oor0aK91H01NWghnUfSkOeQTkelFFbFssWk/kXMUxAOxw2COuK7Dx14msNbMM9lC8c/lhHBPA+lFFRKCk02ctXCU6tWNaW8dvmcbE0gYeUzbieMd63ZW1fT7OKe4Qi3f7rZoorGs05Ri1uZYqq4zhGyfMyCTX7p4TEWOCPWs+2vbm2kaS2meORvlLKcEiiitYU4w+FHX7GEbxS0IVmdZRITlwc5PrWxJ4jvJZ0eWQ/Ku0BeMCiinKCkrMU6UJ6yWxrWPiQcq+MkY5re028iljAjPPpRRXnYilGn70TzMZhacIuUUblrdjYFZuc1IxWVvk5zRRSjJySTPn5RSbaJSjwBQwwGHGe9G0N1NFFdFWChNxRzwk5RuKIsdO1NdNy420UVnayGpO5ARjAIxmpkTC5/GiioW5pJ6DGGxSTyDUZXJyT9BRRSsOI+NQCalwo6+lFFWkRJ6nnXxG/5DFr2P2Vf/Q3ooor6XCK9GPoebVXvs//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_35_39474=[""].join("\n");
var outline_f38_35_39474=null;
var title_f38_35_39475="Tuberculosis";
var content_f38_35_39475=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Tuberculosis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/35/39475/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39475/contributors\" id=\"au2397\">",
"       Claire Murphy, RN, MSN, NP-C",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39475/contributors\" id=\"au431\">",
"       John Bernardo, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/35/39475/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39475/contributors\" id=\"se1494\">",
"       C Fordham von Reyn, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/35/39475/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39475/contributors\" id=\"de1811\">",
"       Elinor L Baron, MD, DTMH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/35/39475?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      TUBERCULOSIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Tuberculosis (TB) is a disease caused by the bacteria Mycobacterium tuberculosis. It most commonly affects the lungs, although it can affect other parts of the body. Medications are available to treat TB and must be taken as prescribed by your provider. Depending on the medication(s) prescribed, the duration can be from three months to nine months or more.",
"    </p>",
"    <p>",
"     Worldwide, TB remains a leading cause of death. In the United States, TB is on the decline; the number of cases reported in 2010 is the lowest since the 1950s.",
"    </p>",
"    <p>",
"     TB can be fatal if not recognized and treated. However, TB is treatable and preventable. Identifying and treating those who are infected, but who have not yet become ill with active TB, can prevent the spread of TB in the community.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HOW DOES TUBERCULOSIS OCCUR?",
"     </span>",
"    </p>",
"    <p>",
"     The tuberculosis (TB) bacteria are spread through the air from a person who is ill with active TB. The bacteria are contained in small, airborne droplets created by coughing or sneezing. Anyone who inhales these droplets is called a \"contact.\" A contact can be someone you spend a lot of time with, such as a family member, friend, or co-worker.",
"    </p>",
"    <p>",
"     The contact person does not usually develop active TB immediately. In some cases, the person's immune system is able to remove the bacteria and",
"     <span class=\"nowrap\">",
"      he/she",
"     </span>",
"     does not develop the disease.",
"    </p>",
"    <p>",
"     In other cases, the person develops an immune response that controls the bacteria by \"walling it off\" inside the body. This causes the bacteria to become dormant or asleep. The person does not develop active TB or become ill at this time, but is said to have latent TB infection (LTBI). Up to one-third of the world's population is infected with LTBI.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Latent TB",
"     </span>",
"     &nbsp;&mdash;&nbsp;During this latent stage of TB, also called TB infection, the person is well and cannot spread the infection to others. If the person is treated at this stage, active TB can usually be prevented. Treatment is recommended for individuals who are at increased risk for the development of active TB. (See",
"     <a class=\"local\" href=\"#H15\">",
"      'Treatment of latent tuberculosis'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Active TB",
"     </span>",
"     &nbsp;&mdash;&nbsp;Active TB may develop if latent infection is not fully treated. This is called reactivation TB, and it occurs in 5 to 10 percent of people with latent infection.",
"    </p>",
"    <p>",
"     Reactivation TB may occur if the individual's immune system becomes weakened and is no longer able to contain the dormant bacteria. The bacteria then become active and make the person sick with TB. This is called TB disease.",
"    </p>",
"    <p>",
"     The greatest risk for developing reactivation TB disease is within the first two years following the initial infection. Reactivation can also occur in people with HIV, diabetes mellitus, malnutrition, or those who take medications that weaken the immune system, such as steroids or cancer chemotherapy. It can also occur with aging and weakening of the immune system. Reactivation may also occur for other, unknown reasons.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      HOW IS LATENT TUBERCULOSIS DIAGNOSED?",
"     </span>",
"    </p>",
"    <p>",
"     Latent tuberculosis (LTBI) can be diagnosed with a skin test or with a blood test.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Skin testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;The tuberculosis (TB) skin test is known as the tuberculin skin test (sometimes also called a purified protein derivative test [PPD]) and is one method of detecting LTBI. In a person who is newly infected, the skin test usually becomes positive within 4 to 10 weeks after exposure to a person with TB. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=see_link\">",
"      \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     TB skin tests are performed by injecting a small amount of a solution just beneath the surface of the skin, usually on the forearm. The solution contains an inactivated portion of the TB bacteria. Most individuals previously infected with TB develop a skin reaction (a red or swollen bump) at this site.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Reasons for skin testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tuberculin skin tests are performed for persons who are at risk of having LTBI:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If the person is a healthcare or laboratory worker who may be a new employee to a healthcare facility or have contact with patients infected with TB.",
"      </li>",
"      <li>",
"       If the person knows he or she was exposed to someone with active TB. If the first test is negative, a second test usually will be performed 8 to 10 weeks later.",
"      </li>",
"      <li>",
"       If the person requires a medication that may weaken the immune system, such as steroids or some rheumatologic medications.",
"      </li>",
"      <li>",
"       If the person has HIV infection.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Interpreting the results",
"     </span>",
"     &nbsp;&mdash;&nbsp;The skin test should be examined 48 to 72 hours after the solution is injected under the skin. The skin is examined to determine if there is swelling (the size of the bump). The area may also be reddened, but redness should not be measured.",
"    </p>",
"    <p>",
"     A trained healthcare provider (not the patient or a family member) interprets the test as positive or negative based on the size of the bump and criteria for what size of reaction is considered positive in certain patient groups. Anyone who has a bump larger than 15 mm is considered to have a positive test, and some people with a bump that is 5 mm (eg, HIV) or 10 mm (eg, recent immigrant from a region with a high rate of TB) are considered to have a positive test if they are at higher risk for developing TB.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      What does a positive TB skin test mean?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The TB skin test indicates that TB bacteria are in the body. It cannot determine if a person has active TB disease or LTBI. Further testing is needed to determine if the person has active or LTBI. People who have active TB usually have symptoms, such as a cough (usually persisting for several weeks), fevers, night sweats,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     unexplained weight loss. (See",
"     <a class=\"local\" href=\"#H14\">",
"      'Further testing'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Skin testing after a positive test in the past",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anyone who has had a positive reaction to the TB skin test in the past will usually have a positive reaction in the future. Even after taking medication to treat TB, the reaction to the skin test will remain positive. Therefore, anyone who has a positive skin test does not need to have skin testing again. Repeat testing can rarely cause a large and painful skin reaction at the injection site.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      BCG vaccine",
"     </span>",
"     &nbsp;&mdash;&nbsp;A TB vaccine called Bacillus Calmette-Guerin (BCG) is given in many countries to prevent infection with TB. It usually is given to infants, although it may be given again at other times. BCG offers protection against TB in children, but typically does not offer continuing protection until adulthood. BCG is not routinely used to prevent TB in the United States.",
"    </p>",
"    <p>",
"     This vaccine may or may not cause a positive skin test. In the United States, a positive reaction to a TB skin test is interpreted as positive, regardless of prior BCG vaccination. Previous BCG vaccination should NOT stop a person from obtaining a TB skin test unless the person had a positive reaction in the past. (See",
"     <a class=\"local\" href=\"#H10\">",
"      'Skin testing after a positive test in the past'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Two-step skin testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some people, the first TB skin test is falsely negative because the immune system's response to TB has weakened over time. This may occur in people who were exposed to TB many years before. If the first skin test is negative, a second skin test may be done one to two weeks later. Performing the first test may \"boost\" the immune system, allowing it to react if the person was previously exposed to TB.",
"    </p>",
"    <p>",
"     If the person has two negative tests, this is considered a true negative. If the second test is positive, further testing will be done to determine if the person has active or LTBI. (See",
"     <a class=\"local\" href=\"#H14\">",
"      'Further testing'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Two-step testing establishes a baseline in people who will need skin testing at regular intervals in the future (eg, healthcare workers, employees and residents of institutions, such as prisons or nursing homes).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Blood tests for TB",
"     </span>",
"     &nbsp;&mdash;&nbsp;Blood tests known as interferon gamma release assays (IGRAs) are now available in most areas to test for TB infection. The blood test may be offered instead of, or in addition to, the skin test. Blood tests may simplify TB testing because they do not require the person to make a return trip to read the test reaction. In addition, blood test results for LTBI are not affected by prior immunization with BCG vaccine or by prior infection with harmless bacteria from the environment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Further testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;If the TB skin test or blood test is positive, a healthcare provider will ask some specific questions, perform a physical examination, and obtain a chest x-ray to determine if person has active TB, either currently or in the past. In some cases, the person will be referred to a TB specialist for this evaluation.",
"    </p>",
"    <p>",
"     If these tests indicate that the person has active, rather than LTBI, the treatment regimen is different than that of someone with LTBI. (See",
"     <a class=\"local\" href=\"#H19\">",
"      'Active tuberculosis'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      TREATMENT OF LATENT TUBERCULOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Latent tuberculosis infection (LTBI) is treated with a medication or medications to kill the dormant bacteria. Treating LTBI greatly reduces the risk of the infection progressing to active tuberculosis (TB) later in life (ie, it is given to prevent reactivation). (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9432?source=see_link\">",
"      \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     While undergoing treatment for TB (either infection or disease), it is important to avoid drinking alcohol and taking acetaminophen (Tylenol&reg;). Both of these substances can make the liver work harder, potentially increasing the risk of liver injury from the medications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Isoniazid",
"     </span>",
"     &nbsp;&mdash;&nbsp;One of the most commonly used treatments for LTBI is isoniazid (INH). Isoniazid is a pill that is taken once per day for nine months. It is important to take the medicine every day and to finish the entire course of treatment since missing days or discontinuing the medicine early may not prevent active TB.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Rifampin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Another treatment option is a medication called rifampin. Rifampin is taken as two capsules every day for four months. Rifampin interacts with many other medications, such as hormonal birth control methods (skin patch, pills, vaginal ring), blood thinners, certain medications for high blood pressure, and many others. Therefore, it is important to discuss possible drug interactions with a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H65809011\">",
"     <span class=\"h2\">",
"      Rifapentine",
"     </span>",
"     &nbsp;&mdash;&nbsp;A rifampin-like medication, rifapentine, may be prescribed along with INH in some situations. It usually is taken once a week with the INH under direct observation by a trained healthcare worker. Its toxicities and drug interaction properties are similar to those of rifampin.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Monitoring during treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who are being treated for TB should be monitored by a healthcare provider at least once per month to monitor for any signs of medication toxicity, such as liver injury. Signs of liver injury may include: unexplained tiredness, loss of appetite, nausea, vomiting, dark-colored urine, jaundice (yellowing of the skin or the white portion of the eye), fatigue, abdominal pain, or rarely, unexplained bruises. Anyone who experiences one or more of these problems should stop their medication immediately and notify their healthcare provider.",
"    </p>",
"    <p>",
"     In certain special cases, monthly monitoring may also include blood tests to monitor the function of the liver or blood counts.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      ACTIVE TUBERCULOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Active tuberculosis (TB) disease occurs when the TB bacteria become &ldquo;active&rdquo; and cause a person to become ill. This usually occurs in the lung, although TB can affect any part of the body, including the lymph nodes, brain, kidneys, or bones. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"      \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If there is evidence on a chest x-ray or other signs that active pulmonary (lungs) TB is present, sputum cultures will be performed to culture (grow) the bacteria in the laboratory. This usually involves coughing up a \"deep\" specimen of phlegm from the chest. The phlegm is then sent to a laboratory and cultured to determine if TB bacteria are present. Other tests, such as a bronchoscopy or biopsy, may also be needed. A tissue biopsy may be performed to obtain specimens for culture if TB is suspected in other organs (such as lymph nodes or kidney). (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/14/32993?source=see_link\">",
"      \"Patient information: Flexible bronchoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     While waiting for the results of the culture (some results are positive within a day or two, but it may take as long as two months for the bacteria to grow in the laboratory), treatment with several (usually four) TB drugs is usually recommended. It is important to use more than one medicine and to take the medicines exactly as prescribed to reduce the risk of the bacteria becoming resistant to one (or more) of the medicines.",
"    </p>",
"    <p>",
"     Infection caused by a strain of TB that has become resistant to standard TB drugs is more difficult to treat, and may require four to six medications and a longer duration of treatment. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/53/5978?source=see_link\">",
"      \"Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/52/32586?source=see_link\">",
"      \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      TUBERCULOSIS AND PUBLIC HEALTH",
"     </span>",
"    </p>",
"    <p>",
"     Tuberculosis (TB) is a disease that can easily be spread by anyone with active disease. As a result, United States law requires that anyone with active TB must be reported to the health department. Health department staff will work with the patient's healthcare provider and the patient to make sure that a safe and effective treatment regimen is completed.",
"    </p>",
"    <p>",
"     Directly observed therapy (DOT) is a program used by public health departments to ensure that a patient safely takes his or her medication exactly as prescribed. With this program, a health worker watches a person swallow the TB medication every day. DOT may help to improve cure rates. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10341?source=see_link\">",
"      \"Adherence to tuberculosis treatment\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The health department can also help to identify people who have been in contact with a person with active TB. Contacts are advised to have TB testing and treatment, if necessary.",
"    </p>",
"    <p>",
"     Public health programs for TB are essential for several reasons:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       To reduce the number of new cases of TB (by identifying and treating people with LTBI in order to prevent disease from developing)",
"      </li>",
"      <li>",
"       To limit spread of the disease in the community (by monitoring and assuring safe, complete treatment of people with active TB).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498804183\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181962777\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/57/25489?source=see_link\">",
"      Patient information: Tuberculosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/59/43955?source=see_link\">",
"      Patient information: Swollen neck nodes in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/6/31842?source=see_link\">",
"      Patient information: Chronic pulmonary aspergillosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/23/24946?source=see_link\">",
"      Patient information: Multiple pulmonary nodules (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/1/23570?source=see_link\">",
"      Patient information: Single pulmonary nodule (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181962803\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/14/32993?source=see_link\">",
"      Patient information: Flexible bronchoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10341?source=see_link\">",
"      Adherence to tuberculosis treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40136?source=see_link\">",
"      BCG vaccination",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/10/1194?source=see_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39673?source=see_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/52/32586?source=see_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9098?source=see_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18649?source=see_link\">",
"      Epidemiology of tuberculosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4298?source=see_link\">",
"      Treatment of latent tuberculosis infection in HIV-infected patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9432?source=see_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/19002?source=see_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/21/19802?source=see_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/52/20294?source=see_link\">",
"      Tuberculosis transmission and control",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=see_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/53/5978?source=see_link\">",
"      Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37160?source=see_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/tuberculosis.html\">",
"      www.nlm.nih.gov/medlineplus/tuberculosis.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 311-3435",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/tb/\">",
"      www.cdc.gov/tb/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www3.niaid.nih.gov/topics/tuberculosis/\">",
"      www3.niaid.nih.gov/topics/tuberculosis/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/35/39475/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/35/39475?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39475/abstract/1\">",
"      Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000; :CD001363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39475/abstract/2\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603.",
"     </a>",
"    </li>",
"    <li>",
"     American Thoracic Society/Center for Disease Control Statement Committee on Latent Tuberculosis Infection Membership List, June 2000. Targeted testing and treatment of latent TB infection. Available online at www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm. Accessed October 23, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39475/abstract/4\">",
"      Blumberg HM, Leonard MK Jr, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005; 293:2776.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f38_35_39475=[""].join("\n");
var outline_f38_35_39475=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           TUBERCULOSIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HOW DOES TUBERCULOSIS OCCUR?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           HOW IS LATENT TUBERCULOSIS DIAGNOSED?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           TREATMENT OF LATENT TUBERCULOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           ACTIVE TUBERCULOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           TUBERCULOSIS AND PUBLIC HEALTH",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f38_35_39476="CT blastic lytic and mixed metastases";
var content_f38_35_39476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    CT blastic lytic and mixed metastases",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The reconstructed CT&nbsp;images are from three different patients and reflect different patterns of metastatic bone disease. The bone windows of the spine are projected as sagittal reconstructions. The first (A) is a patient with breast carcinoma complicated by blastic metastatic disease of the thoracolumbar spine (white arrow). The second (B) is a patient with multiple myeloma and multiple lytic lesions in the thoracolumbar spine (red arrow). The third (C) is a patient with breast carcinoma with both blastic (white arrow) and lytic (red arrow) disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_35_39476=[""].join("\n");
var outline_f38_35_39476=null;
var title_f38_35_39477="Possible role of low birth weight in the pathogenesis of essential hypertension";
var content_f38_35_39477=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Possible role of low birth weight in the pathogenesis of essential hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39477/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39477/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39477/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39477/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39477/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39477/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/35/39477/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of primary (essential) hypertension remains incompletely understood. Among the factors that have been intensively studied include salt intake, obesity and insulin resistance, the renin-angiotensin system, and the sympathetic nervous system. In the past few years, a number of other factors have been evaluated, including genetics, endothelial dysfunction (as manifested by changes in endothelin and nitric oxide), and low birth weight, frequently accompanying preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although this hypothesis is not universally accepted, the data supporting a role for low birth weight in the development of essential hypertension in adulthood are presented in this topic review. Other factors potentially associated with primary (essential) hypertension are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=see_link\">",
"     \"Salt intake, salt restriction, and essential hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34630?source=see_link\">",
"     \"Obesity and weight reduction in hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36804?source=see_link\">",
"     \"Low-renin essential (primary) hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9159?source=see_link\">",
"     \"Genetic factors in the pathogenesis of essential hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34770?source=see_link\">",
"     \"Neurovascular abnormalities in the pathogenesis of primary (essential) hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIRTH WEIGHT AND BLOOD PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Babies that are small at birth are more likely to have higher blood pressures during adolescence and to be hypertensive as adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/2\">",
"     2",
"    </a>",
"    ]. Small-for-age babies are also more likely to have metabolic abnormalities that have been associated with the later development of hypertension and coronary disease including insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/3\">",
"     3",
"    </a>",
"    ], diabetes mellitus, and hyperlipidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/4\">",
"     4",
"    </a>",
"    ], frequently in association with abdominal (visceral) obesity (eg, the metabolic syndrome).",
"   </p>",
"   <p>",
"    The effect of low birth weight upon adult blood pressure was first described in 1988 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/5\">",
"     5",
"    </a>",
"    ]. The relationship was confirmed in both men and women using data from the Nurses' Health Study and the Health Professionals Follow-up Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Multiple surveys of children also show a relation between birth weight and blood pressure, but of a lesser degree than in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/8\">",
"     8",
"    </a>",
"    ]. An analysis of data from four populations across the entire life span demonstrated that for every one-kilogram higher birth weight, systolic blood pressure was 5.2 mmHg lower at ages 64 to 71, but only 1 to 3 mmHg lower in adolescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/9\">",
"     9",
"    </a>",
"    ]. The relationship with adult blood pressure may be even more attenuated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental support for maternal undernutrition causing fetal growth restriction and adult hypertension (and possibly nephrosclerosis) has been provided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The offspring of female rats given a low protein diet during pregnancy were smaller and developed higher blood pressures than controls as they matured, even though they were fed a normal diet after birth.",
"   </p>",
"   <p>",
"    The blood pressure in children is more closely correlated to the blood pressure in the mother than the father [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/8\">",
"     8",
"    </a>",
"    ]. Although this may in part relate to X-linked genes, the prenatal environment is also strongly related to the mother. Furthermore, higher blood pressure in the mother partly reflects her own fetal experience, which in turn influences the intrauterine environment that she provides for her children, thereby creating a vicious cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the above findings, which provided an estimate that a one-kilogram higher birthweight is associated with a 5.2 mmHg lower systolic blood pressure in adult life, a systematic review of 55 studies suggests a much less impressive association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/12\">",
"     12",
"    </a>",
"    ]. After appropriate statistical adjustments, the estimate was a 0.6 mmHg lower blood pressure per one kg higher birthweight. The authors conclude, \"Claims of a strong inverse association between birthweight and subsequent blood pressure may chiefly reflect the impact of random error, selective emphasis of particular results, and inappropriate adjustment for current weight and for confounding factors. These findings suggest that birthweight is of little relevance to blood pressure levels in later life.\" Support for this conclusion comes from a large cohort study in which higher newborn and maternal weight were stronger predictors of adult blood pressure than low birthweight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the association is less clear among African-Americans. The few studies that directly compared the relationship in this group between birth weight and, subsequently, the development of hypertension have reported conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, only a limited number of individuals have thus far been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Possible mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of hypotheses have been proposed to explain the possible association between low birth weight and subsequent hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. The most logical hypothesis that is well supported by both experimental and clinical evidence is \"congenital oligonephropathy\", which suggests that impaired intrauterine growth leads to impaired renal development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The decrease in the number of nephrons results in compensatory hypertrophy in the nephrons present; the associated intraglomerular hypertension can then lead over a period of years to glomerular sclerosis and the development of hypertension similar to that seen with nephron loss in chronic renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Experimental support for this hypothesis includes the observations that the rats with induced intrauterine growth retardation have offspring with markedly fewer nephrons, and these rats develop progressive glomerular sclerosis as adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/23\">",
"     23",
"    </a>",
"    ]. The kidneys of low birth weight human infants have also been shown to be small with reduced numbers of glomeruli, a finding that may increase the risk of developing renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The most direct confirmation is the finding that white hypertensive patients had significantly fewer glomeruli per kidney than matched normotensive controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the association between low nephron number and the development of hypertension may not exist for African Americans. An autopsy study of 62 African American and 60 white subjects showed that, whereas the average number of glomeruli was lower for white hypertensive compared to white normotensive subjects, there was no difference in the number of glomeruli between African American hypertensive and African American normotensive subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/14\">",
"     14",
"    </a>",
"    ]. The conclusive determination of an association between nephron number and hypertension will ultimately require large prospective studies using optimal radiographic techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRETERM BIRTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prematurity may also increase the risk of hypertension via decreased glomerulogenesis independent of birth weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. A meta-analysis of 10 studies including 3083 individuals from eight countries reported the association of prematurity with adolescent or adult blood pressure (measured at an average age of 18 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/28\">",
"     28",
"    </a>",
"    ]. Those who were born premature had modestly but significantly higher systolic blood pressures (by 2.5 mmHg), regardless of weight. After restricting to the five highest quality studies, the average difference in systolic blood pressure was more pronounced (3.8 mmHg higher among those born premature).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     POSTNATAL WEIGHT GAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the evidence supporting a role of low birth weight in adult hypertension, its contribution may be quantitatively small. The rapid postnatal \"catch-up\" in body weight that such infants typically undergo may contribute to a greater extent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that overfeeding during the first few weeks after birth programs the infant for later obesity, insulin resistance, and endothelial dysfunction, which, in turn may result in diabetes, hypertension, and coronary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Observations regarding the beneficial effects of breast feeding on subsequent blood pressure lend further support to this hypothesis, since breast milk usually results in slower early growth due to its lower caloric content and lower initial volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/34\">",
"     34",
"    </a>",
"    ]. It is also possible that postnatal weight gain could affect adult blood pressure via other mechanisms, since a significant association between weight gain velocity in the early years and blood pressure in young adulthood has been described that is independent of adult adiposity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39477/abstract/33,35-37\">",
"     33,35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low birth weight as well as prematurity independent of birth weight may contribute to the development of primary (essential) hypertension in adulthood. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Birth weight and blood pressure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Preterm birth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A leading hypothesis to explain this is that impaired renal development results in compensatory hypertrophy and intraglomerular hypertension, which lead to glomerular sclerosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Possible mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The contribution of low birth weight may be quantitatively small and it is possible that the rapid postnatal \"catch-up\" in body weight contributes to a greater extent. A possible mechanism is that overfeeding during the first few weeks after birth may program the infant for later obesity, insulin resistance, and endothelial dysfunction causing diabetes, hypertension, and coronary disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Postnatal weight gain'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/1\">",
"      Ferreira I, Peeters LL, Stehouwer CD. Preeclampsia and increased blood pressure in the offspring: meta-analysis and critical review of the evidence. J Hypertens 2009; 27:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/2\">",
"      Davies AA, Smith GD, May MT, Ben-Shlomo Y. Association between birth weight and blood pressure is robust, amplifies with age, and may be underestimated. Hypertension 2006; 48:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/3\">",
"      Phillips DI, Barker DJ, Hales CN, et al. Thinness at birth and insulin resistance in adult life. Diabetologia 1994; 37:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/4\">",
"      Barker DJ, Hales CN, Fall CH, et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993; 36:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/5\">",
"      Gennser G, Rymark P, Isberg PE. Low birth weight and risk of high blood pressure in adulthood. Br Med J (Clin Res Ed) 1988; 296:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/6\">",
"      Curhan GC, Chertow GM, Willett WC, et al. Birth weight and adult hypertension and obesity in women. Circulation 1996; 94:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/7\">",
"      Curhan GC, Willett WC, Rimm EB, et al. Birth weight and adult hypertension, diabetes mellitus, and obesity in US men. Circulation 1996; 94:3246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/8\">",
"      Law CM, Shiell AW. Is blood pressure inversely related to birth weight? The strength of evidence from a systematic review of the literature. J Hypertens 1996; 14:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/9\">",
"      Law CM, de Swiet M, Osmond C, et al. Initiation of hypertension in utero and its amplification throughout life. BMJ 1993; 306:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/10\">",
"      Regina S, Lucas R, Miraglia SM, et al. Intrauterine food restriction as a determinant of nephrosclerosis. Am J Kidney Dis 2001; 37:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/11\">",
"      &Oslash;glaend B, Forman MR, Romundstad PR, et al. Blood pressure in early adolescence in the offspring of preeclamptic and normotensive pregnancies. J Hypertens 2009; 27:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/12\">",
"      Huxley R, Neil A, Collins R. Unravelling the fetal origins hypothesis: is there really an inverse association between birthweight and subsequent blood pressure? Lancet 2002; 360:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/13\">",
"      Filler G, Yasin A, Kesarwani P, et al. Big mother or small baby: which predicts hypertension? J Clin Hypertens (Greenwich) 2011; 13:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/14\">",
"      Hughson MD, Douglas-Denton R, Bertram JF, Hoy WE. Hypertension, glomerular number, and birth weight in African Americans and white subjects in the southeastern United States. Kidney Int 2006; 69:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/15\">",
"      Hemachandra AH, Klebanoff MA, Furth SL. Racial disparities in the association between birth weight in the term infant and blood pressure at age 7 years: results from the collaborative perinatal project. J Am Soc Nephrol 2006; 17:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/16\">",
"      Langley-Evans SC. Hypertension induced by foetal exposure to a maternal low-protein diet, in the rat, is prevented by pharmacological blockade of maternal glucocorticoid synthesis. J Hypertens 1997; 15:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/17\">",
"      IJzerman RG, Stehouwer CD, de Geus EJ, et al. Low birth weight is associated with increased sympathetic activity: dependence on genetic factors. Circulation 2003; 108:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/18\">",
"      Hoy WE, Hughson MD, Bertram JF, et al. Nephron number, hypertension, renal disease, and renal failure. J Am Soc Nephrol 2005; 16:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/19\">",
"      Samuel T, Hoy WE, Douglas-Denton R, et al. Determinants of glomerular volume in different cortical zones of the human kidney. J Am Soc Nephrol 2005; 16:3102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/20\">",
"      Bergvall N, Iliadou A, Johansson S, et al. Genetic and shared environmental factors do not confound the association between birth weight and hypertension: a study among Swedish twins. Circulation 2007; 115:2931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/21\">",
"      Lopes AA, Port FK. The low birth weight hypothesis as a plausible explanation for the black/white differences in hypertension, non-insulin-dependent diabetes, and end-stage renal disease. Am J Kidney Dis 1995; 25:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/22\">",
"      Eriksson J, Fors&eacute;n T, Tuomilehto J, et al. Fetal and childhood growth and hypertension in adult life. Hypertension 2000; 36:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/23\">",
"      Schreuder MF, Nyengaard JR, Fodor M, et al. Glomerular number and function are influenced by spontaneous and induced low birth weight in rats. J Am Soc Nephrol 2005; 16:2913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/24\">",
"      Hughson M, Farris AB 3rd, Douglas-Denton R, et al. Glomerular number and size in autopsy kidneys: the relationship to birth weight. Kidney Int 2003; 63:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/25\">",
"      Schmidt IM, Chellakooty M, Boisen KA, et al. Impaired kidney growth in low-birth-weight children: distinct effects of maturity and weight for gestational age. Kidney Int 2005; 68:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/26\">",
"      Keller G, Zimmer G, Mall G, et al. Nephron number in patients with primary hypertension. N Engl J Med 2003; 348:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/27\">",
"      Schreuder MF, Nauta J. Prenatal programming of nephron number and blood pressure. Kidney Int 2007; 72:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/28\">",
"      de Jong F, Monuteaux MC, van Elburg RM, et al. Systematic review and meta-analysis of preterm birth and later systolic blood pressure. Hypertension 2012; 59:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/29\">",
"      Keijzer-Veen MG, Kleinveld HA, Lequin MH, et al. Renal function and size at young adult age after intrauterine growth restriction and very premature birth. Am J Kidney Dis 2007; 50:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/30\">",
"      Hughson MD. Low birth weight and kidney function: is there a relationship and is it determined by the intrauterine environment? Am J Kidney Dis 2007; 50:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/31\">",
"      Singhal A, Lucas A. Early origins of cardiovascular disease: is there a unifying hypothesis? Lancet 2004; 363:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/32\">",
"      Stettler N, Stallings VA, Troxel AB, et al. Weight gain in the first week of life and overweight in adulthood: a cohort study of European American subjects fed infant formula. Circulation 2005; 111:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/33\">",
"      Ben-Shlomo Y, McCarthy A, Hughes R, et al. Immediate postnatal growth is associated with blood pressure in young adulthood: the Barry Caerphilly Growth Study. Hypertension 2008; 52:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/34\">",
"      Martin RM, Ness AR, Gunnell D, et al. Does breast-feeding in infancy lower blood pressure in childhood? The Avon Longitudinal Study of Parents and Children (ALSPAC). Circulation 2004; 109:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/35\">",
"      Vohr BR, Allan W, Katz KH, et al. Early predictors of hypertension in prematurely born adolescents. Acta Paediatr 2010; 99:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/36\">",
"      Thiering E, Br&uuml;ske I, Kratzsch J, et al. Peak growth velocity in infancy is positively associated with blood pressure in school-aged children. J Hypertens 2012; 30:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39477/abstract/37\">",
"      Jones A, Charakida M, Falaschetti E, et al. Adipose and height growth through childhood and blood pressure status in a large prospective cohort study. Hypertension 2012; 59:919.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3853 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_35_39477=[""].join("\n");
var outline_f38_35_39477=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIRTH WEIGHT AND BLOOD PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Possible mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRETERM BIRTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      POSTNATAL WEIGHT GAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9159?source=related_link\">",
"      Genetic factors in the pathogenesis of essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36804?source=related_link\">",
"      Low-renin essential (primary) hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34770?source=related_link\">",
"      Neurovascular abnormalities in the pathogenesis of primary (essential) hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34630?source=related_link\">",
"      Obesity and weight reduction in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=related_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_35_39478="Medical management of cyanotic congenital heart disease in adults";
var content_f38_35_39478=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical management of cyanotic congenital heart disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39478/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39478/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39478/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39478/contributors\">",
"     Thomas P Graham, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39478/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39478/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39478/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/35/39478/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Centers specialized in the management of adult patients with congenital heart disease provide the optimal combination of clinical expertise, facilities for advanced diagnosis and therapy, structured care, and access to new and evolving therapies. The 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    adult congenital heart disease guidelines recommended that all adults with congenital heart disease of moderate or great complexity (including those with cyanotic heart disease) should undergo initial evaluation and longitudinal coordination of care by such a specialized center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cyanosis is caused by right to left intracardiac or extracardiac shunts. In adults, the most common causes of cyanotic congenital heart disease are Eisenmenger syndrome and tetralogy of Fallot. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6007?source=see_link\">",
"     \"Evaluation and prognosis of Eisenmenger syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13752?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medical management of adult patients with cyanotic congenital heart disease is discussed here. Management of Eisenmenger syndrome patients includes following recommendations pertinent to all patients to cyanotic heart disease as well as other recommendations specific to Eisenmenger syndrome. These later recommendations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=see_link\">",
"     \"Medical management of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF CYANOTIC CONGENITAL HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult patients with cyanotic heart disease should be seen at least annually by an adult congenital heart disease specialist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Endocarditis prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 AHA guidelines on the prevention of infective endocarditis recommend antimicrobial prophylaxis for all patients with unrepaired cyanotic congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Erythrocytosis and anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cyanosis develop secondary erythrocytosis. This is a physiologic response, since the cyanotic blood simulates the bone marrow to produce more red blood cells in an attempt to improve tissue oxygenation. Stable erythrocytosis and a new equilibrium are usually established at an appropriate level.",
"   </p>",
"   <p>",
"    In some patients, however, hematopoiesis increases dramatically and the hemoglobin rises to over 20",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    with an hematocrit of more than 65 percent. Symptoms of hyperviscosity may develop, such as headache, loss of concentration, muscle weakness, and fatigue. Volume depletion can cause identical symptoms and must be excluded.",
"   </p>",
"   <p>",
"    The treatment for symptomatic hyperviscosity is the lowering of red blood cell mass via phlebotomy, which should be carried out slowly with simultaneous infusion of isovolumic fluid (",
"    <a class=\"graphic graphic_algorithm graphicRef62212 \" href=\"mobipreview.htm?30/35/31294\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/3\">",
"     3",
"    </a>",
"    ]. Frequent phlebotomies and iron deficiency anemia should be avoided, since rebound erythropoiesis can occur, with production of iron deficient red blood cells (microspherocytes). Microspherocytes have reduced oxygen carrying capacity as well as increased rigidity and fragility. As a result, there is an",
"    <strong>",
"     increase",
"    </strong>",
"    in whole blood viscosity (with the associated symptoms noted above) as well as possible symptoms of iron deficiency anemia (weakness, headache, irritability, and varying degrees of fatigue and exercise intolerance).",
"   </p>",
"   <p>",
"    There is debate about a potential increase in risk of cerebrovascular events in patients with rebound erythropoiesis and microspherocytosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 162 patients with cyanotic congenital heart disease were retrospectively evaluated for any well-documented cerebrovascular events that occurred at &ge;18 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/4\">",
"       4",
"      </a>",
"      ]. Events related to procedures, endocarditis, or brain abscess were excluded. Twenty-two patients (13.6 percent) had 29 cerebrovascular events (a rate of about 1 percent per year). Patients who had a cerebrovascular event had a significantly increased tendency to develop hypertension, atrial fibrillation, microcytosis (mean corpuscular volume &lt;82), and a history of phlebotomy. Even when patients with hypertension or atrial fibrillation were excluded, there was an increased risk of cerebrovascular events associated with microcytosis.",
"     </li>",
"     <li>",
"      In another report, 112 patients with cyanotic congenital heart disease followed for almost seven years were divided into two groups: those with \"compensated\" erythrocytosis (stable hematocrit of 46 to 73 percent, iron replete, and absent or mild viscosity symptoms), and those with \"decompensated\" erythrocytosis (unstable rising hematocrit of 62 to 75 percent, iron deficiency, and marked to severe hyperviscosity symptoms) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/5\">",
"       5",
"      </a>",
"      ]. No patient in either group suffered a stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these reports differed with respect to the implications of microspherocytosis, they both concluded that phlebotomy in patients with Eisenmenger syndrome and secondary erythrocytosis should be conservative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Guidelines and recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rather than solely using a target hematocrit, phlebotomy should be performed only in patients with intrusive symptoms of hyperviscosity, and then only with caution in the setting of iron deficiency. Some experts also recommend preoperative phlebotomy to improve hemostasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2008",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines recommend therapeutic phlebotomy for hemoglobin greater than 20",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      and hematocrit &gt;65 percent, associated with headache, increasing fatigue, or other symptoms of hyperviscosity in the absence of dehydration or anemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Repeated routine phlebotomies are",
"      <strong>",
"       not",
"      </strong>",
"      recommended because of the risk of iron depletion, decreased oxygen-carrying capacity, and stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptomatic anemia can occur in cyanotic patients and is most often due to iron deficiency resulting from rebound erythrocytosis or bleeding. The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend avoidance of iron deficiency in patients with cyanotic heart disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Eisenmenger syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/1\">",
"     1",
"    </a>",
"    ]. The treatment of iron deficiency is iron therapy which should be administered with care since iron supplementation may lead to rapid increases in red cell mass. Although there are no specific data regarding timing, we recommend that iron supplementation be instituted when the mean corpuscular volume is less than 82, since microspherocytes may increase the cerebrovascular risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/4\">",
"     4",
"    </a>",
"    ]. Iron should be discontinued when the hematocrit begins to rise, usually within 7 to 10 days. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25578?source=see_link\">",
"     \"Treatment of anemia due to iron deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hemostasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanotic patients have an increased risk of hemorrhage due to a number of hemostatic abnormalities documented in up to 20 percent of patients; these include elevations in the prothrombin and partial thromboplastin times, reduced coagulation factors, thrombocytopenia, and abnormal platelet function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. The extent to which these abnormalities contribute to clinical bleeding risk is uncertain. However, pulmonary bleeding and menorrhagia are common. Thus, while patients with Eisenmenger syndrome also have an increased risk of thrombotic complications, we recommend that anticoagulants and antiplatelet drugs should generally be",
"    <strong>",
"     avoided",
"    </strong>",
"    in these patients unless clear indications arise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pulmonary bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoptysis is external bleeding and does not reflect the extent of intrapulmonary hemorrhage, which is a serious and life-threatening problem for Eisenmenger and other cyanotic patients and can reflect rupture of the pulmonary trunk or a bronchial artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Bronchoscopy is associated with significant risk and rarely discloses the cause of hemoptysis; as a result, this procedure should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/12\">",
"     12",
"    </a>",
"    ]. Pulmonary computed tomographic angiography should be performed to determine the presence and extent of intrapulmonary hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/24/14727?source=see_link\">",
"     \"Etiology and evaluation of hemoptysis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29558?source=see_link\">",
"     \"Overview of massive hemoptysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines note that anticoagulation is contraindicated in patients with active or chronic hemoptysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Menorrhagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menorrhagia is a common problem in women with cyanotic heart disease and, if severe, can lead to iron deficiency anemia. Suppression of menorrhagia with hormonal stimulation is often helpful; however, hysterectomy is occasionally required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20122?source=see_link\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted, we do",
"    <strong>",
"     NOT",
"    </strong>",
"    recommend routine anticoagulation for patients with cyanotic heart disease. Exceptions to this rule include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atrial fibrillation",
"     </li>",
"     <li>",
"      Documented pulmonary thrombosis or embolism",
"     </li>",
"     <li>",
"      Transient ischemic attack or stroke without evidence of microcytosis or other identifiable and treatable cause",
"     </li>",
"     <li>",
"      Deep venous thrombosis",
"     </li>",
"     <li>",
"      Placement of an indwelling device (such as a permanent pacemaker) in the right side of the heart. However, such devices should be avoided in patients with congenital heart disease related pulmonary hypertension with persistent intravascular shunting and other patients with cyanotic heart disease. In the presence of such devices, anticoagulation may not protect against thromboembolic complications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=see_link&amp;anchor=H12#H12\">",
"       \"Medical management of Eisenmenger syndrome\", section on 'Endocardial pacing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanotic patients are subject to a number of other problems:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hyperuricemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with cyanotic congenital heart diseases, the serum uric acid rises in proportion to the degree of hypoxemia and hemodynamic deterioration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Hyperuricemia can lead to gout but rarely to renal failure, since the hyperuricemia is primarily due to reduced excretion rather than increased production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27541?source=see_link\">",
"     \"Uric acid renal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy is not necessary in asymptomatic patients. Among patients who develop gout,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    is preferred; nonsteroidal antiinflammatory drugs should be avoided because they interfere with platelet function and hemostasis and may impair renal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1416?source=see_link\">",
"     \"Asymptomatic hyperuricemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36266?source=see_link\">",
"     \"Prevention of recurrent gout\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H14\">",
"     'Renal dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pigment gallstones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased red blood cell turnover and subsequent production of unconjugated bilirubin can result in pigment (calcium bilirubinate) gallstones. The major risk of cholelithiasis is the development of acute cholecystitis with the need for emergency surgery. Surgery is not recommended until patients become symptomatic (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15511?source=see_link\">",
"     \"Treatment of acute cholecystitis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Orthopedic problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthopedic problems, such as scoliosis, are present in approximately 25 to 30 percent of patients with congenital heart disease. The etiology of scoliosis is unknown but can be disabling, can contribute to cyanosis and functional incapacity due to pulmonary restriction, and may require consideration of high-risk surgical intervention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=see_link&amp;anchor=H22#H22\">",
"     \"Diseases of the chest wall\", section on 'Kyphoscoliosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertrophic osteoarthropathy occurs in patients with cyanotic congenital heart disease (as well as in patients with a variety of other disorders and as a primary condition). Periostitis associated with this condition may cause aching and tenderness, especially in the long bones of the legs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35496?source=see_link&amp;anchor=H13#H13\">",
"     \"Malignancy and rheumatic disorders\", section on 'Hypertrophic osteoarthropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Renal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal dysfunction in cyanotic patients is primarily manifested as decreased urate clearance, leading to hyperuricemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/16\">",
"     16",
"    </a>",
"    ], and, in occasional patients, proteinuria that is associated with a glomerulopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/16,18,19\">",
"     16,18,19",
"    </a>",
"    ]. The BUN and serum creatinine concentration are typically normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/16\">",
"     16",
"    </a>",
"    ] but susceptibility to radiopaque contrast media and dehydration remains a concern.",
"   </p>",
"   <p>",
"    The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend that uric acid and creatinine levels be assessed at least yearly in Eisenmenger syndrome patients. Drugs that can impair renal function, such as ACE inhibitors, diuretics, and nonsteroidal antiinflammatory drugs should be avoided or used with caution. If administration of radiographic contrast agent is planned, the glomerular filtration rate should be assessed, intravenous fluids administered as appropriate and other precautions considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Neurological complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cyanotic heart disease are at risk for paradoxical cerebral emboli which may lead to stroke or brain abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/1\">",
"     1",
"    </a>",
"    ]. As noted above, the impact of microspherocytosis on the risk of cerebrovascular events is uncertain, but a conservative approach toward phlebotomy is generally recommended. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Erythrocytosis and anemia'",
"    </a>",
"    above.) Atrial arrhythmias and transvenous pacing leads may increase the risk of embolic events. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Anticoagulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Nonischemic neurologic complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/54/24422?source=see_link\">",
"     \"Neurologic complications of congenital heart disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following additional considerations were noted in the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During long-distance flights, cyanotic patients should drink nonalcoholic and noncaffeinated fluids to avoid dehydration and the diuretic effects of alcohol and caffeine. Supplemental oxygenation may be considered.",
"     </li>",
"     <li>",
"      Competitive sports should be avoided in cyanotic patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=see_link&amp;anchor=H26#H26\">",
"       \"Risk of sudden cardiac death in athletes\", section on 'Congenital heart diseases'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Maternal and fetal outcomes are adversely affected in cyanotic patients.",
"     </li>",
"     <li>",
"      Given the high risk of hospitalization",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgery in patients with cyanotic heart disease, these patients should be seen and followed by an adult congenital heart disease specialist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cardiac reoperation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for potential reoperation should include review of prior operative notes and consideration of conditions that may increase the risk of reoperation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/1\">",
"     1",
"    </a>",
"    ]. These include presence of adhesions, enlarged right heart structures, or great vessel abnormalities that increase the risk of injury with sternotomy. Peripheral vascular abnormalities may be present due to prior cardiac catheterization or operation (eg, absent radial pulse in patients with prior Blalock-Taussig shunt). Perioperative death related to cardiac reoperation is a significant contributor to overall mortality in adults with congenital heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Imaging with ultrasound, cine angiography, cardiovascular magnetic resonance imaging (CMRI), or computed tomography (CT) as dictated by local availability and preference may be helpful to delineate cardiac and great vessel anatomy.",
"   </p>",
"   <p>",
"    Pre-operative coronary angiography to rule out associated coronary artery disease is recommended for men &ge;35 years old, premenopausal women &ge;35 years old with risk factors for atherosclerosis, and postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39478/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26211352\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adult patients with cyanotic heart disease should be seen at least annually by an adult congenital heart disease specialist. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Management of cyanotic congenital heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with unrepaired cyanotic congenital heart disease should receive antimicrobial prophylaxis for endocarditis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Endocarditis prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As indicated in the 2008",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines, therapeutic phlebotomy is for hemoglobin greater than 20",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      and hematocrit &gt;65 percent, associated with headache, increasing fatigue, or other symptoms of hyperviscosity in the absence of dehydration or anemia. Repeated routine phlebotomies are",
"      <strong>",
"       not",
"      </strong>",
"      recommended because of the risk of iron depletion, decreased oxygen-carrying capacity, and stroke. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Guidelines and recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cyanotic patients have an increased risk of hemorrhage due to a number of hemostatic abnormalities. Therefore, anticoagulants and antiplatelet agents should generally be avoided unless clear indications arise. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hemostasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal dysfunction in cyanotic patients is primarily manifested as decreased urate clearance, leading to hyperuricemia, and, in occasional patients, proteinuria. The BUN and serum creatinine concentration are typically normal but precautions should be taken when radiopaque contrast media is administered and dehydration should be avoided. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Renal dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with cyanotic heart disease are at risk for paradoxical cerebral emboli which may lead to stroke or brain abscess. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Neurological complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/1\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1 (Accessed on May 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/3\">",
"      Territo MC, Rosove MH. Cyanotic congenital heart disease: hematologic management. J Am Coll Cardiol 1991; 18:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/4\">",
"      Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol 1996; 28:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/5\">",
"      Perloff JK, Marelli AJ, Miner PD. Risk of stroke in adults with cyanotic congenital heart disease. Circulation 1993; 87:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/6\">",
"      Spence MS, Balaratnam MS, Gatzoulis MA. Clinical update: cyanotic adult congenital heart disease. Lancet 2007; 370:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/7\">",
"      Ware JA, Reaves WH, Horak JK, Solis RT. Defective platelet aggregation in patients undergoing surgical repair of cyanotic congenital heart disease. Ann Thorac Surg 1983; 36:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/8\">",
"      Colon-Otero G, Gilchrist GS, Holcomb GR, et al. Preoperative evaluation of hemostasis in patients with congenital heart disease. Mayo Clin Proc 1987; 62:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/9\">",
"      Ekert H, Gilchrist GS, Stanton R, Hammond D. Hemostasis in cyanotic congenital heart disease. J Pediatr 1970; 76:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/10\">",
"      Wedemeyer AL, Edson JR, Krivit W. Coagulation in cyanotic congenital heart disease. Am J Dis Child 1972; 124:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/11\">",
"      Vongpatanasin W, Brickner ME, Hillis LD, Lange RA. The Eisenmenger syndrome in adults. Ann Intern Med 1998; 128:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/12\">",
"      Niwa K, Perloff JK, Kaplan S, et al. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol 1999; 34:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/13\">",
"      Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998; 19:1845.",
"     </a>",
"    </li>",
"    <li>",
"     Territo, MC, Rosove, M, Perloff, JK. Cyanotic congenital heart disease: Hematologic management, renal function, and urate metabolism. In: Congenital Heart Disease in Adults, Perloff, JK, Child, JS (Eds), WB Saunders, Philadelphia 1991. p.93.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/15\">",
"      Young D. Hyperuricemia in cyanotic congenital heart disease. Am J Dis Child 1980; 134:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/16\">",
"      Ross EA, Perloff JK, Danovitch GM, et al. Renal function and urate metabolism in late survivors with cyanotic congenital heart disease. Circulation 1986; 73:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/17\">",
"      Oya H, Nagaya N, Satoh T, et al. Haemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome. Heart 2000; 84:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/18\">",
"      Flanagan MF, Hourihan M, Keane JF. Incidence of renal dysfunction in adults with cyanotic congenital heart disease. Am J Cardiol 1991; 68:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/19\">",
"      Perloff JK, Latta H, Barsotti P. Pathogenesis of the glomerular abnormality in cyanotic congenital heart disease. Am J Cardiol 2000; 86:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/20\">",
"      Oechslin EN, Harrison DA, Connelly MS, et al. Mode of death in adults with congenital heart disease. Am J Cardiol 2000; 86:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39478/abstract/21\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1423 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_35_39478=[""].join("\n");
var outline_f38_35_39478=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26211352\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MANAGEMENT OF CYANOTIC CONGENITAL HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Endocarditis prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Erythrocytosis and anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Guidelines and recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hemostasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pulmonary bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Menorrhagia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pigment gallstones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Orthopedic problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Neurological complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cardiac reoperation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26211352\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1423\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1423|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?30/35/31294\" title=\"algorithm 1\">",
"      Eisenmenger high hct management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1416?source=related_link\">",
"      Asymptomatic hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/24/14727?source=related_link\">",
"      Etiology and evaluation of hemoptysis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6007?source=related_link\">",
"      Evaluation and prognosis of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/20/7496?source=related_link\">",
"      Medical management of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/54/24422?source=related_link\">",
"      Neurologic complications of congenital heart disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29558?source=related_link\">",
"      Overview of massive hemoptysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13752?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36266?source=related_link\">",
"      Prevention of recurrent gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15511?source=related_link\">",
"      Treatment of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25578?source=related_link\">",
"      Treatment of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_35_39479="Clinical manifestations and evaluation of metabolic alkalosis";
var content_f38_35_39479=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and evaluation of metabolic alkalosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39479/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39479/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39479/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39479/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39479/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39479/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/35/39479/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H16729811\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic alkalosis, which is usually accompanied by hypokalemia, is defined as a disorder that causes elevations in the serum bicarbonate concentration and arterial pH. In a patient with an uncomplicated (simple) metabolic alkalosis, both parameters are above normal. However, this may not be present in patients with mixed acid-base disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of metabolic alkalosis requires, sequentially, both the development or generation of alkalosis (related to the source of the additional bicarbonate) and the maintenance of the metabolic alkalosis (related to why the disorder persists and is not corrected by renal excretion of the excess bicarbonate). These issues are discussed in detail in other topics (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10692?source=see_link\">",
"     \"Pathogenesis of metabolic alkalosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/22/8551?source=see_link\">",
"     \"Causes of metabolic alkalosis\"",
"    </a>",
"    ) but are briefly reviewed here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An elevation in the serum bicarbonate concentration is due to hydrogen loss in the urine or gastrointestinal tract, hydrogen ion movement into cells, the administration of sodium or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/35/7731?source=see_link\">",
"       potassium bicarbonate",
"      </a>",
"      or an organic anion salt that is metabolized to bicarbonate such as citrate,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      volume contraction around a relatively constant amount of extracellular bicarbonate (called a contraction alkalosis). This is called the \"generation phase\" of metabolic alkalosis.",
"     </li>",
"     <li>",
"      An inability to excrete the excess bicarbonate in the urine is due to intravascular volume contraction, reduced effective arterial blood volume (including heart failure and cirrhosis), chloride depletion, hypokalemia, renal impairment, or combinations of these factors. This is called the \"maintenance phase\" of metabolic alkalosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39479/abstract/1-3\">",
"       1-3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with metabolic alkalosis usually have a respiratory compensation characterized by hypoventilation and an elevation in arterial PCO2 that initially lowers the arterial pH toward normal. However, the beneficial pH effect of hypoventilation is blunted because the elevation in arterial PCO2 increases renal acid excretion, producing a further rise in serum bicarbonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39479/abstract/4\">",
"     4",
"    </a>",
"    ]. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=see_link&amp;anchor=H12584074#H12584074\">",
"     \"Simple and mixed acid-base disorders\", section on 'Metabolic alkalosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=see_link&amp;anchor=H351038251#H351038251\">",
"     \"Simple and mixed acid-base disorders\", section on 'Limitations of the respiratory compensation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and evaluation of the patient with metabolic alkalosis will be reviewed here. The causes, pathogenesis, and treatment of metabolic alkalosis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/22/8551?source=see_link\">",
"     \"Causes of metabolic alkalosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10692?source=see_link\">",
"     \"Pathogenesis of metabolic alkalosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/14/14568?source=see_link\">",
"     \"Treatment of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16729818\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16729826\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with metabolic alkalosis may be asymptomatic or complain of symptoms that are primarily related to either the underlying etiology of the metabolic alkalosis or accompanying electrolyte abnormalities. Symptoms can, for example, be due to volume depletion (which may produce lassitude, easy fatigability, muscle cramps, and postural dizziness) and hypokalemia (which may produce muscle weakness, cardiac arrhythmias, and, if persistent, polyuria and polydipsia due to impaired urinary concentrating ability",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    direct stimulation of thirst). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24457?source=see_link&amp;anchor=H11#H11\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\", section on 'Symptoms related to volume depletion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=see_link&amp;anchor=H3819731#H3819731\">",
"     \"Clinical manifestations and treatment of hypokalemia\", section on 'Manifestations of hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical manifestations directly related to the",
"    <strong>",
"     metabolic alkalosis",
"    </strong>",
"    are uncommon. This is in contrast to symptoms such as paresthesias, carpopedal spasm, and lightheadedness that often occur in acute",
"    <strong>",
"     respiratory",
"    </strong>",
"    <strong>",
"     alkalosis",
"    </strong>",
"    (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37703?source=see_link\">",
"     \"Hyperventilation syndrome\"",
"    </a>",
"    ). This difference is probably related to several factors. Metabolic alkalosis probably causes a smaller change in intracellular pH and brain pH than acute respiratory alkalosis because rapid shifts in arterial CO2 tension are almost immediately transmitted throughout the total body water, including the intracellular fluid compartment, the brain, and the cerebrospinal fluid. In contrast, alterations in blood HCO3 concentration cause slower and less pronounced pH changes within the intracellular compartments and across the blood brain barrier.",
"   </p>",
"   <p>",
"    An example of the clinical impact of sudden changes in PCO2 is demonstrated by \"posthypercapnic metabolic alkalosis.\" This condition can produce severe neurological manifestations including seizures and coma. Although the biochemical findings indicate metabolic alkalosis, the clinical manifestations are more likely due to the acute fall in arterial (and brain) pCO2 and not the high HCO3 concentration itself. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/22/8551?source=see_link&amp;anchor=H8#H8\">",
"     \"Causes of metabolic alkalosis\", section on 'Posthypercapnic alkalosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Muscular spasms, tetany, and paresthesia can occur with severe metabolic alkalosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39479/abstract/5-7\">",
"     5-7",
"    </a>",
"    ], but these findings are most likely when the ionized calcium and magnesium concentrations are also reduced (Bartter syndrome, Gitelman syndrome, chronic diuretic use). Severe metabolic alkalosis can cause agitation, disorientation, seizures, and coma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39479/abstract/5-8\">",
"     5-8",
"    </a>",
"    ], especially when metabolic alkalosis develops in patients with chronic liver disease. In such patients, the alkaline systemic pH will increase the concentration of unionized nitrogen compounds such as ammonia, which enhances penetration into the central nervous system and therefore toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4346?source=see_link&amp;anchor=H3#H3\">",
"     \"Hepatic encephalopathy in adults: Treatment\", section on 'Treatments based upon the ammonia hypothesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16729833\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal findings on physical examination, when present, reflect the cause of the metabolic alkalosis. Hypovolemic patients (eg, vomiting, diuretic therapy for hypertension) may have signs of true volume depletion, such as reduced skin turgor, low estimated jugular venous pressure, and postural hypotension. In contrast, patients with effective arterial blood volume depletion due to heart failure or cirrhosis who develop metabolic alkalosis (most often due to diuretic therapy) may have peripheral edema, ascites,",
"    <span class=\"nowrap\">",
"     and/or,",
"    </span>",
"    in heart failure, pulmonary edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16729840\">",
"    <span class=\"h2\">",
"     Arterial blood gases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic alkalosis is associated with a respiratory compensation that should raise the PCO2 by about 0.7 mmHg for every 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    elevation in the plasma bicarbonate concentration, thereby minimizing the increase in arterial pH. The respiratory compensation is most effective acutely and then becomes less effective over time. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=see_link&amp;anchor=H12584074#H12584074\">",
"     \"Simple and mixed acid-base disorders\", section on 'Metabolic alkalosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=see_link&amp;anchor=H351038251#H351038251\">",
"     \"Simple and mixed acid-base disorders\", section on 'Limitations of the respiratory compensation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16729847\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16729855\">",
"    <span class=\"h2\">",
"     When the cause is not apparent from the history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most common causes of metabolic alkalosis are external loss of gastric secretions due to vomiting or nasogastric suction and diuretic therapy. These and other causes of metabolic alkalosis (",
"    <a class=\"graphic graphic_table graphicRef85833 \" href=\"mobipreview.htm?8/10/8364\">",
"     table 1",
"    </a>",
"    ) are often apparent from the history. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/22/8551?source=see_link\">",
"     \"Causes of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the etiology of metabolic alkalosis is not always apparent from the history. Several examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with vomiting or diuretic ingestion who are unwilling or unable to provide this information. Self-induced vomiting and surreptitious diuretic or laxative abuse associated with the anorexia nervosa-bulimia nervosa spectrum are relatively common and must always be considered in patients with unexplained metabolic alkalosis, especially in women. Surreptitious vomiting may be associated with dental and skin findings that strongly suggest the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33816?source=see_link&amp;anchor=H1013501#H1013501\">",
"       \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\", section on 'Dental'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33816?source=see_link&amp;anchor=H338694#H338694\">",
"       \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\", section on 'Skin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The history may not be helpful in patients with metabolic alkalosis due to primary mineralocorticoid excess syndromes (most often primary aldosteronism), disorders that mimic mineralocorticoid excess including glycyrrhizic acid (licorice) ingestion, ectopic ACTH syndrome, the syndrome of apparent mineralocorticoid excess, and genetic disorders involving renal tubular transport such as Bartter, Gitelman, or Liddle syndrome. Primary aldosteronism and its mimics are usually associated with hypertension and mild volume expansion due to the stimulatory effect of aldosterone on sodium reabsorption, whereas patients with vomiting, diuretic therapy, Bartter syndrome, and Gitelman syndrome usually present with volume contraction and relatively low blood pressure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/22/8551?source=see_link\">",
"       \"Causes of metabolic alkalosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link\">",
"       \"Clinical features of primary aldosteronism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23226?source=see_link\">",
"       \"Bartter and Gitelman syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40838?source=see_link\">",
"       \"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25399?source=see_link\">",
"       \"Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diarrhea typically generates a metabolic acidosis. However, certain conditions associated with diarrhea may produce a metabolic alkalosis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Laxative abuse, which is often denied by the patient. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6246?source=see_link\">",
"       \"Factitious diarrhea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Villous adenoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29589?source=see_link\">",
"       \"Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital chloridorrhea, which is a rare hereditary disorder that produces watery chloride-rich diarrhea, hypokalemia, and metabolic alkalosis. The cause is a mutation in the gene encoding the HCO3-Cl exchanger normally present in the colon and, to a lesser extent, the small intestine. This exchanger is also called solute carrier family 26, member 3 (SLC26A3); chloride diarrhea anion exchanger (CLD); and downregulated-in-adenoma (DRA) transporter. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5210?source=see_link\">",
"       \"Overview of the causes of chronic diarrhea in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29589?source=see_link\">",
"       \"Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The alkalosis in these conditions is in part related to relatively high stool chloride and potassium concentrations, resulting in potassium depletion and hypokalemia. The loss of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/52/25411?source=see_link\">",
"       ammonium chloride",
"      </a>",
"      and other organic chloride salts in the stool generates bicarbonate. Hypokalemia leads to the generation and excretion of ammonium chloride by the kidney, which also generates bicarbonate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39479/abstract/1,9-11\">",
"       1,9-11",
"      </a>",
"      ]. Renal tubular bicarbonate reabsorption is increased, and this maintains the alkalosis by minimizing excretion of the excess bicarbonate (",
"      <a class=\"graphic graphic_figure graphicRef82488 \" href=\"mobipreview.htm?42/0/43020\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39479/abstract/12\">",
"       12",
"      </a>",
"      ]. How these changes occur is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10692?source=see_link&amp;anchor=H5#H5\">",
"       \"Pathogenesis of metabolic alkalosis\", section on 'Hypokalemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16729862\">",
"    <span class=\"h2\">",
"     Diagnostic approach in unexplained metabolic alkalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the etiology of metabolic alkalosis is not apparent from the history and physical examination, measurement of the urine chloride, urine sodium, and urine pH can be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16729869\">",
"    <span class=\"h3\">",
"     Disorders associated with a low urine chloride concentration",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16729876\">",
"    <span class=\"h4\">",
"     Vomiting or nasogastric suction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spot urine chloride concentration is always",
"    <strong>",
"     appropriately low (less than 20",
"     <span class=\"nowrap\">",
"      meq/L",
"     </span>",
"     and often below 10",
"     <span class=\"nowrap\">",
"      meq/L)",
"     </span>",
"    </strong>",
"    in metabolic alkalosis due to vomiting or nasogastric suction, reflecting both hypovolemia and the associated hypochloremia (unless the patient is also ingesting diuretics) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39479/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This reflects extracellular fluid volume contraction and chloride depletion which exist in these patients. The spot urine sodium concentration is also often reduced to less than 20",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    as a result of the volume contraction. However, the urine sodium concentration may increase intermittently. Although extracellular fluid volume contraction stimulates renal sodium, chloride, and water reabsorption, the high serum bicarbonate concentration and high-filtered bicarbonate load will intermittently exceed the renal bicarbonate reabsorptive capacity. When this occurs, the loss of bicarbonate into the urine must be accompanied by an equimolar quantity of cations, mainly sodium and potassium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39479/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. At these times, the urine pH is typically high, greater than 6.5. Thus, the spot urine sodium concentration will intermittently increase despite extracellular fluid volume contraction. In contrast, the urine chloride concentration remains low (",
"    <a class=\"graphic graphic_table graphicRef63175 \" href=\"mobipreview.htm?17/8/17547\">",
"     table 2",
"    </a>",
"    ). This is further described by the following sequence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sodium wasting with bicarbonaturia occurs in the first one to three days after the onset of vomiting. The urine sodium concentration will be above 20",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"     </li>",
"     <li>",
"      Thereafter, the dual stimuli of volume and chloride depletion increase renal sodium, chloride, and bicarbonate reabsorption to a level that markedly reduces the urine sodium concentration.",
"     </li>",
"     <li>",
"      The sodium wasting (and a higher-than-expected urine sodium concentration) may recur if the serum bicarbonate concentration increases further due, for example, to worsening of the vomiting or to removal of additional gastric secretions (eg, nasogastric suction) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39479/abstract/15\">",
"       15",
"      </a>",
"      ]. Although the period of sodium wasting is usually short-lived in patients with vomiting, it can be prolonged if the alkalosis is very severe and the increase in filtered bicarbonate continues to overwhelm the kidney's reabsorptive capacity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gastric alkalosis is usually effectively treated with intravenous saline (and potassium) infusion. When saline expands the extracellular volume,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    can be excreted in the urine (the infused chloride is retained and increases the chloride concentration). When the extracellular volume has been restored, the urine chloride concentration increases. Thus, after the initiation of saline therapy, a substantial rise in the urine chloride is a sign that volume repletion has been attained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16729883\">",
"    <span class=\"h4\">",
"     Diuretic-induced alkalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretics that block sodium chloride reabsorption (thiazide and loop diuretics) produce a high",
"    <strong>",
"    </strong>",
"    urine chloride concentration when they are active. However, the urine chloride concentration falls to low levels when their effect has dissipated. Thus, patients who surreptitiously take diuretics will often have wide swings in the urine chloride concentration from day to day as the diuretic effect waxes and wanes. This finding in a patient with metabolic alkalosis is virtually diagnostic of diuretic use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16729890\">",
"    <span class=\"h4\">",
"     Other causes of metabolic alkalosis associated with low urine chloride concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urine chloride can be low with other forms of metabolic alkalosis associated with extracellular fluid volume contraction and chloride depletion. As examples, the urine chloride is usually low when metabolic alkalosis develops in patients with laxative abuse, cystic fibrosis with excessive sweating (loss of a large volume of chloride rich sweat) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39479/abstract/16\">",
"     16",
"    </a>",
"    ], congenital chloride diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39479/abstract/17\">",
"     17",
"    </a>",
"    ], and in infants given a chloride-deficient synthetic formulae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39479/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16729897\">",
"    <span class=\"h3\">",
"     Settings in which the urine chloride is not low",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the low urine chloride concentration in most patients with metabolic alkalosis who are hypovolemic, the urine chloride concentration is",
"    <strong>",
"     not",
"    </strong>",
"    low (it is usually greater than 40",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    when metabolic alkalosis occurs in patients who are volume expanded due to the various forms of primary mineralocorticoid excess or a disorder that mimics mineralocorticoid excess. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary aldosteronism",
"     </li>",
"     <li>",
"      Liddle syndrome",
"     </li>",
"     <li>",
"      Excess licorice ingestion (glycyrrhizic acid)",
"     </li>",
"     <li>",
"      Apparent mineralocorticoid excess syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such patients are usually hypertensive. These disorders and the diagnostic approach to the patient with hypertension and hypokalemia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25399?source=see_link\">",
"     \"Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40838?source=see_link\">",
"     \"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disorders resulting from genetic mutations that cause persistent renal salt wasting, such as Bartter or Gitelman syndromes, will also result in an elevated urine chloride concentration. However, these patients will be volume contracted and relatively hypotensive. They are functionally similar to persistently acting loop or thiazide diuretics. (",
"    <a class=\"graphic graphic_table graphicRef85833 \" href=\"mobipreview.htm?8/10/8364\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23226?source=see_link\">",
"     \"Bartter and Gitelman syndromes\"",
"    </a>",
"    .) Patients taking loop or thiazide diuretics will have an elevated urine chloride concentration when the drug is active (the urine chloride concentration falls to low levels when the effect has worn off).",
"   </p>",
"   <p>",
"    In addition, marked potassium depletion with severe hypokalemia (serum potassium concentration less than 2",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    can cause metabolic alkalosis with a high urine chloride concentration. It is believed that the potassium depletion reversibly impairs renal tubular chloride reabsorption, leading to a rise in urinary chloride excretion that is independent of volume status. This form of metabolic alkalosis does not improve with sodium chloride volume expansion but resolves with potassium repletion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39479/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16729904\">",
"    <span class=\"h3\">",
"     Utility of urine chemistries in metabolic alkalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usefulness of the urine chloride concentration was illustrated in a study that included 25 adult patients with unexplained metabolic alkalosis and hypokalemia: the final diagnosis was diuretic abuse in five, surreptitious vomiting in eight, and suspected Bartter or Gitelman syndrome in twelve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39479/abstract/20\">",
"     20",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean urine chloride concentration was 1.3",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in the patients with surreptitious vomiting, 76",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      with diuretic abuse, and 230",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      with suspected Bartter or Gitelman syndrome. The urine chloride concentration in those with diuretic abuse would be expected be much lower if measured after the diuretic effect had worn off.",
"     </li>",
"     <li>",
"      The mean urine sodium concentration was 73",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      with diuretic abuse and 160",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      with suspected Bartter syndrome. The mean urine sodium concentration was 90",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in the patients with surreptitious vomiting, illustrating that the urine sodium concentration may be elevated despite hypovolemia in some patients with metabolic alkalosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16729911\">",
"    <span class=\"h3\">",
"     Hypokalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with metabolic alkalosis frequently have concurrent hypokalemia. This is usually due to urinary potassium losses, even in patients with vomiting (the potassium concentration in gastric secretions is only 5 to 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and not high enough to induce hypokalemia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39479/abstract/15\">",
"     15",
"    </a>",
"    ]. The increase in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    delivery to the cortical collecting tubule (where potassium is secreted) combines with increased aldosterone activity (due to either hypovolemia or primary excess) to promote sodium reabsorption and potassium (and proton) secretion at this site (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"mobipreview.htm?12/31/12797\">",
"     figure 2",
"    </a>",
"    ). The physiology is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25891?source=see_link&amp;anchor=H4#H4\">",
"     \"Potassium balance in acid-base disorders\", section on 'Metabolic alkalosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16729918\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolic alkalosis, which is usually accompanied by hypokalemia, is defined as a disorder that causes elevations in the serum bicarbonate concentration and arterial pH.",
"      <strong>",
"      </strong>",
"      The pathogenesis of metabolic alkalosis requires, sequentially, both the development or generation of alkalosis (related to the source of the additional bicarbonate) and the maintenance of the metabolic alkalosis (related to why the disorder persists and is not corrected by renal excretion of the excess bicarbonate) (see",
"      <a class=\"local\" href=\"#H16729811\">",
"       'Introduction'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An elevation in the serum bicarbonate concentration is due to hydrogen loss in the urine or gastrointestinal tract, hydrogen ion movement into cells, the administration of sodium or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/35/7731?source=see_link\">",
"       potassium bicarbonate",
"      </a>",
"      or an organic anion salt that is metabolized to bicarbonate such as citrate,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      volume contraction around a relatively constant amount of extracellular bicarbonate (called a contraction alkalosis). This is called the \"generation phase\" of metabolic alkalosis.",
"     </li>",
"     <li>",
"      An inability to excrete the excess bicarbonate in the urine is due to intravascular volume depletion, reduced effective arterial blood volume (including heart failure and cirrhosis), chloride depletion, hypokalemia, renal impairment, or combinations of these factors. This is called the \"maintenance phase\" of metabolic alkalosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with metabolic alkalosis may be asymptomatic or complain of symptoms that are primarily related to either the underlying etiology of the alkalosis (eg, volume depletion) or accompanying electrolyte abnormalities (eg, hypokalemia). Metabolic alkalosis due to Bartter or Gitelman syndrome or chronic diuretic use can be associated with neuromuscular irritability, spasms, and tetany. This may also occur with severe metabolic alkalosis of other etiologies. Abnormal findings on physical examination, when present, may reflect the cause of the metabolic alkalosis. (See",
"      <a class=\"local\" href=\"#H16729818\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two most common causes of metabolic alkalosis are loss of gastric secretions due to vomiting or nasogastric suction and diuretic therapy. These and other causes of metabolic alkalosis (",
"      <a class=\"graphic graphic_table graphicRef85833 \" href=\"mobipreview.htm?8/10/8364\">",
"       table 1",
"      </a>",
"      ) are often apparent from the history. However, the etiology of metabolic alkalosis is not always apparent from the history. Several examples include (see",
"      <a class=\"local\" href=\"#H16729855\">",
"       'When the cause is not apparent from the history'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with vomiting or diuretic ingestion who are unwilling or unable to provide this information, such as those with self-induced vomiting, and surreptitious diuretic or laxative abuse.",
"     </li>",
"     <li>",
"      Patients with metabolic alkalosis due to primary mineralocorticoid excess syndromes (most often primary aldosteronism), disorders that mimic mineralocorticoid excess including glycyrrhizic acid (licorice) ingestion, ectopic ACTH syndrome, the syndrome of apparent mineralocorticoid excess, and genetic disorders involving renal tubular electrolyte transport such as Bartter, Gitelman, or Liddle syndrome.",
"     </li>",
"     <li>",
"      Patients with certain causes off chloride-rich diarrhea, including laxative abuse, villous adenoma, and congenital chloridorrhea.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the etiology of metabolic alkalosis is not apparent from the history and physical examination, measurement of the urine chloride, urine sodium, and urine pH can be helpful. (See",
"      <a class=\"local\" href=\"#H16729862\">",
"       'Diagnostic approach in unexplained metabolic alkalosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The spot urine chloride concentration is always appropriately low (less than 20",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      and often below 10",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      when metabolic alkalosis is due to vomiting or nasogastric suction, reflecting hypovolemia, chloride depletion, and hypochloremia. The spot urine sodium concentration is also often reduced to less than 20",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      as a result of the volume depletion. However, the urine sodium concentration increases intermittently when bicarbonaturia occurs (and sodium and potassium are excreted to maintain electroneutrality). Under those conditions, the urine pH exceeds 7. However, the urine chloride concentration is persistently reduced whether or not bicarbonaturia exists, and it is therefore a superior indicator of volume status. (See",
"      <a class=\"local\" href=\"#H16729876\">",
"       'Vomiting or nasogastric suction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metabolic alkalosis with a low urine chloride also occurs in patients who use diuretics (after the diuretic effect has dissipated). Patients who surreptitiously take diuretics will often have wide swings in the urine chloride concentration from day to day as the diuretic effect waxes and wanes. This finding in a patient with metabolic alkalosis is virtually diagnostic of diuretic use. (See",
"      <a class=\"local\" href=\"#H16729883\">",
"       'Diuretic-induced alkalosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The urine chloride concentration may be low when metabolic alkalosis develops in patients with laxative abuse, cystic fibrosis with excessive sweating (loss of a large volume of chloride rich sweat), congenital chloride diarrhea, and in infants given a chloride-deficient synthetic formulae. (See",
"      <a class=\"local\" href=\"#H16729890\">",
"       'Other causes of metabolic alkalosis associated with low urine chloride concentration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to the low urine chloride concentration in most patients with metabolic alkalosis who are hypovolemic, the urine chloride concentration is",
"      <strong>",
"       not",
"      </strong>",
"      low (it is usually greater than 40",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      in patients who are taking loop or thiazide diuretics when the drug is still active (before the effect has worn off). Similarly, disorders resulting from genetic mutations that cause persistent renal salt wasting, such as Bartter or Gitelman syndromes, also result in elevated urine chloride concentration. However, these patients will be volume contracted and relatively hypotensive. They are functionally similar to persistently acting loop or thiazide diuretics (",
"      <a class=\"graphic graphic_table graphicRef85833 \" href=\"mobipreview.htm?8/10/8364\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16729897\">",
"       'Settings in which the urine chloride is not low'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metabolic alkalosis with a relatively high urine chloride concentration occurs in patients with any form of primary mineralocorticoid excess or the disorders that mimic mineralocorticoid excess (",
"      <a class=\"graphic graphic_table graphicRef85833 \" href=\"mobipreview.htm?8/10/8364\">",
"       table 1",
"      </a>",
"      ).",
"      <strong>",
"      </strong>",
"      Under these conditions, the patients are generally volume expanded and hypertensive. (See",
"      <a class=\"local\" href=\"#H16729897\">",
"       'Settings in which the urine chloride is not low'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/1\">",
"      Galla JH. Metabolic alkalosis. J Am Soc Nephrol 2000; 11:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/2\">",
"      Seldin DW, Rector FC Jr. Symposium on acid-base homeostasis. The generation and maintenance of metabolic alkalosis. Kidney Int 1972; 1:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/3\">",
"      Luke RG, Galla JH. It is chloride depletion alkalosis, not contraction alkalosis. J Am Soc Nephrol 2012; 23:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/4\">",
"      Madias NE, Adrogu&eacute; HJ, Cohen JJ. Maladaptive renal response to secondary hypercapnia in chronic metabolic alkalosis. Am J Physiol 1980; 238:F283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/5\">",
"      Mennen M, Slovis CM. Severe metabolic alkalosis in the emergency department. Ann Emerg Med 1988; 17:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/6\">",
"      Fitzgibbons LJ, Snoey ER. Severe metabolic alkalosis due to baking soda ingestion: case reports of two patients with unsuspected antacid overdose. J Emerg Med 1999; 17:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/7\">",
"      Gawarammana IB, Coburn J, Greene S, et al. Severe hypokalaemic metabolic alkalosis following ingestion of gaviscon. Clin Toxicol (Phila) 2007; 45:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/8\">",
"      Stephani J, Wagner M, Breining T, et al. Metabolic alkalosis, acute renal failure and epileptic seizures as unusual manifestations of an upside-down stomach. Case Rep Gastroenterol 2012; 6:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/9\">",
"      Perez GO, Oster JR, Rogers A. Acid-base disturbances in gastrointestinal disease. Dig Dis Sci 1987; 32:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/10\">",
"      Oster JR, Materson BJ, Rogers AI. Laxative abuse syndrome. Am J Gastroenterol 1980; 74:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/11\">",
"      Babior BM. Villous adenoma of the colon. Study of a patient with severe fluid and electrolyte disturbances. Am J Med 1966; 41:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/12\">",
"      FULLER GR, MACLEOD MB, PITTS RF. Influence of administration of potassium salts on the renal tubular reabsorption of bicarbonate. Am J Physiol 1955; 182:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/13\">",
"      Sherman RA, Eisinger RP. The use (and misuse) of urinary sodium and chloride measurements. JAMA 1982; 247:3121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/14\">",
"      Koch SM, Taylor RW. Chloride ion in intensive care medicine. Crit Care Med 1992; 20:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/15\">",
"      Kassirer JP, Schwartz WB. The response of normal man to selective depletion of hydrochloric acid. Factors in the genesis of persistent gastric alkalosis. Am J Med 1966; 40:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/16\">",
"      Priou-Guesdon M, Malinge MC, Augusto JF, et al. Hypochloremia and hyponatremia as the initial presentation of cystic fibrosis in three adults. Ann Endocrinol (Paris) 2010; 71:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/17\">",
"      Aichbichler BW, Zerr CH, Santa Ana CA, et al. Proton-pump inhibition of gastric chloride secretion in congenital chloridorrhea. N Engl J Med 1997; 336:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/18\">",
"      Roy S 3rd, Arant BS Jr. Hypokalemic metabolic alkalosis in normotensive infants with elevated plasma renin activity and hyperaldosteronism: role of dietary chloride deficiency. Pediatrics 1981; 67:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/19\">",
"      Garella S, Chazan JA, Cohen JJ. Saline-resistant metabolic alkalosis or \"chloride-wasting nephropathy\". Report of four patients with severe potassium depletion. Ann Intern Med 1970; 73:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39479/abstract/20\">",
"      Gladziwa U, Schwarz R, Gitter AH, et al. Chronic hypokalaemia of adults: Gitelman's syndrome is frequent but classical Bartter's syndrome is rare. Nephrol Dial Transplant 1995; 10:1607.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2312 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-235EC14115-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_35_39479=[""].join("\n");
var outline_f38_35_39479=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16729918\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16729811\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16729818\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16729826\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16729833\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16729840\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16729847\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16729855\">",
"      When the cause is not apparent from the history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16729862\">",
"      Diagnostic approach in unexplained metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16729869\">",
"      - Disorders associated with a low urine chloride concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16729876\">",
"      Vomiting or nasogastric suction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16729883\">",
"      Diuretic-induced alkalosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16729890\">",
"      Other causes of metabolic alkalosis associated with low urine chloride concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16729897\">",
"      - Settings in which the urine chloride is not low",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16729904\">",
"      - Utility of urine chemistries in metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16729911\">",
"      - Hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16729918\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2312\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2312|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/0/43020\" title=\"figure 1\">",
"      HCO3 reabsorption plasma K",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/31/12797\" title=\"figure 2\">",
"      Collecting tubule transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2312|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/10/8364\" title=\"table 1\">",
"      Differential diagnosis of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/8/17547\" title=\"table 2\">",
"      Urine electrolytes vomiting",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29589?source=related_link\">",
"      Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40838?source=related_link\">",
"      Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23226?source=related_link\">",
"      Bartter and Gitelman syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33816?source=related_link\">",
"      Bulimia nervosa and binge eating disorder in adults: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/22/8551?source=related_link\">",
"      Causes of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6246?source=related_link\">",
"      Factitious diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/51/25399?source=related_link\">",
"      Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/15/4346?source=related_link\">",
"      Hepatic encephalopathy in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37703?source=related_link\">",
"      Hyperventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5210?source=related_link\">",
"      Overview of the causes of chronic diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/28/10692?source=related_link\">",
"      Pathogenesis of metabolic alkalosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25891?source=related_link\">",
"      Potassium balance in acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/14/14568?source=related_link\">",
"      Treatment of metabolic alkalosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_35_39480="Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome";
var content_f38_35_39480=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39480/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39480/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39480/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39480/contributors\">",
"     Bob Lowenberg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39480/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39480/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/35/39480/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons who are exposed to cytotoxic agents are at risk of developing acute myeloid leukemia (t-AML), myelodysplastic syndrome (t-MDS), and myelodysplastic",
"    <span class=\"nowrap\">",
"     syndrome/myeloproliferative",
"    </span>",
"    neoplasms",
"    <span class=\"nowrap\">",
"     (t-MDS/MPN).",
"    </span>",
"    These conditions lie along a continuum of disease and are categorized by the 2008 WHO classification system as therapy-related myeloid neoplasms (t-MN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/1\">",
"     1",
"    </a>",
"    ]. This is a heterogeneous and poorly defined group of patients who have a shorter median survival than patients with de novo AML, MDS, or",
"    <span class=\"nowrap\">",
"     MDS/MPN.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    epidemiology, diagnosis, and treatment of t-MN are discussed here. The treatment of de novo AML and MDS are discussed separately. Additional information regarding the pathophysiology behind the development of t-AML is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29146?source=see_link\">",
"     \"Treatment of acute myeloid leukemia in older adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=see_link\">",
"     \"Pathogenesis of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy-related myeloid neoplasms (t-MN) account for approximately 10 to 20 percent of all cases of AML, MDS, and",
"    <span class=\"nowrap\">",
"     MDS/MPN.",
"    </span>",
"    The incidence among patients treated with cytotoxic agents varies according to the underlying disease, specific agents, timing of exposure, and dose. Patients can present at any age, but the median age at diagnosis is 61 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The risk associated with alkylating agents and radiation appears to increase with age, while the risk associated with topoisomerase II inhibitors appears to be constant across all ages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/1\">",
"     1",
"    </a>",
"    ]. Some patients may have a heritable predisposition to the development of t-MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proportion of patients with a prior hematologic malignancy or a prior solid tumor is approximately equal and accounts for the large majority of cases. Five to 20 percent of patients will have a history of exposure to cytotoxic therapy for benign disorders while a similar proportion will have undergone an autologous hematopoietic cell transplantation (HCT).",
"   </p>",
"   <p>",
"    As an example, in a series of 306 patients with t-MDS or t-AML, 77 had previously had Hodgkin lymphoma, 70 had non-Hodgkin lymphoma, 24 had multiple myeloma or another hematologic malignant disease, 117 had various solid tumors, and 18 had nonmalignant diseases, primarily autoimmune diseases or prior renal transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/5\">",
"     5",
"    </a>",
"    ]. These patients had been variably treated with combined radiotherapy and chemotherapy (139), chemotherapy alone (121), or radiotherapy alone (43); the majority of patients treated with radiotherapy alone had received radiation to large portals containing active marrow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of t-MN is variable but most patients have symptoms similar to patients with de novo AML or MDS. Symptoms most commonly relate to complications of pancytopenia (ie, anemia, neutropenia, and thrombocytopenia), including weakness and easy fatigue, infections of variable severity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemorrhagic findings such as gingival bleeding, ecchymoses, epistaxis, or menorrhagia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The latency period between first exposure to a cytotoxic agent and the development of t-MN ranges from one to 10 years and varies by cytotoxic agent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      t-MN after exposure to alkylating agents or radiation therapy typically presents after a latency period of approximately five to seven years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/6-9\">",
"       6-9",
"      </a>",
"      ]. Two-thirds of these patients are first recognized by evidence of myelodysplasia (usually trilineage dysplasia), marrow failure, and pancytopenia. The chromosomal abnormalities seen in these t-MNs often involve complex abnormalities and monosomies such as -5 or -7 that have been associated with unfavorable risk.",
"     </li>",
"     <li>",
"      t-MN that develops after the use of topoisomerase II inhibitors has a considerably shorter latency period of one to three years and most often presents with overt leukemia and rarely with MDS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/10-16\">",
"       10-16",
"      </a>",
"      ]. The cytogenetic alterations typically apparent in these t-MNs often involve 11q26 abnormalities, such as t(9;11), or 21q22 abnormalities, such as t(8;21) or t(3;21).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The latency periods with other agents are not as clear. In addition, patients often have a history of exposure to multiple agents making the responsible factor difficult to determine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of therapy-related myeloid neoplasm (t-MN) is made when evaluation of the peripheral blood and bone marrow demonstrates morphologic, immunophenotypic, and cytogenetic changes consistent with the diagnosis of AML, MDS, or",
"    <span class=\"nowrap\">",
"     MDS/MPN",
"    </span>",
"    in a patient with prior exposure to cytotoxic agents. Details on the diagnosis of these specific disorders are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is also possible for a patient to develop t-MN after treatment for a de novo myeloid neoplasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Such cases may be identified by performing cytogenetic testing and immunophenotype evaluation at apparent relapse and comparing the karyotype and immunophenotype at relapse with that at the time of the initial diagnosis. The emergence of a distinctly different karyotype suggests, but does not prove, a therapy-related origin, rather than recurrence of the original leukemic clone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Subclassification",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, t-AML, t-MDS, and",
"    <span class=\"nowrap\">",
"     t-MDS/MPN",
"    </span>",
"    lie along a continuum of disease and are categorized by the current WHO system as t-MN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/1\">",
"     1",
"    </a>",
"    ]. It is possible to further subclassify patients by blast count, cytogenetics, and morphologic features, but such classification typically has little impact on management or outcome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the blast count in the bone marrow or peripheral blood exceeds 20 percent, the term t-AML can be used.",
"     </li>",
"     <li>",
"      If the blast count is 20 percent or less, the term t-MDS is used except in cases associated with t(8;21) or inv(16) where a diagnosis of t-AML is given even if the blast count is less than 20 percent.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       t-MDS/MPN",
"      </span>",
"      is differentiated from MDS based upon the same clinical, laboratory, and morphologic features used to differentiate them in non-treatment related cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cytotoxic agents that have been implicated",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the diagnosis of t-MN is based upon a history of exposure to cytotoxic chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy for a neoplastic or non-neoplastic disorder. Several cytotoxic agents have been implicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alkylating agents &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , nitrogen mustard,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      C,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"       thioTEPA",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/27/37302?source=see_link\">",
"       lomustine",
"      </a>",
"      , and others",
"     </li>",
"     <li>",
"      Topoisomerase II inhibitors &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/55/4983?source=see_link\">",
"       teniposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/5/37973?source=see_link\">",
"       amsacrine",
"      </a>",
"      , and actinomycin",
"     </li>",
"     <li>",
"      Antimetabolites &mdash; thiopurines,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"     </li>",
"     <li>",
"      Antitubulin agents (usually in combination with other agents) &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31123?source=see_link\">",
"       vindesine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"     </li>",
"     <li>",
"      Ionizing radiation therapy given as large fields that include the bone marrow",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of other agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , L-asparaginase, radioisotopes, and hematopoietic growth factors is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/1\">",
"     1",
"    </a>",
"    ]. Registry data suggest that growth factors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    may play a role in the emergence of a t-MN clone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PRE-TREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with t-MN can pose a clinical challenge for several reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients may have:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Baseline organ insufficiency related to prior therapy",
"     </li>",
"     <li>",
"      Low normal hematopoietic stem cell reserve",
"     </li>",
"     <li>",
"      Prior damage to bone marrow stroma",
"     </li>",
"     <li>",
"      Chronic immunosuppression",
"     </li>",
"     <li>",
"      Colonization with antibiotic-resistant organisms",
"     </li>",
"     <li>",
"      Increased incidence of unfavorable cytogenetic abnormalities",
"     </li>",
"     <li>",
"      Frequent expression of the multi-drug resistance phenotype",
"     </li>",
"     <li>",
"      Persistence of the primary malignant disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pre-treatment evaluation in patients with t-MN is similar to that performed for patients with de novo AML. In addition, a search for an HLA-compatible donor for allogeneic hematopoietic cell transplantation (HCT) should be undertaken at an early stage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link&amp;anchor=H2#H2\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal approaches for patients with t-MN are uncertain; the limited data that are available come from clinical experience and retrospective analyses. As a result, clinical practice varies widely. Some experts favor supportive care while others advocate more aggressive therapy including allogeneic hematopoietic cell transplantation (HCT) since they may be curative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. The patient's age, co-morbidities, performance status, and persistence of the primary malignant disease may be the overriding factors that favor one strategy over another.",
"   </p>",
"   <p>",
"    As a general rule, we encourage patients to participate in clinical trials, whenever available. For those patients who are not candidates for clinical trials or for those who do not wish to participate, we offer the following approach that takes into account the patient's performance status and tumor karyotype. We generally treat patients with t-MN identically except for patients with therapy-related acute promyelocytic leukemia (t-APL) who are treated with a different approach (",
"    <a class=\"graphic graphic_algorithm graphicRef79891 \" href=\"mobipreview.htm?32/8/32896\">",
"     algorithm 1",
"    </a>",
"    ). Patients with t-APL treated with standard all-trans-retinoic acid (ATRA) plus anthracycline-based chemotherapy or ATRA plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/47/16119?source=see_link\">",
"     arsenic trioxide",
"    </a>",
"    have high rates of complete remission (70 to 90 percent) and a median survival of over three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=see_link\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Assessment of performance status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's performance status as measured by the Eastern Cooperative Oncology Group (ECOG) scoring system provides guidance as to whether a patient with t-MN is fit enough to survive the typical intensive chemotherapy induction used for patients with AML (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 1",
"    </a>",
"    ). Patients who are fully ambulatory (ie, ECOG 0 or 1) will likely be able to tolerate induction chemotherapy whereas patients who are in bed at least part of the day (ie, ECOG 3 or 4) are at a high risk of dying during induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We reserve intensive remission induction chemotherapy for patients who have a good performance status at diagnosis. Less fit patients may benefit from less intensive therapy, such as the DNA methyl transferase inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    ). For patients with a poor performance status at diagnosis, we suggest supportive, symptom-directed care alone. This generally includes the use of blood and platelet transfusions for cytopenias and antibiotics for infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Risk stratification by karyotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a patient is determined to be a candidate for induction chemotherapy, the tumor cytogenetics are used to further evaluate prognosis and the chance of obtaining a complete response to induction chemotherapy. The same risk stratification by karyotype that has been used prognostically in patients with de novo AML demonstrates prognostic value in patients with t-MN. Different stratification schemes have been used to group patients by karyotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17274?source=see_link&amp;anchor=H2#H2\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One commonly used system is described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Favorable &mdash; t(8;21), inv(16), t(15;17)",
"     </li>",
"     <li>",
"      Intermediate &mdash; normal, t(9;11), other abnormalities not described as favorable or unfavorable",
"     </li>",
"     <li>",
"      Unfavorable &mdash; 3q21q26 abnormalities, del 5q, del 7q, t(6;9), other 11q23 abnormalities, 12p abnormalities, 17p abnormalities, monosomies 5 or 7, trisomies 8 or 13, or complex aberrant karyotypes described as at least 3 unrelated abnormalities excluding cases with t(8;21), inv(16), and t(15;17)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 90 percent of cases of t-MN demonstrate a clonal chromosomal abnormality, most often complex in nature. The abnormalities seen are the same as those seen in de novo AML, but differ in frequency. In an illustrative report, patients with t-MN were less likely to have normal cytogenetics (approximately 10 versus 40 percent, respectively) and more likely to have an unfavorable cytogenetic profile (approximately 46 versus 20 percent) when compared with patients with de novo AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different cytotoxic exposures may result in diverse mutagenic damage that is reflected in part by recurring cytogenetic abnormalities. One study compared the outcomes of 181 patients who developed t-MN after chemotherapy (with or without radiation therapy (RT)) with 47 patients who developed t-MN after RT alone and 222 patients who presented with primary MDS or de novo AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/29\">",
"     29",
"    </a>",
"    ]. The proportion of patients with normal karyotypes was 14, 43, and 45 percent in the patients with t-MN after RT, those with primary MDS, and those with de novo AML, respectively. Deletions or loss of chromosome 5",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    7 were observed in 63, 26, and 23 percent, respectively. The cytogenetic risk group was a strong predictor of survival regardless of whether the leukemia developed after chemotherapy, RT, or de novo. When compared with those who had received chemotherapy, patients with t-MN after RT had a higher frequency of more favorable cytogenetics (65 versus 12 percent), and this was reflected by better survival rates that were similar to those in patients with de novo",
"    <span class=\"nowrap\">",
"     MDS/AML.",
"    </span>",
"    Thus, cytogenetics, and not merely prior exposures, are the strongest predictors for outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with t-AML, those with favorable cytogenetics have a longer median overall survival than those with normal or unfavorable karyotypes. However, despite favorable cytogenetics, patients with t-AML do worse than patients with de novo AML in the same risk group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following examples illustrate the range of findings in studies that have evaluated karyotype stratification in patients with t-AML:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest comparative analysis included 200 patients with t-AML and 2653 patients with de novo AML treated with AML induction therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/32\">",
"       32",
"      </a>",
"      ]. When compared with patients with de novo AML, patients with t-AML had similar rates of complete remission (63 versus 67 percent), refractory disease (25 versus 22 percent), and early death (12 versus 9 percent). Patients with t-AML had significantly lower rates of relapse-free survival (25 versus 40 percent) and overall survival (26 versus 38 percent) at four years.",
"     </li>",
"     <li>",
"      Another comparative analysis included 93 patients with t-AML and 1091 patients with de novo AML treated with AML induction therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/27\">",
"       27",
"      </a>",
"      ]. Patients with t-AML had a significantly shorter median overall survival after treatment (10 versus 15 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/27\">",
"       27",
"      </a>",
"      ]. Cytogenetic analysis revealed a higher percent of unfavorable cytogenetic profiles in patients with t-AML when compared with de novo AML (46 versus 20 percent). The high frequency of adverse cytogenetics may explain to a large extent the unfavorable risk of t-AML. Favorable and unfavorable cytogenetics had prognostic value in both patient groups. However, the survival of patients with t-AML was generally shorter than that of those with de novo AML within the same cytogenetic risk group. When updated to include 121 patients with t-AML, the median overall survival times for patients with t-AML with favorable, intermediate, and unfavorable cytogenetics were 27, 13, and 6 months, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report of 306 patients with t-MDS or t-AML found a median survival rate of approximately 7 to 9 months, which varied with karyotype [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/5\">",
"       5",
"      </a>",
"      ]. The longest median overall survival rates were seen in patients with normal karyotypes or recurring balanced rearrangements (approximately 11 months each). The shortest median survival was seen in patients with abnormalities of both chromosomes 5 and 7 (approximately 5 months). The shorter survival in this series compared with the larger series described above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/27\">",
"       27",
"      </a>",
"      ] likely reflects a higher percentage of patients who received only supportive care rather than induction chemotherapy in this series.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment approach by karyotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with de novo AML are usually treated with intensive induction chemotherapy that includes an anthracycline and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    followed by post-remission therapy. Patients with favorable karyotypes may do well with standard induction therapy while patients with unfavorable karyotypes do poorly with all known treatment options. As a result, our treatment approach for patients with a good performance status depends upon the cytogenetic risk group (",
"    <a class=\"graphic graphic_algorithm graphicRef79891 \" href=\"mobipreview.htm?32/8/32896\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Favorable karyotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with t-MN associated with inv(16), t(8;21) or t(15;17) have a favorable karyotype and are likely to obtain a complete remission with conventional induction chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/8,33-35\">",
"     8,33-35",
"    </a>",
"    ]. Some of these patients may achieve long-term survival after consolidation therapy. This favorable outcome is largely supported by retrospective analyses that have demonstrated complete remission rates over 85 percent for this subgroup as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of 121 patients with t-MN treated with conventional induction chemotherapy reported a median overall survival of 27 months in patients who had inv(16), t(8;21) or t(15;17) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/33\">",
"       33",
"      </a>",
"      ]. The rate of survival after 5 years for the 13 patients with t-MN with inv(16) was 62 percent compared with 78 percent for those with de novo AML with inv(16) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An international workshop analysis of 39 patients with t-MN and inv(16) treated with induction chemotherapy reported a complete remission rate of 85 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/34\">",
"       34",
"      </a>",
"      ]. Patients younger than 55 years (26 patients) had a median survival longer than three years.",
"     </li>",
"     <li>",
"      Another international workshop analysis of patients with 21q22 translocations reported one-, two-, and five-year overall survival rates of 58, 33, and 18 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/35\">",
"       35",
"      </a>",
"      ]. Patients with t(8;21) specifically had a median overall survival of 19 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with a good performance status and cytogenetics showing inv(16) or t(8;21), we suggest treatment with standard induction chemotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    and an anthracycline followed by high-dose cytarabine consolidation. Patients with t(15;17) should be treated according to de novo APL protocols. There are clearly competing risks for long-term survival even in these \"favorable risk\" t-MN patients, especially persistence or recurrence of their primary cancer or chronic organ dysfunction from primary cytotoxic therapies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=see_link\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Details on the administration of standard induction chemotherapy and consolidation chemotherapy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17274?source=see_link\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Intermediate karyotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a normal karyotype or those who have other abnormalities not described as favorable or unfavorable are considered to have an intermediate risk karyotype. This group comprises approximately 25 percent of patients with t-MN. There is limited information on this subgroup of patients to guide therapy, but they appear to have a greater frequency of relapse after conventional induction therapy and consolidation.",
"   </p>",
"   <p>",
"    The treatment most likely to cure t-AML is allogeneic hematopoietic cell transplantation (HCT). Several small case series and one large retrospective analysis have described the outcomes of these patients and the long term survival appears to be about 20 to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/20,28,33\">",
"     20,28,33",
"    </a>",
"    ]. However, chronic and cumulative toxicities from prior chemoradiotherapy have impact on the ability to perform HCT and adversely affect survival. Early deaths from regimen-related toxicity are more common after HCT for therapy-related leukemia than for primary AML. The two largest series are described below.",
"   </p>",
"   <p>",
"    A case series of 121 patients with t-AML reported a median overall survival time for patients with intermediate-risk karyotype treated with conventional chemotherapy of 13 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An international retrospective analysis of 868 persons who underwent allogeneic transplantation for t-MN (314 of whom had intermediate-risk cytogenetics) reported the following outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rates of treatment-related mortality at one and five years were 41 and 48 percent, respectively.",
"     </li>",
"     <li>",
"      Grade II to IV acute graft versus host disease (GVHD) was seen in 39 percent. Approximately one-third of patients developed chronic GVHD.",
"     </li>",
"     <li>",
"      Relapse was seen in 27 and 31 percent of patients by one and five years, respectively.",
"     </li>",
"     <li>",
"      Disease-free survival was 32 and 21 percent at one and five years, respectively.",
"     </li>",
"     <li>",
"      Overall, 37 and 22 percent of patients were alive at one and five years, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Four risk factors emerged as having an adverse effect on both disease-free and overall survival:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age greater than 35 years",
"     </li>",
"     <li>",
"      Poor-risk cytogenetics",
"     </li>",
"     <li>",
"      T-AML not in remission or advanced t-MDS",
"     </li>",
"     <li>",
"      Donor other than an HLA-identical sibling or a",
"      <span class=\"nowrap\">",
"       partially/well-matched",
"      </span>",
"      unrelated donor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The survival rate at five years for persons with 0, 1, 2, 3, or 4 of these risk factors was 50, 26, 21, 10, and 4 percent respectively.",
"   </p>",
"   <p>",
"    Conventional treatment with induction chemotherapy followed by consolidation chemotherapy has not been directly compared with induction chemotherapy followed by allogeneic HCT in this patient group. In addition, patients with t-MN appear to have a higher rate of adverse outcomes with HCT when compared with patients with de novo AML. This is likely related to the patient-associated factors described earlier. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pre-treatment evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with a good performance status and cytogenetics showing an intermediate-risk profile, we suggest treatment with standard induction chemotherapy followed by an allogeneic HCT (if an HLA-matched donor is available) rather than consolidation chemotherapy. Induction chemotherapy is followed by consolidation chemotherapy for those patients who do not have a matched donor. This preference places a high value on the uncertain yet potential chance of long term survival with allogeneic HCT and places a low value on the treatment related morbidity and mortality associated with this procedure. Older or less fit patients may also choose this option with the understanding that the risks associated with HCT are much higher in these populations.",
"   </p>",
"   <p>",
"    Details on the administration of standard induction chemotherapy and HCT are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17274?source=see_link\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Unfavorable karyotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unfavorable karyotypes include those with 3q21q26 abnormalities, del 5, del 7, monosomies 5 or 7, 11q23 abnormalities, 12p abnormalities, 17p abnormalities, or a complex aberrant karyotypes described as at least 3 abnormalities excluding cases with t(8;21), inv(16), t(9;11), and t(15;17). These former patients do poorly with all known treatment options. Unfortunately, this accounts for the largest group of patients with t-MN (48 percent) and median overall survival with conventional chemotherapy is only six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39480/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since conventional therapy results in unacceptable outcomes, this creates a significant therapeutic dilemma. Our preference is always to consider an appropriate clinical trial. In patients of relatively young age (eg, less than 40 years), conventional chemotherapy may be tried as remission induction to be followed immediately by an early allogeneic hematopoietic cell transplantation. Other patients with unfavorable karyotypes, especially those of higher age, may be encouraged to enroll in a clinical trial of an investigational therapy. As an alternative, less fit and especially elderly patients may choose treatment with supportive care alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/30/34275?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The World Health Organization (WHO) classification of therapy-related myeloid neoplasms (t-MN) includes cases of acute myeloid leukemia (t-AML), myelodysplastic syndrome (t-MDS), or myelodysplastic",
"      <span class=\"nowrap\">",
"       syndrome/myeloproliferative",
"      </span>",
"      neoplasms",
"      <span class=\"nowrap\">",
"       (t-MDS/MPN)",
"      </span>",
"      that develop in patients who have a history of exposure to cytotoxic agents or radiation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The latency period between first exposure to a cytotoxic agent and the development of t-MN ranges from one to 10 years. Patients typically present with symptoms related to complications of pancytopenia including weakness and easy fatigue, infections of variable severity,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bleeding. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of t-MN is made when evaluation of the peripheral blood and bone marrow demonstrates morphologic, immunophenotypic, and cytogenetic changes consistent with the diagnosis of AML, MDS, or",
"      <span class=\"nowrap\">",
"       MDS/MPN",
"      </span>",
"      in a patient with prior exposure to cytotoxic agents or radiation. While individual patients can be subclassified as having t-AML, t-MDS, or",
"      <span class=\"nowrap\">",
"       t-MDS/MPN,",
"      </span>",
"      they are clinically considered as a group and treated in a similar fashion. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While the pretreatment evaluation of patients with t-MN is similar to that of patients with de novo AML, there are a number of complicating factors that impact on the outcomes of patients with t-MN. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pre-treatment evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link&amp;anchor=H2#H2\">",
"       \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Pretreatment evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is a paucity of data on the treatment of t-MN and clinical practice varies widely. Given the uncertainty over the ideal treatment regimen, patients should be encouraged to participate in prospective trials, whenever available. For patients who are not candidates for prospective trials or for those who do not wish to participate in trials, we offer the following approach that takes into account the patient's performance status and leukemia karyotype (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef79891 \" href=\"mobipreview.htm?32/8/32896\">",
"       algorithm 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We reserve chemotherapy for patients who are fully ambulatory (ie, performance status 0 to 2) or have reversible leukemia-related illness. For patients with a poor performance status from chronic co-morbidities at diagnosis, we suggest supportive, symptom-directed care alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Assessment of performance status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a good performance status and cytogenetics showing inv(16) or t(8;21), we suggest treatment with standard induction chemotherapy followed by high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      consolidation rather than allogeneic hematopoietic cell transplantation (HCT) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients with t(15;17), should be treated according to de novo APL protocols. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Favorable karyotype'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=see_link\">",
"       \"Initial treatment of acute promyelocytic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a good performance status and cytogenetics showing an intermediate-risk profile, we suggest treatment with standard induction chemotherapy followed by an allogeneic HCT (if an HLA-matched donor is available) rather than consolidation chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients who are unwilling to assume the high rate of short-term mortality and long-term morbidity associated with HCT may choose consolidation chemotherapy. For those without a matched donor, consolidation chemotherapy is given after induction. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Intermediate karyotype'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since conventional therapy results in poor outcomes, patients with unfavorable karyotypes are encouraged to enroll in a clinical trial of an investigational therapy. As an alternative, patients may choose treatment with supportive care alone. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Unfavorable karyotype'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/2\">",
"      Takeyama K, Seto M, Uike N, et al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol 2000; 71:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/3\">",
"      Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012; 119:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/4\">",
"      Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol 2008; 35:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/5\">",
"      Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/6\">",
"      Rowley JD, Golomb HM, Vardiman JW. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood 1981; 58:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/7\">",
"      Traweek ST, Slovak ML, Nademanee AP, et al. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 1994; 84:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/8\">",
"      Kantarjian HM, Keating MJ, Walters RS, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 4:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/9\">",
"      Gundestrup M, Klarskov Andersen M, Sveinbjornsdottir E, et al. Cytogenetics of myelodysplasia and acute myeloid leukaemia in aircrew and people treated with radiotherapy. Lancet 2000; 356:2158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/10\">",
"      Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/11\">",
"      Ratain MJ, Rowley JD. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol 1992; 3:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/12\">",
"      Pedersen-Bjergaard J. Insights into leukemogenesis from therapy-related leukemia. N Engl J Med 2005; 352:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/13\">",
"      Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007; 25:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/14\">",
"      Pui CH, Relling MV. Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol 2000; 109:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/15\">",
"      Zhang MH, Wang XY, Gao LS. [140 cases of acute leukemia caused by bimolane]. Zhonghua Nei Ke Za Zhi 1993; 32:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/16\">",
"      Xue Y, Lu D, Guo Y, Lin B. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. Leuk Res 1992; 16:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/17\">",
"      Arana-Yi C, Block AW, Sait SN, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine. Leuk Res 2008; 32:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/18\">",
"      Montesinos P, Gonz&aacute;lez JD, Gonz&aacute;lez J, et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. J Clin Oncol 2010; 28:3872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/19\">",
"      Imagawa J, Harada Y, Shimomura T, et al. Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia. Blood 2010; 116:6018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/20\">",
"      Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997; 89:2578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/21\">",
"      Yakoub-Agha I, de La Salmoni&egrave;re P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000; 18:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/22\">",
"      Hale GA, Heslop HE, Bowman LC, et al. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant 1999; 24:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/23\">",
"      Kr&ouml;ger N, Brand R, van Biezen A, et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 2006; 37:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/24\">",
"      Rizzieri DA, O'Brien JA, Broadwater G, et al. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. Cancer 2009; 115:2922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/25\">",
"      Dayyani F, Kantarjian H, O'Brien S, et al. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer 2011; 117:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/26\">",
"      Larson RA, Wernli M, Le Beau MM, et al. Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. Blood 1988; 72:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/27\">",
"      Schoch C, Kern W, Schnittger S, et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004; 18:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/28\">",
"      Armand P, Kim HT, DeAngelo DJ, et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 2007; 13:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/29\">",
"      Nardi V, Winkfield KM, Ok CY, et al. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 2012; 30:2340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/30\">",
"      Larson RA. Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms. J Clin Oncol 2012; 30:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/31\">",
"      Borthakur G, Lin E, Jain N, et al. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer 2009; 115:3217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/32\">",
"      Kayser S, D&ouml;hner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011; 117:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/33\">",
"      Kern W, Haferlach T, Schnittger S, et al. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 2004; 22:2510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/34\">",
"      Andersen MK, Larson RA, Mauritzson N, et al. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002; 33:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/35\">",
"      Slovak ML, Bedell V, Popplewell L, et al. 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. Genes Chromosomes Cancer 2002; 33:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39480/abstract/36\">",
"      Litzow MR, Tarima S, P&eacute;rez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; 115:1850.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4506 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-543E46505B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_35_39480=[""].join("\n");
var outline_f38_35_39480=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Subclassification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cytotoxic agents that have been implicated",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PRE-TREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Assessment of performance status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Risk stratification by karyotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment approach by karyotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Favorable karyotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Intermediate karyotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Unfavorable karyotype",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4506\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4506|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?32/8/32896\" title=\"algorithm 1\">",
"      Management of tMN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4506|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=related_link\">",
"      Pathogenesis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17274?source=related_link\">",
"      Post-remission therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_35_39481="Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias";
var content_f38_35_39481=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39481/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39481/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39481/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39481/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39481/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39481/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39481/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39481/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/35/39481/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardias are broadly categorized based upon the width of the QRS complex on the electrocardiogram (ECG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A narrow QRS complex (&lt;120 milliseconds) reflects rapid activation of the ventricles via the normal His-Purkinje system, which in turn suggests that the arrhythmia originates above or within the His bundle (ie, a supraventricular tachycardia). The site of origin may be in the sinus node, the atria, the atrioventricular (AV) node, the His bundle, or some combination of these sites.",
"     </li>",
"     <li>",
"      A widened QRS (&ge;120 milliseconds) occurs when ventricular activation is abnormally slow. The most common reason that a QRS is widened is because the arrhythmia originates below the His bundle in the bundle branches, Purkinje fibers, or ventricular myocardium (eg, ventricular tachycardia). Alternatively, a supraventricular arrhythmia can produce a widened QRS if there are either pre-existing or rate-related abnormalities within the His-Purkinje system (eg, supraventricular tachycardia with aberrancy), or if conduction occurs over an accessory pathway. Thus, wide QRS complex tachycardias may be either supraventricular or ventricular in origin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=see_link\">",
"       \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will provide a broad overview of the different causes of narrow QRS complex tachycardia and an approach to their evaluation and diagnosis. Detailed discussions of specific narrow complex tachycardias (eg, AVNRT, AVRT, and AT) and a broad discussion of wide complex tachycardias are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436411\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reentry is the most common cause of narrow QRS complex tachycardia. Increased automaticity and triggered activity occur less frequently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436418\">",
"    <span class=\"h2\">",
"     Mechanisms of reentry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reviewed briefly, reentry requires two distinct electrical conduction pathways or tissues with different electrophysiologic properties that are linked proximally and distally, forming an anatomic or functional circuit (",
"    <a class=\"graphic graphic_figure graphicRef52134 \" href=\"mobipreview.htm?9/50/10017\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. The reentrant circuit may become repetitively activated, producing a sustained reentrant tachycardia. The type of arrhythmia that ensues with narrow QRS tachycardias is determined by the characteristics and location of the reentrant circuit (",
"    <a class=\"graphic graphic_figure graphicRef82249 \" href=\"mobipreview.htm?38/33/39441\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The mechanisms of reentry are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436425\">",
"    <span class=\"h2\">",
"     Automaticity and triggered activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other mechanisms of narrow QRS complex tachycardia include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enhanced normal automaticity (as in sinus tachycardia)",
"     </li>",
"     <li>",
"      Abnormal automaticity (resulting in an ectopic atrial or junctional tachycardia)",
"     </li>",
"     <li>",
"      \"Triggered activity\", which may underlie some arrhythmias due to digitalis intoxication (such as atrial tachycardia with or without AV block or arrhythmias in the setting of acute ischemia or infarction)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These mechanisms are considered in detail in topics dealing with the specific arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21864?source=see_link&amp;anchor=H5#H5\">",
"     \"Focal atrial tachycardia\", section on 'Mechanisms and etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28072?source=see_link\">",
"     \"Basic approach to arrhythmias due to digoxin toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436578\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to a rapid heart rate can be quite variable depending on how fast the heart is beating, resultant blood pressure and tissue perfusion, underlying comorbidities, and the sensitivity of the individual patient to the symptoms. Patients with a narrow QRS complex tachycardia can present with a variety of symptoms, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Syncope or presyncope",
"     </li>",
"     <li>",
"      Lightheadedness or dizziness",
"     </li>",
"     <li>",
"      Diaphoresis",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Shortness of breath",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most commonly, patients with a narrow QRS complex tachycardia present with palpitations, the sensation of a rapid or irregular heart beat felt in the anterior chest or neck. Usually the symptoms are abrupt in onset, although this may vary depending on the specific arrhythmia. Palpitations may be associated with diaphoresis, lightheadedness, or dizziness.",
"   </p>",
"   <p>",
"    Patients with a narrow QRS complex tachycardia may also report shortness of breath or chest discomfort. While shortness of breath or chest discomfort can occur in any patient, those with underlying cardiac comorbidities (eg, coronary heart disease, cardiomyopathy or valvular heart disease with or without heart failure) are more likely to present in this fashion, particularly at higher heart rates (&gt;150 beats per minute).",
"   </p>",
"   <p>",
"    Syncope is a rare presentation for persons presenting with a narrow QRS complex tachycardia, since in most instances the heart rate is not so rapid as to impair ventricular function and cardiac output. However, a narrow QRS complex tachycardia with a very rapid ventricular rate (&gt;250 beats per minute, as might be seen in persons with atrial fibrillation or flutter and an accessory pathway) may result in diminished cardiac output and syncope. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Atrial rate'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The physical examination in a patient with narrow QRS complex tachycardia reveals a rapid pulse which may be regular or irregular depending on the underlying cardiac rhythm. Cardiac auscultation also reveals a rapid heartbeat. While other physical examination findings may be present in situations where the tachycardia has led to or exacerbated another condition (eg, hypotension following syncope, lung congestion in a patient with heart failure), there are no other specific physical examination findings which are universally seen in patients with a narrow complex tachycardia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H436522\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a narrow QRS complex tachycardia is usually suspected in a patient with palpitations when a pulse greater than 100 beats per minute is present on physical examination. The differentiation between narrow and wide QRS complex tachycardia requires only a surface electrocardiogram (ECG) which shows a heart rate greater than 100 beats per minute along with narrow QRS complexes that are less than 120 milliseconds in duration. A variety of arrhythmias result in the ECG appearance of a narrow QRS complex tachycardia. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Types of narrow QRS complex tachycardia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Once a narrow QRS complex tachycardia has been identified, further scrutiny of the ECG is required to identify the specific arrhythmia in a particular patient, as diagnostic evaluation and therapy will differ depending on the underlying arrhythmia. (See",
"    <a class=\"local\" href=\"#H684866\">",
"     'Evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Invasive electrophysiology testing is not required to broadly make the diagnosis of a narrow QRS complex tachycardia, but on rare occasions it is needed to diagnose (and potentially treat with catheter ablation) the specific arrhythmia. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Electrophysiologic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF NARROW QRS COMPLEX TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Narrow QRS complex tachycardias can be divided into those that require only atrial tissue for their initiation and maintenance, and those that require the AV junction (",
"    <a class=\"graphic graphic_table graphicRef58019 \" href=\"mobipreview.htm?38/7/39035\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The narrow QRS complex tachycardias include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sinus tachycardia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14742?source=see_link\">",
"       \"Sinus tachycardia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atrioventricular nodal reentrant tachycardia (AVNRT) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24793?source=see_link\">",
"       \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atrioventricular reentrant (or reciprocating) tachycardia (AVRT) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=see_link\">",
"       \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atrial tachycardia (AT) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21864?source=see_link\">",
"       \"Focal atrial tachycardia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inappropriate sinus tachycardia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14742?source=see_link&amp;anchor=H6#H6\">",
"       \"Sinus tachycardia\", section on 'Inappropriate sinus tachycardia'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sinoatrial nodal reentrant tachycardia (SANRT) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34166?source=see_link\">",
"       \"Sinoatrial nodal reentrant tachycardia (SANRT)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intraatrial reentrant tachycardia (IART) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/9/9368?source=see_link\">",
"       \"Intraatrial reentrant tachycardia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Junctional ectopic tachycardia",
"     </li>",
"     <li>",
"      Nonparoxysmal junctional tachycardia",
"     </li>",
"     <li>",
"      Fascicular tachycardia (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26858?source=see_link&amp;anchor=H22#H22\">",
"       \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\", section on 'Idiopathic left ventricular tachycardia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atrial fibrillation (AF) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=see_link\">",
"       \"Overview of atrial fibrillation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atrial flutter (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13256?source=see_link\">",
"       \"Overview of the evaluation and management of atrial flutter\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Multifocal atrial tachycardia (MAT) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38216?source=see_link\">",
"       \"Multifocal atrial tachycardia\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Paroxysmal SVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term paroxysmal supraventricular tachycardia (PSVT) is applied to intermittent SVTs with abrupt onset and offset other than AF, atrial flutter, and MAT. PSVT occurs with an incidence of 35 per 100,000 person-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/4\">",
"     4",
"    </a>",
"    ]. Because they have distinct clinical characteristics, these narrow complex tachycardias are usually considered separately.",
"   </p>",
"   <p>",
"    PSVTs are often due to reentry, although the sites of reentry vary (",
"    <a class=\"graphic graphic_figure graphicRef82249 \" href=\"mobipreview.htm?38/33/39441\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. The major causes are AVNRT, which accounts for approximately 60 percent of cases; AVRT, which accounts for approximately 30 percent of cases; and, in about 10 percent of cases, an AT or SANRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/5\">",
"     5",
"    </a>",
"    ]. Junctional ectopic tachycardia and nonparoxysmal junctional tachycardia are rare in adults but can represent a larger portion of PSVTs in children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AVNRT is characterized by two pathways within the AV node or perinodal atrial tissue. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24793?source=see_link\">",
"       \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      AVRT is characterized by an extranodal accessory pathway connecting the atrium and ventricle. The ECG shows delta waves during sinus rhythm if there is antegrade conduction via the accessory pathway, leading to a diagnosis of Wolff-Parkinson-White syndrome (WPW). The delta waves are lost during an episode of orthodromic AVRT, the most common tachyarrhythmia in patients with WPW. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=see_link\">",
"       \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17370?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      SANRT and intraatrial reentrant tachycardia (IART) are the two major types of paroxysmal reentrant supraventricular tachycardias in which the reentrant circuit does not involve the AV or accessory pathways. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34166?source=see_link\">",
"       \"Sinoatrial nodal reentrant tachycardia (SANRT)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/9/9368?source=see_link\">",
"       \"Intraatrial reentrant tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H684866\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of a patient with a narrow QRS complex tachycardia involves two primary components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assessment of the patient for symptoms and signs of hemodynamic stability (or instability)",
"     </li>",
"     <li>",
"      Assessment of the patient's electrocardiogram (ECG) for clues to the type of tachycardia present",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Often these steps are performed near simultaneously in an acute care setting, as the provider can be assessing the patient at the same time that the ECG is being obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Assessing the patient for hemodynamic stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important clinical determination to make when a narrow QRS tachycardia is noted is whether the patient is experiencing signs and symptoms related to the rapid heart rate. These can include hypotension, shortness of breath, chest pain suggestive of coronary ischemia, shock,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased level of consciousness (",
"    <a class=\"graphic graphic_algorithm graphicRef76920 \" href=\"mobipreview.htm?19/36/20035\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Determining whether a patient's symptoms are related to the tachycardia depends upon several factors, including age and the presence of underlying cardiac disease. As an example, PSVT with a heart rate of 200",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    may be tolerated by an otherwise healthy young adult with no or few symptoms (eg, palpitations). On the other hand, AF at a rate of 120",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    may precipitate angina in an elderly patient with significant coronary heart disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodynamically unstable and not sinus rhythm &ndash; If a patient has clinically significant hemodynamic instability potentially due to a narrow QRS complex tachycardia, an attempt should be made as quickly as possible to determine whether the rhythm is sinus tachycardia (ST). If the rhythm is not ST, or if there is any doubt that the rhythm is ST,",
"      <strong>",
"       urgent conversion",
"      </strong>",
"      to sinus rhythm is recommended. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Similar to sinus rhythm'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6473?source=see_link\">",
"       \"Overview of the acute management of tachyarrhythmias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17977?source=see_link\">",
"       \"Basic principles and technique of cardioversion and defibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemodynamically unstable and sinus rhythm &ndash; If it is certain that the patient's rhythm is ST and clinically significant cardiac symptoms are present, management should be focused on the underlying cardiac disorder and on treating any contributing cause of the rapid heart rate (such as coronary ischemia, respiratory or cardiac failure, hypovolemia, anemia, fever, pain, or anxiety). In patients with ST and certain forms of heart disease, such as coronary disease or aortic stenosis, treatment may need to be directed at the heart rate itself. In such cases, cautious use of an intravenous beta blocker is appropriate (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      5 mg intravenously every 2 minutes until the heart rate is controlled, to a total of 15 mg, followed by an oral regimen). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14742?source=see_link\">",
"       \"Sinus tachycardia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=see_link\">",
"       \"Beta blockers in the management of acute coronary syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/43/41654?source=see_link\">",
"       \"Medical management of symptomatic aortic stenosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemodynamically stable &ndash; If the patient is not experiencing hemodynamic instability, a nonemergent approach to the diagnosis of the patient's rhythm can be undertaken [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/1\">",
"       1",
"      </a>",
"      ]. A close examination of the 12-lead ECG should permit the correct identification of the arrhythmia in 80 percent of cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/6\">",
"       6",
"      </a>",
"      ]. In some patients, increasing the ECG paper speed (from the standard 25",
"      <span class=\"nowrap\">",
"       mm/second",
"      </span>",
"      to 50",
"      <span class=\"nowrap\">",
"       mm/second)",
"      </span>",
"      can improve the likelihood of a correct diagnosis, or simple vagal blocking maneuvers may slow the ventricular rate to better elucidate the underlying rhythm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'ECG identification of atrial activity'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H14\">",
"       'ECG characterization of atrial activity'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Assessing the ECG for regularity of the rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the determination of hemodynamic stability, the next step in the assessment of a narrow QRS complex tachycardia is to determine if the rhythm appears to be regular or irregular (",
"    <a class=\"graphic graphic_algorithm graphicRef76920 \" href=\"mobipreview.htm?19/36/20035\">",
"     algorithm 1",
"    </a>",
"    ). While the majority of narrow QRS complex tachycardias are associated with a regular ventricular rate (with atrial fibrillation being the most notable exception), underlying conduction system disease and certain drug toxicities (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ) can lead to irregular appearing rhythms due to intermittent block of conduction between the atria and the ventricles.",
"   </p>",
"   <p>",
"    Examples of regular and irregular rhythms include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Regular &ndash; sinus tachycardia, atrioventricular nodal reentrant tachycardia, atrioventricular reciprocating tachycardia",
"     </li>",
"     <li>",
"      Irregular &ndash; atrial fibrillation, multifocal atrial tachycardia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the rhythm is irregular, the ECG should be scrutinized for discrete atrial activity and for any evidence of a pattern to the irregularity. If the rhythm is irregularly irregular (that is, no pattern can be detected), the arrhythmia will almost always be either:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atrial fibrillation, where no discernible discrete P waves (",
"      <a class=\"graphic graphic_waveform graphicRef73958 \" href=\"mobipreview.htm?6/32/6663\">",
"       waveform 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef53988 \" href=\"mobipreview.htm?4/14/4325\">",
"       waveform 2",
"      </a>",
"      ) can be identified (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26278?source=see_link\">",
"       \"The electrocardiogram in atrial fibrillation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Multifocal atrial tachycardia, in which discrete P waves of several morphologies (",
"      <a class=\"graphic graphic_waveform graphicRef70173 \" href=\"mobipreview.htm?13/22/13671\">",
"       waveform 3",
"      </a>",
"      ) are present (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38216?source=see_link\">",
"       \"Multifocal atrial tachycardia\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the rhythm is irregular but has some periods of regularity, other arrhythmias (Mobitz I second degree AV block)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drug toxicity (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity) should be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18087?source=see_link\">",
"     \"Second degree atrioventricular block: Mobitz type I (Wenckebach block)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28072?source=see_link\">",
"     \"Basic approach to arrhythmias due to digoxin toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     ECG identification of atrial activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characterization of atrial activity is essential to the diagnosis of narrow complex tachycardias (",
"    <a class=\"graphic graphic_algorithm graphicRef76920 \" href=\"mobipreview.htm?19/36/20035\">",
"     algorithm 1",
"    </a>",
"    ). However, the first step in this process, the identification of P waves, can be difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H684679\">",
"    <span class=\"h3\">",
"     Methods to aid in identifying P waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;In ideal circumstances, P waves can be easily seen on the surface electrocardiogram (ECG). However, due to the rapid rate of the tachycardia, P waves are often superimposed on other parts of the surface ECG. In cases where P waves cannot be clearly identified, the Valsalva maneuver, carotid sinus massage (CSM), or the administration of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    may help to clarify the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/8\">",
"     8",
"    </a>",
"    ]. These maneuvers may also terminate the arrhythmia in some cases (especially if the rhythm is AVNRT or AVRT). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Termination of the arrhythmia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Valsalva maneuver",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Valsalva maneuver induces a temporary slowing of SA nodal activity and AV nodal conduction by stimulating baroreceptors in the aorta, which triggers a reflex increase in vagus nerve activity and sympathetic withdrawal. Patients must be cooperative enough to comply with instructions and must be continually monitored on a cardiac monitor in order for this maneuver to be successful. The process of performing and interpreting the hemodynamic responses to the Valsalva maneuver is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21224?source=see_link&amp;anchor=H7#H7\">",
"     \"Vagal maneuvers\", section on 'Valsalva maneuver'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Valsalva maneuver is generally safe and well-tolerated, though it does require some effort on the patient's part to perform. While the Valsalva maneuver may not be as effective as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    in slowing the AV nodal conduction rate, it can often be accomplished while preparing for an adenosine challenge, especially in patients not eligible for carotid sinus massage. Additionally, the Valsalva maneuver may terminate some narrow complex tachycardias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Carotid sinus massage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid sinus massage induces a temporary slowing of SA nodal activity and AV nodal conduction. External pressure on the carotid bulb stimulates baroreceptors in the carotid sinus, which triggers a reflex increase in vagus nerve activity and sympathetic withdrawal. The process of performing carotid sinus massage is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21224?source=see_link&amp;anchor=H4#H4\">",
"     \"Vagal maneuvers\", section on 'Carotid sinus massage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carotid sinus massage is generally safe and well tolerated, but potential complications include profound hypotension and bradycardia (including transient loss of consciousness), transient ischemic attack or stroke, and arrhythmias. Due to these potential complications, carotid sinus massage should be performed with simultaneous electrocardiographic and blood pressure monitoring. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21224?source=see_link&amp;anchor=H16#H16\">",
"     \"Vagal maneuvers\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Intravenous adenosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"     Adenosine",
"    </a>",
"    interacts with A1 receptors on the surface of cardiac cells, activating potassium channels and causing an increase in potassium conductance (IK). Adenosine also indirectly reduces calcium influx (ICa) into cells by antagonizing catecholamine-stimulated adenylate cyclase. The resulting effects include a slowing of the sinus rate and an increase in the AV nodal conduction delay, similar to the effects seen with the Valsalva maneuver and carotid sinus massage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"     Adenosine",
"    </a>",
"    is used for the intravenous management of paroxysmal narrow QRS complex tachycardias in which the AV node is involved. However, like the Valsalva maneuver and carotid sinus massage, adenosine can have both diagnostic and therapeutic effects, terminating some AV node dependent arrhythmias and producing transient AV nodal block that can clarify diagnoses such as atrial flutter or atrial tachycardia. Adenosine is cleared from the circulation extremely rapidly, with a half-life of less than five seconds, which reduces the likelihood of serious untoward effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H684770\">",
"    <span class=\"h5\">",
"     Administration and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;For intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    administration, the patient should be supine and should have electrocardiographic and blood pressure monitoring. It is valuable to perform a 12-lead rhythm strip during administration of adenosine, as there are often clues at the time of termination as to the mechanism of the PSVT. The drug is administered by rapid intravenous injection over one to two seconds at a peripheral site, followed by a normal saline flush. The rapid administration of both the drug and the saline flush is most easily accomplished through a three-way stopcock. The usual initial dose is 6 mg, which can be followed by a maximal single dose of 12 mg if not successful. Repeated dosing beyond the 12 mg bolus is not usually effective. If a central intravenous access site is used, the initial dose should not exceed 3 mg and may be as little as 1 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/3,8\">",
"     3,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    are blocked by methylxanthines such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    and caffeine and potentiated by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    . Heart transplant recipients exhibit a supersensitive response to adenosine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    are facial flushing (18 percent), shortness of breath, palpitations, chest pain, and lightheadedness. Patients should be warned regarding these symptoms before adenosine administration. Transient asystole is a rare complication.",
"   </p>",
"   <p>",
"    In patients with an accessory pathway capable of antegrade (atrium to ventricle) conduction, AF can degenerate into ventricular fibrillation. As a result, caution should be used when giving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    if an accessory pathway with antegrade conduction is a possible mechanism, and emergency resuscitation equipment should be available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17370?source=see_link&amp;anchor=H8472027#H8472027\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\", section on 'Atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H684777\">",
"    <span class=\"h3\">",
"     Possible outcomes following vagal maneuvers or adenosine administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the Valsalva maneuver, carotid sinus massage, or the intravenous administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    to patients with a narrow QRS complex tachycardia, one of four possible results may be seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The slowing of SA nodal activity can cause a temporary decrease in the atrial rate (in patients with sinus tachycardia).",
"     </li>",
"     <li>",
"      The slowing of AV nodal conduction can lead to AV nodal block, which may \"unmask\" atrial electrical activity (ie, reveal P waves or flutter waves) by decreasing the number of QRS complexes that obscure the electrical baseline (",
"      <a class=\"graphic graphic_waveform graphicRef76876 \" href=\"mobipreview.htm?33/18/34086\">",
"       waveform 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The transient slowing of AV nodal conduction can terminate some narrow QRS complex arrhythmias by interrupting a reentry circuit that requires AV nodal conduction (especially AVNRT and AVRT). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Termination of the arrhythmia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In some cases, no response is obtained. Usually the lack of any response would suggest inadequate performance of the vagal maneuver or inadequate dosing of the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"      (either insufficient dose or administration which was too slow such that the adenosine was metabolized prior to arrival in the heart).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Termination of the arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the Valsalva maneuver, carotid sinus massage, or the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    may terminate the arrhythmia, especially if the rhythm is atrioventricular nodal reentrant tachycardia (AVNRT) or atrioventricular reentrant (or reciprocating) tachycardia (AVRT). A continuous electrocardiogram (ECG) tracing should be recorded during these maneuvers, because the response may aid in the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Termination of the tachycardia with a P wave after the last QRS complex is most common in AVRT or AVNRT and is rarely seen with atrial tachycardia (AT).",
"     </li>",
"     <li>",
"      Termination of the tachycardia with a QRS complex can be seen with AVRT, AVNRT, or AT.",
"     </li>",
"     <li>",
"      If the tachycardia continues despite successful induction of at least some degree of AV nodal blockade, the rhythm is almost certainly AT or atrial flutter; AVRT is excluded, and AVNRT is very unlikely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the use of carotid sinus massage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    does not terminate the tachycardia or permit a diagnosis for the tachycardia that was terminated, further evaluation begins with characterization of the atrial activity (P waves) on the ECG. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'ECG characterization of atrial activity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     ECG characterization of atrial activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification and characterization of atrial activity (ie, the P wave) is central to the diagnosis of narrow QRS complex tachycardias (",
"    <a class=\"graphic graphic_algorithm graphicRef76920 \" href=\"mobipreview.htm?19/36/20035\">",
"     algorithm 1",
"    </a>",
"    ). The evaluation of atrial activity includes assessment of four features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The atrial rate",
"     </li>",
"     <li>",
"      The P wave morphology (ie, identical to normal sinus rhythm, retrograde, or abnormal) (see",
"      <a class=\"local\" href=\"#H16\">",
"       'P wave morphology'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      The position of the P wave in relation to the preceding and following QRS complexes (ie, the RP relationship) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/6\">",
"       6",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H20\">",
"       'RP relationship'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      The relationship between atrial and ventricular rates (1:1 or otherwise)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is uncommon that any one of these features can identify the mechanism of an arrhythmia. In combination, however, these features (particularly the P wave morphology and RP relationship) often provide a probable diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Atrial rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is substantial overlap between the atrial rates of most narrow QRS complex tachycardias. Thus, this feature in isolation is rarely diagnostic. The exception is with very fast atrial rates (eg &gt;250",
"    <span class=\"nowrap\">",
"     beats/minute),",
"    </span>",
"    which are generally associated with one of two diagnoses: atrial flutter or atrial tachycardia (AT).",
"   </p>",
"   <p>",
"    Atrial flutter has several unique features that often make it easily distinguishable from other narrow QRS complex tachycardias, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The atrial rate is typically 250 to 350 beats per minute. Classically, the atrial rate is close to 300 beats per minute with 2:1 AV conduction, resulting in a ventricular rate of 150 beats per minute.",
"     </li>",
"     <li>",
"      The P waves typically exhibit a classic \"sawtooth\" pattern without an isoelectric baseline; these complexes are referred to as flutter waves or \"F\" waves (",
"      <a class=\"graphic graphic_waveform graphicRef82303 \" href=\"mobipreview.htm?3/44/3785\">",
"       waveform 5",
"      </a>",
"      ). If this pattern is not evident initially, vagal stimulation and intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"      can reduce the ventricular rate and make the \"F\" waves more evident (",
"      <a class=\"graphic graphic_waveform graphicRef76876 \" href=\"mobipreview.htm?33/18/34086\">",
"       waveform 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Atypical reentrant circuits (often seen post-operatively or post-ablation) and the influence of antiarrhythmic drugs can alter these classic findings, resulting in atypical flutter waves (",
"    <a class=\"graphic graphic_waveform graphicRef68846 \" href=\"mobipreview.htm?23/35/24119\">",
"     waveform 6",
"    </a>",
"    ). The electrocardiographic and electrophysiologic features of atrial flutter are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12165?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type II atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     P wave morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The P wave morphology provides insight into the site of origin of atrial activity, and therefore the mechanism of the tachycardia. The P wave should be evaluated in as many leads as possible, ideally all 12 leads of a surface ECG, although in some situations a single-lead ECG strip may be all that is available for review.",
"   </p>",
"   <p>",
"    The P wave morphology can be classified into one of three general categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Similar to sinus rhythm",
"     </li>",
"     <li>",
"      Retrograde",
"     </li>",
"     <li>",
"      Abnormal",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     Similar to sinus rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most reliable way to determine if the P wave in a narrow complex tachycardia is consistent with an origin from the sinus node is to compare the P wave during the tachycardia to that from the same patient during sinus rhythm. Although sinus P wave morphology can vary slightly with changes in heart rates, the P wave during the tachycardia should be nearly identical to that seen on the baseline ECG in all 12 leads.",
"   </p>",
"   <p>",
"    If a baseline ECG is not available, characteristics of the P wave can still suggest origin from the region of the sinus node. A sinus P wave is usually upright in leads I, aVL, and the inferior leads II, III, and aVF, and negative in lead aVR. These features indicate that atrial activity is proceeding in a right-to-left and superior-to-inferior direction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37687?source=see_link&amp;anchor=H4#H4\">",
"     \"ECG tutorial: Basic principles of ECG analysis\", section on 'P wave'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At atrial rates greater than approximately 140 beats per minute or in the presence of first degree AV block, the P wave tends to merge into the preceding T or U wave, making P wave identification difficult (",
"    <a class=\"graphic graphic_waveform graphicRef78938 \" href=\"mobipreview.htm?5/41/5780\">",
"     waveform 7",
"    </a>",
"    ). In such cases, slowing of the ventricular response using the Valsalva maneuver, carotid sinus massage, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    may allow for better analysis of the P waves.",
"   </p>",
"   <p>",
"    If P wave morphology is consistent with origination from the sinus node, the differential diagnosis of the tachycardia includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sinus tachycardia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14742?source=see_link&amp;anchor=H4#H4\">",
"       \"Sinus tachycardia\", section on 'Electrocardiographic features'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inappropriate sinus tachycardia (IST) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14742?source=see_link&amp;anchor=H6#H6\">",
"       \"Sinus tachycardia\", section on 'Inappropriate sinus tachycardia'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sinoatrial nodal reentrant tachycardia (SANRT) (",
"      <a class=\"graphic graphic_waveform graphicRef76364 \" href=\"mobipreview.htm?17/28/17862\">",
"       waveform 8",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34166?source=see_link\">",
"       \"Sinoatrial nodal reentrant tachycardia (SANRT)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atrial tachycardia (AT), usually originating near the sinus node (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21864?source=see_link&amp;anchor=H9#H9\">",
"       \"Focal atrial tachycardia\", section on 'Electrocardiographic features'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    P wave morphology alone is not sufficient to distinguish these arrhythmias from one another. In persons with a P wave morphology that is consistent with origination from the sinus node, additional ECG features that assist in the diagnosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial rate &ndash; In sinus tachycardia and IST, the rate typically ranges from 100 to 180 beats per minute. Faster atrial rates suggest an AT.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Onset/offset",
"      </span>",
"      pattern &ndash; Sinus tachycardia and IST have smooth, gradual changes in rate. Both SANRT and AT have an abrupt onset and offset, although the rate in AT can vary significantly with autonomic tone.",
"     </li>",
"     <li>",
"      Relationship between atrial and ventricular activity &ndash; In sinus tachycardia and IST, there is usually a 1:1 relationship between atrial and ventricular activity.",
"     </li>",
"     <li>",
"      The response to vagal maneuvers or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"      &ndash; With ST or IST, there is a gradual slowing of the atrial and ventricular rates, followed by a gradual resumption of the previous rate. In contrast, SNRT can terminate abruptly with these maneuvers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216772\">",
"    <span class=\"h4\">",
"     Abnormal P waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any P wave that does not have the characteristics of a sinus P wave is considered an abnormal P wave. Abnormal P waves that are due to retrograde conduction from the ventricle to the atrium are a specific subset of abnormal P waves. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Retrograde P waves'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Abnormal P waves that are not retrograde are most consistent with atrial tachycardias, although some patients with atrioventricular reciprocating tachycardia have abnormal P waves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h5\">",
"     Retrograde P waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;P waves that are due to retrograde conduction from the ventricle to the atrium are a specific subset of abnormal P waves. These P waves have a characteristic morphology and suggest certain diagnoses, specifically:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atrioventricular nodal reentrant tachycardia (AVNRT)",
"     </li>",
"     <li>",
"      Atrioventricular reentrant (or reciprocating) tachycardia (AVRT)",
"     </li>",
"     <li>",
"      Junctional ectopic tachycardia",
"     </li>",
"     <li>",
"      Nonparoxysmal junctional tachycardia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common retrograde P wave morphology is associated with atrial activation that originates from the AV node and proceeds in an inferior-to-superior direction. Thus, the defining trait of a retrograde P wave is that it is negative in the inferior leads II, III, and aVF. Due to the central location of the AV node, atrial activation proceeds simultaneously leftward and rightward, so the P wave morphology in leads I, aVL, and aVR varies among patients, but it is often relatively narrow. In addition, because the AV node is posteriorly located, the activation is usually posterior-to-anterior, producing a narrow but positive P wave in lead V1.",
"   </p>",
"   <p>",
"    Retrograde P waves due to conduction via an accessory pathway can have a variety of morphologies, depending upon the site of the pathway. However, they are still usually negative in the inferior leads. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17370?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because retrograde P waves are often associated with a short RP interval, they can blend with the terminal portion of the QRS. If a baseline ECG during sinus rhythm is available for comparison, an apparent S wave in the inferior leads or an R' in V1 that is not present during sinus rhythm is often a retrograde P wave (",
"    <a class=\"graphic graphic_figure graphicRef54290 \" href=\"mobipreview.htm?32/3/32830\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/2,6,10\">",
"     2,6,10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'RP relationship'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     RP relationship",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a retrograde P wave, the temporal relationship between the P wave and the R wave divides narrow complex tachycardias into two categories: short RP and long RP tachycardias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h4\">",
"     Short RP tachycardias",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the RP interval is less than one-half of the RR interval, the tachycardia is considered a short RP tachycardia. The differential diagnosis of a short RP tachycardia is generated by considering the P wave morphology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal P wave &ndash; The combination of abnormal P waves and a short RP interval is most often seen in the setting of an atrial tachycardia with AV nodal conduction delay. (See",
"      <a class=\"local\" href=\"#H216772\">",
"       'Abnormal P waves'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retrograde P wave &ndash; The combination of retrograde P waves and a short RP interval is typical of the \"common\" form of AVNRT and of AVRT utilizing an accessory pathway. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Retrograde P waves'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the \"common\" form of AVNRT (which accounts for 90 percent of AVNRT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/11\">",
"     11",
"    </a>",
"    ], reentry occurs in the AV node and perinodal tissues. Antegrade conduction occurs down the slow pathway and retrograde conduction up the fast pathway (",
"    <a class=\"graphic graphic_figure graphicRef79760 \" href=\"mobipreview.htm?1/35/1598\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef50122 \" href=\"mobipreview.htm?42/30/43501\">",
"     figure 5",
"    </a>",
"    ). This slow-fast pattern gives rise to retrograde P waves that may be inapparent if obscured by the QRS complex (",
"    <a class=\"graphic graphic_figure graphicRef54290 \" href=\"mobipreview.htm?32/3/32830\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AVRT utilizing an accessory pathway can be either orthodromic or antidromic. Orthodromic AVRT is more common, and in this form of the arrhythmia, antegrade conduction occurs through the AV node, producing a narrow QRS complex, and retrograde conduction to the atrium occurs over an AV bypass tract (",
"    <a class=\"graphic graphic_figure graphicRef71302 \" href=\"mobipreview.htm?15/35/15926\">",
"     figure 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, during antidromic AVRT, antegrade conduction occurs through the AV bypass tract and retrograde conduction occurs through the AV node or a second accessory pathway. This pattern of activation results in a wide QRS complex (thus, antidromic AVRT is not a narrow QRS complex tachycardia). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h4\">",
"     Long RP tachycardias",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the RP interval is more than one-half of the RR interval, the tachycardia is considered a long RP tachycardia. As with short RP tachycardias, the differential diagnosis is generated by combining the PR relationship with the P wave morphology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retrograde P waves &ndash; The combination of retrograde P waves and a long RP interval is usually caused by either \"atypical\" AVNRT or by AVRT with a slowly conducting accessory pathway; this combination can also be seen in atrial tachycardia with a focus that is close to the AV node [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Retrograde P waves'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormal P waves &ndash; The combination of abnormal P wave morphology and a long RP interval usually suggests some form of atrial tachycardia. However, this pattern can also occur in the atypical or uncommon form of AVNRT and in AVRT with a slowly conducting accessory pathway (also called \"permanent junctional reciprocating tachycardia\" or PJRT) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H216772\">",
"       'Abnormal P waves'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The atypical form of AVNRT, which accounts for 10 percent of AVNRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/11\">",
"     11",
"    </a>",
"    ], is characterized by antegrade conduction down a fast pathway and retrograde conduction through a slow pathway. As a result, the P wave occurs very late in the cardiac cycle (positioning it near to the next QRS complex) (",
"    <a class=\"graphic graphic_figure graphicRef56806 \" href=\"mobipreview.htm?22/16/22799\">",
"     figure 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In AVRT with a slowly conducting accessory pathway (also called \"permanent junctional reciprocating tachycardia\" or PJRT), antegrade conduction probably occurs through the AV node, and retrograde conduction through a slowly conducting accessory pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. Because of slow conduction through the retrograde limb of the circuit, the retrograde P wave occurs late in the cardiac cycle. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Undetectable P waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;If atrial activity is not evident despite the use of carotid sinus massage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    to \"unmask\" atrial activity, the most common rhythm is AVNRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/2\">",
"     2",
"    </a>",
"    ]. Other possible rhythms are atrial fibrillation (AF), AVRT, and junctional tachycardia.",
"   </p>",
"   <p>",
"    Although AF is typically an irregularly irregular rhythm, when the ventricular rate is very rapid, it may appear to be more regular. Vagal maneuvers produce a transient decrease in the ventricular rate with AF, which may make the irregularity more evident.",
"   </p>",
"   <p>",
"    Junctional tachycardia is an arrhythmia arising from a discrete focus within the AV node or His bundle. In children, junctional tachycardia, also known as junctional ectopic tachycardia (JET), is usually associated with significant underlying heart disease. In adults, this rhythm, generally called nonparoxysmal junctional tachycardia (NPJT), is seen with acute myocardial infarction, digitalis toxicity, and myocarditis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16615?source=see_link\">",
"     \"Supraventricular arrhythmias after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atrial activity during junctional tachycardia is variable. Retrograde atrial activation may occur, with a P wave that either follows each QRS complex or is concealed in the QRS complex. If retrograde conduction does not occur, independent atrial activity may be seen, with complete AV dissociation that must be distinguished from AV dissociation due to complete heart block (in complete heart block, the atrial rate exceeds the ventricular rate).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Electrophysiologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, narrow QRS complex tachycardias cannot be discriminated from each other using noninvasive testing. An electrophysiologic study (EPS) can provide a definitive diagnosis, but is not necessary unless it will influence therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39481/abstract/10\">",
"     10",
"    </a>",
"    ]. For some arrhythmias, EPS with ablation can also be curative.",
"   </p>",
"   <p>",
"    EPS and catheter ablation are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/1/3097?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Tachyarrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19866?source=see_link\">",
"     \"Catheter ablation of cardiac arrhythmias: Overview and technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/45/11986?source=see_link\">",
"       \"Patient information: Supraventricular tachycardia (SVT) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A narrow QRS complex (&lt;120 milliseconds) reflects rapid activation of the ventricles via the normal His-Purkinje system, which in turn suggests that the arrhythmia originates above or within the His bundle (ie, a supraventricular tachycardia). The site of origin may be in the sinus node, the atria, the atrioventricular (AV) node, the His bundle, or some combination of these sites. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most commonly, patients with a narrow QRS complex tachycardia present with palpitations, usually abrupt in onset. Other presenting symptoms may include syncope or presyncope, lightheadedness, dizziness, diaphoresis, chest pain, or shortness of breath. (See",
"      <a class=\"local\" href=\"#H436578\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of a narrow QRS complex tachycardia requires only a surface electrocardiogram (ECG) which shows a heart rate greater than 100 beats per minute along with narrow QRS complexes that are less than 120 milliseconds in duration. (See",
"      <a class=\"local\" href=\"#H436522\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of narrow QRS complex tachycardias is broad (",
"      <a class=\"graphic graphic_table graphicRef58019 \" href=\"mobipreview.htm?38/7/39035\">",
"       table 1",
"      </a>",
"      ), including atrial fibrillation (AF), atrial flutter, sinus tachycardia, and a variety of paroxysmal supraventricular tachycardias. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of narrow QRS complex tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of a patient with a narrow QRS complex tachycardia involves two primary components (",
"      <a class=\"graphic graphic_algorithm graphicRef76920 \" href=\"mobipreview.htm?19/36/20035\">",
"       algorithm 1",
"      </a>",
"      ): assessment of the patient for symptoms and signs of hemodynamic stability (or instability), and assessment of the patient's electrocardiogram (ECG) for clues to the type of tachycardia present. (See",
"      <a class=\"local\" href=\"#H684866\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If a patient has clinically significant hemodynamic instability and the rhythm is not sinus tachycardia, or if there is any doubt that the rhythm is sinus tachycardia,",
"      <strong>",
"       urgent conversion",
"      </strong>",
"      to sinus rhythm is recommended.",
"     </li>",
"     <li>",
"      If it is certain that the patient's rhythm is ST and clinically significant cardiac symptoms are present, management should be focused on the underlying cardiac disorder and on treating any contributing cause of the rapid heart rate (such as myocardial ischemia due to coronary heart disease, respiratory or cardiac failure, hypovolemia, anemia, fever, pain, or anxiety).",
"     </li>",
"     <li>",
"      If the patient is not experiencing hemodynamic instability, a nonemergent approach to the diagnosis of the patient's rhythm can be undertaken.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following the determination of hemodynamic stability, the next step in the assessment of a narrow QRS complex tachycardia is to determine if the rhythm appears to be regular or irregular. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Assessing the ECG for regularity of the rhythm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Making a specific diagnosis among the paroxysmal SVTs is more difficult. Following the determination of the regularity or irregularity of the rhythm, the most important feature is the identification and characterization of atrial activity (P waves) (",
"      <a class=\"graphic graphic_algorithm graphicRef76920 \" href=\"mobipreview.htm?19/36/20035\">",
"       algorithm 1",
"      </a>",
"      ). Utilization of vagal maneuvers such as the Valsalva maneuver, carotid sinus massage, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"      administration may be required to identify P waves and may at times ameliorate the abnormal rhythm. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'ECG identification of atrial activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once P waves are identified, the following characteristics should be determined: atrial rate, P wave morphology, RP relationship, and AV relationship. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'ECG characterization of atrial activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overall management of narrow QRS complex tachycardias is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/6/39016?source=see_link\">",
"       \"Management of new onset atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13256?source=see_link\">",
"       \"Overview of the evaluation and management of atrial flutter\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6473?source=see_link\">",
"       \"Overview of the acute management of tachyarrhythmias\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39481/abstract/1\">",
"      Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med 1995; 332:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39481/abstract/2\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003; 108:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39481/abstract/3\">",
"      Ferguson JD, DiMarco JP. Contemporary management of paroxysmal supraventricular tachycardia. Circulation 2003; 107:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39481/abstract/4\">",
"      Orejarena LA, Vidaillet H Jr, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol 1998; 31:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39481/abstract/5\">",
"      Trohman RG. Supraventricular tachycardia: implications for the intensivist. Crit Care Med 2000; 28:N129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39481/abstract/6\">",
"      Kalbfleisch SJ, el-Atassi R, Calkins H, et al. Differentiation of paroxysmal narrow QRS complex tachycardias using the 12-lead electrocardiogram. J Am Coll Cardiol 1993; 21:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39481/abstract/7\">",
"      Accardi AJ, Miller R, Holmes JF. Enhanced diagnosis of narrow complex tachycardias with increased electrocardiograph speed. J Emerg Med 2002; 22:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39481/abstract/8\">",
"      Link MS. Clinical practice. Evaluation and initial treatment of supraventricular tachycardia. N Engl J Med 2012; 367:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39481/abstract/9\">",
"      Ellenbogen KA, Thames MD, DiMarco JP, et al. Electrophysiological effects of adenosine in the transplanted human heart. Evidence of supersensitivity. Circulation 1990; 81:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39481/abstract/10\">",
"      Chauhan VS, Krahn AD, Klein GJ, et al. Supraventricular tachycardia. Med Clin North Am 2001; 85:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39481/abstract/11\">",
"      Akhtar M, Jazayeri MR, Sra J, et al. Atrioventricular nodal reentry. Clinical, electrophysiological, and therapeutic considerations. Circulation 1993; 88:282.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 943 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.150-9E46D5F071-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_35_39481=[""].join("\n");
var outline_f38_35_39481=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H436411\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H436418\">",
"      Mechanisms of reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H436425\">",
"      Automaticity and triggered activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H436578\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H436522\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF NARROW QRS COMPLEX TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Paroxysmal SVT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H684866\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Assessing the patient for hemodynamic stability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Assessing the ECG for regularity of the rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ECG identification of atrial activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H684679\">",
"      - Methods to aid in identifying P waves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Valsalva maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Carotid sinus massage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intravenous adenosine",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H684770\">",
"      - Administration and side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H684777\">",
"      - Possible outcomes following vagal maneuvers or adenosine administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Termination of the arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ECG characterization of atrial activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Atrial rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - P wave morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Similar to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H216772\">",
"      Abnormal P waves",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Retrograde P waves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - RP relationship",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Short RP tachycardias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Long RP tachycardias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Undetectable P waves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Electrophysiologic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/943\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/943|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?19/36/20035\" title=\"algorithm 1\">",
"      Narrow complex tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/943|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/50/10017\" title=\"figure 1\">",
"      Mechanisms of reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/33/39441\" title=\"figure 2\">",
"      Sites of reentry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/3/32830\" title=\"figure 3\">",
"      Typical atrioventricular nodal reentrant tahcycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/35/1598\" title=\"figure 4\">",
"      Common slow fast AVNRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/30/43501\" title=\"figure 5\">",
"      ECG generation in common AVNRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/35/15926\" title=\"figure 6\">",
"      Orthodromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/16/22799\" title=\"figure 7\">",
"      Uncommon fast slow AVNRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/943|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/7/39035\" title=\"table 1\">",
"      Narrow QRS complex tachycardia classification by anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/943|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?6/32/6663\" title=\"waveform 1\">",
"      Atrial fibrillation 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?4/14/4325\" title=\"waveform 2\">",
"      Atrial fibrillation 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?13/22/13671\" title=\"waveform 3\">",
"      Multifocal atrial tachycardia ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?33/18/34086\" title=\"waveform 4\">",
"      Atrial flutter CS massage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?3/44/3785\" title=\"waveform 5\">",
"      ECG atrial flutter tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?23/35/24119\" title=\"waveform 6\">",
"      Atrial flutter Type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?5/41/5780\" title=\"waveform 7\">",
"      ECG strip sinus tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?17/28/17862\" title=\"waveform 8\">",
"      ECG SA nodal reentrant tachycardia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19866?source=related_link\">",
"      Catheter ablation of cardiac arrhythmias: Overview and technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37687?source=related_link\">",
"      ECG tutorial: Basic principles of ECG analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12165?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type II atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17370?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21864?source=related_link\">",
"      Focal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/9/9368?source=related_link\">",
"      Intraatrial reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/1/3097?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/6/39016?source=related_link\">",
"      Management of new onset atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/43/41654?source=related_link\">",
"      Medical management of symptomatic aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38216?source=related_link\">",
"      Multifocal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13256?source=related_link\">",
"      Overview of the evaluation and management of atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/45/11986?source=related_link\">",
"      Patient information: Supraventricular tachycardia (SVT) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18087?source=related_link\">",
"      Second degree atrioventricular block: Mobitz type I (Wenckebach block)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34166?source=related_link\">",
"      Sinoatrial nodal reentrant tachycardia (SANRT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14742?source=related_link\">",
"      Sinus tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16615?source=related_link\">",
"      Supraventricular arrhythmias after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21224?source=related_link\">",
"      Vagal maneuvers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_35_39482="Breast imaging: Mammography and ultrasonography";
var content_f38_35_39482=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Breast imaging: Mammography and ultrasonography",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39482/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39482/contributors\">",
"     Shambhavi Venkataraman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39482/contributors\">",
"     Priscilla J Slanetz, MD, MPH, FACR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39482/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39482/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/35/39482/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/35/39482/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/35/39482/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening mammography is the primary imaging modality for early detection of breast cancer because it is the only method of breast imaging that consistently has been found to decrease breast cancer-related mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Mammography may detect cancer one and a half to four years before a cancer becomes clinically evident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ongoing technologic advancements, to both enhance mammography and develop other breast imaging modalities, seek to provide earlier diagnosis of breast disease; more accurate assessment of disease extent and treatment response; and improve the detection of recurrence.",
"   </p>",
"   <p>",
"    This topic will review mammography technique, performance capabilities of mammography in particular patient groups, interpretation of a mammogram report, and the use of breast ultrasound as an adjunct to mammography. Issues regarding screening for breast cancer, the role of mammography in women with suspected disease, and surveillance for patients with known breast cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10009?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link\">",
"     \"Approach to the long-term survivor of breast cancer\"",
"    </a>",
"    .) Other imaging techniques for breast disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23002?source=see_link\">",
"     \"MRI of the breast and emerging technologies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MAMMOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first x-ray of the breast, obtained in 1913 from a mastectomy specimen, showed the presence of primary tumor in the breast specimen as well as spread to the axillary lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/6\">",
"     6",
"    </a>",
"    ]. Calcifications were reported in radiographs of breast cancer in 1949 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/6\">",
"     6",
"    </a>",
"    ]. Soon after this, patient positioning for radiographs of the breast similar to present day standard views were described.",
"   </p>",
"   <p>",
"    The prototype of the mammography unit was developed in 1965 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/6\">",
"     6",
"    </a>",
"    ]. Many technical advances have been made since then to improve the image quality, as well as to reduce the radiation dose to the patient.",
"   </p>",
"   <p>",
"    A mammogram involves exposing the breast to x-rays. These x-rays are both transmitted through the breast tissue as well as scattered to the surrounding tissue. The x-rays are attenuated based upon the characteristics of the breast tissue, and are then absorbed as latent images on the recording device (",
"    <a class=\"graphic graphic_figure graphicRef51636 \" href=\"mobipreview.htm?39/50/40737\">",
"     figure 1",
"    </a>",
"    ). The latent image is processed and displayed for diagnostic purposes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THE MAMMOGRAPHIC EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine evaluation includes obtaining two views (craniocaudal and mediolateral oblique) of each breast. In the craniocaudal (CC) view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65703 \" href=\"mobipreview.htm?5/58/6054\">",
"     image 1",
"    </a>",
"    ), the breast is lifted and positioned on the plate and compression is applied from above. In the mediolateral oblique (MLO) view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75940 \" href=\"mobipreview.htm?10/59/11191\">",
"     image 2",
"    </a>",
"    ), the breast is compressed and imaged from the side. Breast positioning is critical. Improper positioning may lead to exclusion of parts of the breast from the field of view, risking non-visualization of a cancer (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75653 \" href=\"mobipreview.htm?25/35/26161\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These two standard views ensure adequate imaging of the relatively mobile inferior and lateral parts and the relatively fixed upper and medial parts of the breast. Obtaining two views for each breast aids in distinguishing overlapping structures from true abnormalities.",
"   </p>",
"   <p>",
"    The added benefit of detecting more cancers and lower recall rates with two views outweighs the extra cost and radiation from the second view [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Studies have shown that 11 to 25 percent of cancers could be missed if only one view were obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. When circumstances dictate that only one view is to be obtained, the MLO view, which images a greater amount of breast tissue compared to the CC view, is preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Breast compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate breast compression is necessary to obtain good quality mammograms. Compression increases the image contrast and decreases the radiation dose. Since compression causes homogeneous breast thickness, x-ray penetration is uniform through the tissues. Compression also reduces motion and minimizes superimposition of tissues, improving the diagnostic quality of the study (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74381 \" href=\"mobipreview.htm?14/38/14947\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Compression ideally should be applied until the breast is held firm and immobile. However, the degree of pain and discomfort experienced during the examination affects the utilization of regular mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. One way of making the examination more tolerable is to give patients control over the degree of compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The utility of patient-controlled compression was evaluated in a study of 109 patients undergoing screening mammography. All women were imaged in the same mammography unit. By random assignment, one breast was compressed by the technologist and the other by the patient. Patient-controlled compression was significantly less painful, and preserved image quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other attempts to relieve anxiety and discomfort associated with mammography have included use of a soft breast cushion, premedication with oral analgesics, and application of topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    to the breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/15-20\">",
"     15-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premedication with topical 4 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      gel significantly reduced discomfort during screening mammograms in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/18\">",
"       18",
"      </a>",
"      ]. The topical medication is best applied in the doctor's office by trained medical professionals. The topical anesthetic should be applied sparingly, and not to irritated skin, as case reports of death have been reported when topical anesthetics were applied to large body surface areas for laser hair removal. The US Food and Drug Administration issued an alert in this regard in 2009 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of radiolucent cushions on the compression paddle surface decreased pain in more than 65 percent of 838 women in one series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/20\">",
"       20",
"      </a>",
"      ]. Pain decreased by an average of 53 percent compared to the noncushioned breast in those women who experienced pain relief. There was no compromise in image quality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Radiation dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of screening mammography is to decrease mortality by identifying early stage breast cancer. There is no evidence that routine screening mammography in women, initiated at age 40, is associated with increased risk from radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is concern, however, that women with BRCA1 or BRCA2 mutations are at increased risk for radiation-induced oncogenesis, because of impaired DNA repair mechanisms. For these women, in whom initiation of screening at an early age is usually recommended, the risk of radiation-induced cancer needs to be balanced against the risk of gene-related early onset cancer; the appropriate age to initiate mammogram screening is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For all women, it is important to keep the radiation dose as low as possible without compromising image quality. The development of more efficient emulsions and screens in film screen mammography has decreased the dose per exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Despite technologic improvements, a film screen system does not use all the x-ray photons that pass through the breast. Digital mammography is associated with a lower radiation dose than film screen mammography for the same image quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The radiation dose absorbed by the breast depends upon the breast tissue thickness, with the dose absorbed increasing with the thickness of the breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/29\">",
"     29",
"    </a>",
"    ]. Most mammography equipment delivers a mean glandular dose of 0.1 to 0.2 rads (1 to 2 mGy) per exposure. The American College of Radiology recommends that the mean glandular dose exposure for a breast that is 4.2 cm thick should not exceed 0.3 rads (3 mGy) per image.",
"   </p>",
"   <p>",
"    The effective radiation dose is often expressed in sievert or millisievert (mSv) units. Sievert units account for relative sensitivities of different tissues and organs exposed to radiation. The effective dose received from a routine screening mammogram is 0.7 mSv, equivalent to the dose received from natural background radiation over three months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Film screen mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammogram x-rays pass through the breast tissue and are converted to light by fluorescent screens. This light causes a chemical reaction in the film emulsion that is processed and displayed as a grayscale image. In a film screen (analog) mammogram, the image is captured, displayed, and archived for storage in a film [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/7,30\">",
"     7,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Film has multiple attributes that make it an appropriate medium for mammography:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High spatial resolution (up to 20 line pairs per millimeter) allows demonstration of microcalcifications, lesion margins, and spiculations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High contrast resolution permits differentiation of subtle differences in soft tissue densities.",
"     </li>",
"     <li>",
"      The film is easily displayed.",
"     </li>",
"     <li>",
"      Normal areas of the breast image can be masked to improve visualization of abnormalities.",
"     </li>",
"     <li>",
"      Multiple examinations can be viewed on serial view panels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, film screen mammography has a number of disadvantages, compared to full field digital mammography (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Full field digital mammography'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A limited dynamic range makes it difficult to image all components of the breast (fat and dense tissue) optimally, and to differentiate between small cancers and surrounding breast tissue of similar density.",
"     </li>",
"     <li>",
"      The inability to manipulate the image following exposure may lead to retakes and increased radiation dose to the patient.",
"     </li>",
"     <li>",
"      Film is subject to artifacts from processing and storage.",
"     </li>",
"     <li>",
"      Films may be misfiled, lost, or otherwise not readily retrievable when comparisons are needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two standard cassettes 18 x 24 cm and 24 x 30 cm are available to accommodate breasts of different sizes. Women with larger breasts may require more than two views of each breast to ensure imaging of all breast tissues. Narrow compression paddles (half the width of regular paddle) are also available for women with small breasts and for men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Full field digital mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first digital mammograms were digitized copies of film screen mammograms. Digital mammograms are now obtained directly, with digital detectors used in place of film screen systems. The detectors convert the x-ray photons to an electronic signal. This is changed to a digital value with the help of an analog to digital converter.",
"   </p>",
"   <p>",
"    The digital image is further processed and displayed as a gray scale image [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/30,32-34\">",
"     30,32-34",
"    </a>",
"    ]. The digital image can be processed by the computer and displayed in multiple formats. The digital signal can be sent electronically to the viewing station and displayed on high resolution monitors as a soft copy, or printed on dry laser printers and read on high luminance viewboxes as a hard copy, similar to film screen mammogram.",
"   </p>",
"   <p>",
"    Digital mammography has many advantages over film screen mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Greater contrast resolution, especially in dense breasts. Wider dynamic range and higher contrast resolution enables better visualization of skin and peripheral breast tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ability to post process the image by changing contrast and brightness, and by enlarging the image, increase the ability to detect subtle abnormalities.",
"     </li>",
"     <li>",
"      The ability to send images electronically, making remote reading possible (teleradiology). In addition, images can be made available for simultaneous reading at multiple viewing stations, facilitating double reading and expert consultation as needed.",
"     </li>",
"     <li>",
"      The ability to store images in optical drives for future reference.",
"     </li>",
"     <li>",
"      Lower average radiation dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Digital mammography also has certain disadvantages compared to film screen mammography:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Digital images have less spatial resolution compared to film, which in part is compensated by post processing.",
"     </li>",
"     <li>",
"      Higher-resolution display monitors, which are more expensive than standard monitors, are needed to view the high detail and quality of a digital mammographic image.",
"     </li>",
"     <li>",
"      Digital systems are expensive, with costs being 1.5 to 4.0 times as much as a film-based system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Digital versus film screen mammogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have compared the performance of digital and film screen mammography, and most have found little difference in cancer detection rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/37-46\">",
"     37-46",
"    </a>",
"    ]. The best data come from the randomized Oslo II Study and the DMIST study.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The largest study, the Digital Mammographic Imaging Screening Trial (DMIST), involved 49,528 asymptomatic women who underwent both film and digital mammography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/41\">",
"       41",
"      </a>",
"      ]. The overall diagnostic accuracy was similar with the two modalities, but digital mammography was more accurate for premenopausal and perimenopausal women, and women with dense breasts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. No differences in performance were found between three different digital systems [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/47\">",
"       47",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      An analysis using the DMIST data found that screening all women age 40 and older by digital, rather than film, mammography was not cost-effective, with each quality-adjusted life year (QALY) gained costing $331,000 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/48\">",
"       48",
"      </a>",
"      ]. Targeting screening with digital mammography to women &le;50 years of age was cost-effective ($26,500 per QALY gained).",
"      <br/>",
"     </li>",
"     <li>",
"      The Oslo II Study randomly assigned 25,263 women aged 45 to 69 years to either digital or film screen mammography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. At two years, the rate of breast cancer detection was significantly higher for those assigned to full field digital mammography compared to film mammography (0.59 and 0.38 percent respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/40\">",
"       40",
"      </a>",
"      ]. The positive predictive value was the same for both technologies. Detection rates of invasive cancer were higher with digital mammography but essentially the same for ductal carcinoma in situ [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, film mammography remains an acceptable screening modality for all women. Digital mammography, when available, may offer a small screening advantage in women younger than 50 years old.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Online versus offline reading",
"    </span>",
"    &nbsp;&mdash;&nbsp;At most centers, once the four standard views (two per breast) are obtained, and the image quality is approved by the technologist, the woman leaves the center without knowing the results of the study. The study is later interpreted in batches along with other screening mammograms performed that day. One radiologist usually reads 40 to 60 mammograms as a batch. Written results are conveyed to the referring clinician as well as mailed to the patient. At most centers, the patient is contacted by the radiology department to return for a diagnostic study if additional imaging is required.",
"   </p>",
"   <p>",
"    Batch reading offers many advantages. The interpreting radiologist is not interrupted during interpretation by discussions with the technologist or patients between examinations. Batch reading permits double reading, in which each mammogram is reviewed independently by two radiologists. The prior mammograms of the patient are generally made available for comparison during batch interpretation. The availability of prior studies facilitates the evaluation of subtle changes and may decrease the number of false positive results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to batch reading, some centers perform \"online reading,\" where the mammogram is immediately interpreted by a radiologist. Additional imaging can be performed at the same visit, if needed. Results are conveyed to the patient after the study is completed. Patients report greater satisfaction with this procedure, citing immediate knowledge of their results, having the opportunity to talk to a radiologist on the day of their examination, and reduced anxiety and stress associated with having to return for additional evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In a randomized trial, immediate reading of screening mammograms was associated with less anxiety among women with false positive mammograms three weeks after mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Online reading also has disadvantages. Immediate interpretation necessitates the presence of a radiologist for the entire session that mammograms are scheduled. The need to immediately perform additional views or an ultrasound, when indicated, disrupts the schedule and results in longer waiting time for the scheduled patients. The added radiologist and technologist time, as well as need for additional equipment and space, increases the cost per examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective analysis of 8698 screening mammograms analyzed the rate of recall and cancer detection between immediate and batch interpretation rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/56\">",
"     56",
"    </a>",
"    ]. Rates of additional imaging were higher in the group that had immediate reading, but there was no difference in the number of cancers detected between the two groups. The study also found that comparison studies were available less frequently when studies were interpreted immediately following imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Double reading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Double reading refers to a center whereby two radiologists review every screening mammogram. The aim of double reading is to increase the rate of cancer detection.",
"   </p>",
"   <p>",
"    Double reading is standard practice in many European countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/57,58\">",
"     57,58",
"    </a>",
"    ], but not in the United States. The examination can be interpreted by the two radiologists either independently or interpreted together in consensus.",
"   </p>",
"   <p>",
"    If readers differ in their interpretation of a mammogram study, institutional protocols differ on how this is adjudicated: patients may be called back for follow-up studies if either reader identifies an abnormality (highest reader recall), a third reader may review the films to determine need for follow-up (arbitration), or a group of radiologists, which may or may not include the original readers, discuss the discordant cases (consensus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/59\">",
"     59",
"    </a>",
"    ]. One study found that consensus reading resulted in recall for 45 percent of cases reviewed, with malignancy diagnosed in 11.7 percent of the recalled cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/60\">",
"     60",
"    </a>",
"    ]. Review of data collected from over 1 million screening examinations in women aged 50 to 69 years participating in the Norwegian Breast Cancer Screening Program, where double reading is standard, found that 23.6 percent of the cancers detected (1326 of 5611) were diagnosed in women who were recalled for discordant interpretations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/61\">",
"     61",
"    </a>",
"    ]. About 50 percent of the radiologists in this program were dedicated mammography readers.",
"   </p>",
"   <p>",
"    Several studies have demonstrated benefit for double reading but randomized controlled trials have not been performed to evaluate its impact on long term outcomes. Although not all individual studies have demonstrated an effect on cancer detection rates, a meta-analysis of seventeen studies found that cancer detection rates were improved by 10 percent comparing double and single reading (OR 1.10, 95% CI 1.06-1.14) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/62\">",
"     62",
"    </a>",
"    ]. In this analysis, 2222 women would need to be screened by double reading with arbitration for each additional cancer detected. The recall rate for double reading with arbitration, compared to single reading, was decreased (0.94, 0.92-0.96), although the recall rate was increased for double reading without arbitration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/62\">",
"     62",
"    </a>",
"    ]. In the United States, most often the second reader is solely looking to identify any abnormality that may have been overlooked by the first radiologist, which does lead to increased recall rates and false-positive examinations but greater cancer detection rates.",
"   </p>",
"   <p>",
"    Double reading increases radiologist time and therefore the cost per examination. There may also be a delay before the final interpretation can be made. Two studies found that both patients and clinicians preferred delayed batch reading with double reading to immediate reading, once the benefits of double reading were explained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Computer aided detection (CAD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computer-aided detection (CAD) refers to computer-based technology designed to recognize mammographic patterns and help radiologists identify suspicious areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/65\">",
"     65",
"    </a>",
"    ]. CAD reading of digitalized or digital mammograms places marks in areas of concern, most often calcifications, masses, or asymmetries, for special attention in review by the radiologist; on average, four marks are placed per mammogram. The US Food and Drug Administration approved CAD in 1998 after several studies showed the usefulness of CAD in increasing cancer detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. Among Medicare patients receiving screening mammograms between 2004 and 2008, CAD was used in the interpretation of nearly 75 percent of studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Debate continues over the effectiveness of CAD in breast cancer screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. No randomized trials have been performed to determine its effect on breast cancer mortality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of ten studies reported the effect on cancer detection and recall rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/62\">",
"       62",
"      </a>",
"      ]. When CAD was compared with singly-read mammograms, a small statistically insignificant increase in cancer detection (OR 1.04; 95% CI 0.96-1.13) was found, associated with more false positive readings and higher recall rates (OR 1.10; 1.08-1.12).",
"     </li>",
"     <li>",
"      The effectiveness of CAD for film-screen mammography was evaluated in a study of mammography results between 1998 and 2006 from centers in seven states participating in the Breast Cancer Surveillance Consortium and involving more than 1.6 million mammograms; CAD was implemented in 25 of the 90 facilities participating in the consortium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/72\">",
"       72",
"      </a>",
"      ]. Use of CAD was associated with decreased specificity (OR 0.87, 95% CI 0.85-0.89), lower positive predictive value (OR 0.89, 0.80-0.99), a nonstatistically significant increase in overall sensitivity (OR 1.06, 0.84-1.33) accounted for by an increase in the diagnosis of ductal carcinoma in situ (DCIS) but not invasive breast cancer, and no improvement in stage or lymph node status of detected breast cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CAD increases the detection of ductal carcinoma in situ (DCIS) as CAD software has increased sensitivity to detect calcifications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. Since the natural history of DCIS is indolent and uncertain, the benefit of early detection and treatment for this condition is unclear and the potential for over-treatment of preclinical disease is raised. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/33/6680?source=see_link\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37561?source=see_link\">",
"     \"Ductal carcinoma in situ: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/14998?source=see_link\">",
"     \"Microinvasive breast carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cancer detection rates for single reading with CAD have been compared to double reading [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/73,76-80\">",
"     73,76-80",
"    </a>",
"    ]. These studies find similar rates of cancer detection for the two models of mammographic interpretation. Recall rates have been reported as both higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/81\">",
"     81",
"    </a>",
"    ] and lower [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/76\">",
"     76",
"    </a>",
"    ] for CAD, compared with double reading, and may depend on how discordant readings were managed with double reading.",
"   </p>",
"   <p>",
"    The sensitivity of CAD to identify lesions in retrospective readings of breasts with known cancer has been reported to range from 76 to 94 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/78,82,83\">",
"     78,82,83",
"    </a>",
"    ]. The absence of a CAD finding should not negatively influence the radiologist decision to recall a patient for additional studies.",
"   </p>",
"   <p>",
"    In summary, CAD may improve the sensitivity of mammographic screening to a limited extent. This may be offset by a higher recall rate, and the potential for overdiagnosis. CAD has not been proven to improve mortality rates from breast cancer screening, and the costs associated with the equipment and increased recall rate with CAD may outweigh possible marginal benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ABNORMALITIES ON MAMMOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammogram abnormalities include masses, calcifications, asymmetry, and architectural distortion. The significance of these findings depends on their radiologic appearance as well as the patient's age, race, and ethnicity. Specific mammographic findings of breast cancer are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24138?source=see_link\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most specific mammographic feature of malignancy is a spiculated focal mass. The positive predictive value of a mass with a spiculated margin is 81 percent and with irregular shape is 73 percent (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57593 \" href=\"mobipreview.htm?35/59/36799\">",
"       image 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef77782 \" href=\"mobipreview.htm?29/9/29845\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/84-86\">",
"       84-86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The density of a non-calcified mass is a significant factor in predicting malignancy. Seventy percent of masses with high density were malignant, and 22 percent of masses with low density were malignant in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clustered microcalcifications (calcium particles of various size and shape measuring between 0.1 to 1 mm in diameter and numbering more than four to five per cubic centimeter) are seen in approximately 60 percent of cancers detected mammographically (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62953 \" href=\"mobipreview.htm?22/41/23188\">",
"       image 6",
"      </a>",
"      ). Histologically, these represent intraductal calcifications in areas of necrotic tumor or calcifications within mucin-secreting tumors.",
"     </li>",
"     <li>",
"      Linear branching microcalcifications (",
"      <a class=\"graphic graphic_picture graphicRef73616 \" href=\"mobipreview.htm?6/17/6423\">",
"       picture 2",
"      </a>",
"      ) have a higher predictive value for malignancy than do granular (ie, nonlinear irregular calcifications of varying size and shape) microcalcifications, particularly for high grade DCIS. However, breast cancers, including DCIS, more often present with the granular type of calcifications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Calcifications that are not suspicious for malignancy and considered benign include vascular and skin calcifications, rim-like calcifications, large coarse calcifications (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75088 \" href=\"mobipreview.htm?12/47/13045\">",
"     image 7",
"    </a>",
"    ), and smooth round or oval calcifications (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52281 \" href=\"mobipreview.htm?41/6/42094\">",
"     image 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One prospective study linked findings from 10,641 mammograms performed in 20 facilities over four years with the regional cancer database (Surveillance Epidemiology and End Results program or SEER) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/87\">",
"     87",
"    </a>",
"    ]. Focal mass was the most frequent abnormality (56 percent) identified in women found to have breast cancer, followed by calcifications (29 percent). Asymmetry was a frequent reason for additional evaluation (42 percent), but was a finding in only 12 percent of women with breast cancer. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MAMMOGRAPHY QUALITY CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variation in mammographic quality and standard of practice throughout the United States led to the development of the mammographic accreditation program by the American College of Radiology in 1987 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. The Mammography Quality Standards Act (MQSA) was passed in 1992 by Congress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. The MQSA establishes guidelines for quality control for individual imaging centers and mandates that all US facilities should be accredited by the American College of Radiology.",
"   </p>",
"   <p>",
"    The Breast Imaging Reporting and Data System (BI-RADS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/93\">",
"     93",
"    </a>",
"    ], was developed by the American College of Radiology to standardize the mammography report. BI-RADS was initially developed for mammography, but has now been extended to breast ultrasound and MRI interpretation as well.",
"   </p>",
"   <p>",
"    The BI-RADS manual consists of standardized language to describe the radiological findings and conclusions. One of seven final assessments categories should be used at the conclusion of each report (",
"    <a class=\"graphic graphic_table graphicRef66601 \" href=\"mobipreview.htm?38/19/39227\">",
"     table 1",
"    </a>",
"    ). The final diagnostic assessment categories indicate the relative likelihood of a normal, benign, or malignant diagnosis based solely on the imaging findings. The FDA mandates that all mammography reports include a final BI-RADS assessment category.",
"   </p>",
"   <p>",
"    The use of BI-RADS results in standardized reporting helps guide decision making and also serves as a useful tool in collecting data and in auditing individual practices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     The mammography report",
"    </span>",
"    &nbsp;&mdash;&nbsp;The organization of the report and the language used to describe abnormalities are based on the BI-RADS manual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/93\">",
"     93",
"    </a>",
"    ]. The report contains the following elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indication &mdash; The main indication for the study and type of examination (screening versus diagnostic) is stated. Any previous examinations used for comparison are mentioned in the beginning of the report.",
"     </li>",
"     <li>",
"      Breast density &mdash; All reports have a statement regarding the breast density. Most radiologists use the four categories described in the BI-RADS atlas, based on the proportion of glandular (radiodense) tissue with respect to fatty (radiolucent) tissue. The four main categories are (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52305 \" href=\"mobipreview.htm?29/55/30580\">",
"       image 9",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Predominantly fatty (0 to 25 percent dense)",
"     </li>",
"     <li>",
"      Scattered fibroglandular densities (25 to 50 percent dense)",
"     </li>",
"     <li>",
"      Heterogeneously dense (51 to 75 percent dense), and",
"     </li>",
"     <li>",
"      Dense (greater than 75 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Description of abnormalities &mdash; The main body of the report includes the location and description of any abnormality using standard BI-RADS descriptors. The location of any lesion is described with reference to a quadrant or clock position, and the depth within the breast. The breast is arbitrarily divided into anterior, middle and posterior depth (",
"      <a class=\"graphic graphic_figure graphicRef80647 \" href=\"mobipreview.htm?31/26/32175\">",
"       figure 2",
"      </a>",
"      ). Each breast is divided into four quadrants: upper-outer, upper-inner, lower-outer and lower-inner (",
"      <a class=\"graphic graphic_figure graphicRef72001 \" href=\"mobipreview.htm?26/14/26862\">",
"       figure 3",
"      </a>",
"      ). The location can also be indicated using the breast as a clock with nipple in the center (",
"      <a class=\"graphic graphic_figure graphicRef60065 \" href=\"mobipreview.htm?12/49/13087\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Summary &mdash; The report concludes with a pertinent summary stating the most important findings and the final BIRADS assessment category.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     The BI-RADS categories",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BI-RADS final assessment categories standardize both the reporting of mammographic findings and the recommendations for further management (ie, routine screening, short interval follow-up, or biopsy). Assessments are either incomplete (category 0) or final assessment categories (categories 1 through 6) (",
"    <a class=\"graphic graphic_table graphicRef66601 \" href=\"mobipreview.htm?38/19/39227\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/93\">",
"     93",
"    </a>",
"    ]. It is important to note that the BI-RADS category only refers to the imaging findings and does not take clinical findings or presentation into account. Therefore, if the patient has negative imaging evaluation but has a clinically-suspicious lump, a biopsy may still be indicated even though the BI-RADS category is 1 or 2.",
"   </p>",
"   <p>",
"    These categories are designated as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BI-RADS 0:&nbsp;Incomplete assessment &mdash; Need additional imaging evaluation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prior mammograms for comparison &mdash; This category is used when there is not enough information from the views available to derive a conclusion. This is more commonly used in screening studies, which are interpreted as abnormal when the radiologist is not providing immediate reads.",
"      <br/>",
"      <br/>",
"      Causes for an incomplete evaluation include technical factors such as suboptimal images due to either improper positioning or motion (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66345 \" href=\"mobipreview.htm?7/22/7524\">",
"       image 10",
"      </a>",
"      ); a questionable lesion not fully evaluated on the standard screening views; or unavailability of prior mammograms to confirm stability of a possible focal or diffuse abnormality. The patient is asked to return for additional mammographic views",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an ultrasound, or prior mammograms are required.",
"     </li>",
"     <li>",
"      BI-RADS 1: Negative &mdash; This is a completely negative examination (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65703 \" href=\"mobipreview.htm?5/58/6054\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75940 \" href=\"mobipreview.htm?10/59/11191\">",
"       image 2",
"      </a>",
"      ). The woman should continue with screening mammography and clinical breast examination based on current screening guidelines.",
"     </li>",
"     <li>",
"      BI-RADS 2: Benign findings &mdash; Benign nodules such as fibroadenomas (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54203 \" href=\"mobipreview.htm?43/10/44198\">",
"       image 11",
"      </a>",
"      ) or cysts (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63321 \" href=\"mobipreview.htm?41/50/42785\">",
"       image 12",
"      </a>",
"      ), or benign vascular or parenchymal calcifications (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75088 \" href=\"mobipreview.htm?12/47/13045\">",
"       image 7",
"      </a>",
"      ) may be reported. There is no concern for malignancy and no further action needs to be taken. The rationale in reporting these findings is to document benignity and to prevent unnecessary evaluation. Routine follow-up is recommended.",
"     </li>",
"     <li>",
"      BI-RADS 3: Probably benign finding &mdash; This category is used when there is a finding that does not have characteristic benign features, but the likelihood of malignancy is less than 2 percent. Examples of lesions in this category would include a parenchymal asymmetry (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71340 \" href=\"mobipreview.htm?24/29/25040\">",
"       image 13",
"      </a>",
"      ), calcifications, or a nodule that does not have classic benign imaging features.",
"      <br/>",
"      <br/>",
"      These types of findings are followed at shorter intervals than one year to assess for stability. Generally, the lesion is followed with diagnostic mammography",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ultrasound at six month intervals for one year and annually for an additional two years or every six months for a total of two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/94-96\">",
"       94-96",
"      </a>",
"      ]. Follow-up at shorter intervals may be requested for close surveillance of a lesion that is not clearly benign. At any of these interval follow-ups, the lesion could be downgraded (BI-RADS 2) if it declares itself as clearly benign, or upgraded (BI-RADS 4 or 5) if there is a change with sufficient concern for malignancy.",
"     </li>",
"     <li>",
"      BI-RADS 4: Suspicious abnormality; Biopsy should be considered &mdash; This category implies that there is a lesion with suspicious features for malignancy (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62953 \" href=\"mobipreview.htm?22/41/23188\">",
"       image 6",
"      </a>",
"      ). The chance that the imaging finding is a cancer ranges between 2 and 94 percent. The degree of suspicion or worry for malignancy varies both with the lesion and with the interpreter.",
"      <br/>",
"      <br/>",
"      The BI-RADS 4 category is very broad, and the findings are compatible with both DCIS and invasive breast cancer. Subdivisions of this category were introduced to convey the level of concern, so the patient and her clinician can make an informed decision regarding management. These subcategories are BIRADS 4A (chance of malignancy 2 to 9 percent); 4B (chance of malignancy 10 to 49 percent); and 4C (chance of malignancy 50 to 94 percent).",
"     </li>",
"     <li>",
"      BI-RADS 5: Highly suggestive of malignancy; Appropriate action should be taken &mdash; Lesions which have classic worrisome imaging features such as spiculations (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57593 \" href=\"mobipreview.htm?35/59/36799\">",
"       image 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef77782 \" href=\"mobipreview.htm?29/9/29845\">",
"       picture 1",
"      </a>",
"      ), pleomorphic calcifications (",
"      <a class=\"graphic graphic_picture graphicRef73616 \" href=\"mobipreview.htm?6/17/6423\">",
"       picture 2",
"      </a>",
"      ), and skin retraction are placed in this category. The suspicion for malignancy is 95 to 100 percent.",
"     </li>",
"     <li>",
"      BI-RADS 6: Biopsy-proven malignancy; Appropriate action should be taken &mdash; This includes patients with established biopsy-proven cancers that have yet to be surgically excised who present for further imaging to either evaluate the contralateral breast or assess response to neoadjuvant chemotherapy, or who present for second opinion with interpretation of outside imaging studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical decision making",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     A positive mammography report",
"    </span>",
"    &nbsp;&mdash;&nbsp;All reports with BIRADS 0, 4 or 5 need further intervention. In most institutions, the clinician is contacted to convey the need for biopsy, and both the clinician and patient are contacted to convey the need for further imaging.",
"   </p>",
"   <p>",
"    A BI-RADS designation of 4c or 5 should alert the pathologist that a malignant diagnosis is strongly suspected and that further evaluation of the specimen (and possible rebiopsy) is needed if the biopsy is initially interpreted as benign.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     A negative mammography report",
"    </span>",
"    &nbsp;&mdash;&nbsp;A negative mammogram should not deter further intervention if there is clinical suspicion for malignancy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54454 \" href=\"mobipreview.htm?39/4/40004\">",
"     image 14",
"    </a>",
"    ). The false-negative rate of screening mammography has been reported between 10 to 30 percent, with the false-negative rate being highest in women with markedly dense breast tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/57-59\">",
"     57-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Up to 15 percent of cancers detected on clinical breast examination are not visible even on diagnostic mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/58,60,62\">",
"     58,60,62",
"    </a>",
"    ]. The addition of ultrasound decreases the false negative rate, but still does not exclude the presence of breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The final disposition of a palpable abnormality rests with the clinician in the presence of a negative imaging evaluation as the chance of malignancy ranges between 0 and 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SPECIAL PATIENT POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     The dense breast",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is much variation in the physical composition of the breast. Differing proportions of fat, connective tissue, ductal and lobular elements contribute to differences in mammographic breast density. Mammographic density is not related to the size or firmness of the breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. Breast density is greater in younger women, and is also related to genetic factors, parity, use of estrogen, and body habitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/101,102\">",
"     101,102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reduced sensitivity of mammography in younger women is in part related to increased mammographic density, determined by a higher proportion of breast epithelial and stromal elements in younger breasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/103\">",
"     103",
"    </a>",
"    ]. Menstruating women have variable breast density during different phases of the menstrual cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. Breast density is increased in the luteal compared with follicular phase, suggesting that mammographic sensitivity can be improved by obtaining mammograms during the first and second week after menstruation begins, particularly for women who have used oral contraceptives at some time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/105\">",
"     105",
"    </a>",
"    ]. Use of hormone therapy slows the age-related change from dense to fatty breast tissue; in a longitudinal study, this was more pronounced for women taking combination estrogen and progestin than for those taking estrogen alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/106\">",
"     106",
"    </a>",
"    ]. Short-term (one to two months) cessation of hormone therapy prior to mammography, although advised by some clinicians, had no effect on mammography recall rates in a randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with dense breast parenchyma (50 to 74 percent density) have a three- to fivefold increased risk for breast cancer compared to women with breast density &lt;5 percent, even after adjusting for other associated risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/108\">",
"     108",
"    </a>",
"    ]. This increased risk is particularly important in women who continue to have dense and nodular breast parenchyma beyond menopause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/109,110\">",
"     109,110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased breast density is established as an independent risk factor for breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/111\">",
"     111",
"    </a>",
"    ]. Increased breast density both increases the risk of breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/112,113\">",
"     112,113",
"    </a>",
"    ] and decreases the sensitivity of mammography to detect small lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/112,114,115\">",
"     112,114,115",
"    </a>",
"    ]. In a study that used a case control method and data from three large screening trials, the odds ratio for breast cancer detected at mammogram screening was 3.5 (95% CI 2.0-6.7), comparing women with density in &ge;75 percent of the mammogram and those with breast density in less than 10 percent of the mammogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/112\">",
"     112",
"    </a>",
"    ]. The odds ratio for breast cancer detected within twelve months of a negative mammogram was significantly higher (17.8, 95% CI 4.8-65.9), again comparing women with high and low density breasts as defined above.",
"   </p>",
"   <p>",
"    Digital mammography is more sensitive than film mammography for dense breasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/41,42\">",
"     41,42",
"    </a>",
"    ] and may be preferred, when available, for women with increased breast density. The role of ultrasound as an adjunct to mammography is discussed below. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Role of ultrasound'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The BI-RADS guidelines for mammogram interpretation recommend that breast density be reported in a sentence in every mammogram report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/116\">",
"     116",
"    </a>",
"    ]. The inter-observer reproducibility of BI-RADS breast density reports is only moderate, however [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/117\">",
"     117",
"    </a>",
"    ]. Automated measures of breast density are under development, and may be helpful in identifying women at increased risk for breast cancer who could benefit from measures to reduce risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/118\">",
"     118",
"    </a>",
"    ]. Accurate determination of breast density on two-dimensional images might not be possible, however, as measured density may vary with breast positioning, amount of compression, and distribution of fibrous elements within the breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=see_link&amp;anchor=H9#H9\">",
"     \"Factors that modify breast cancer risk in women\", section on 'Estrogen exposure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H280971309\">",
"    <span class=\"h3\">",
"     Supplemental screening in women with dense breasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recognition of the increased risk of breast cancer in women with dense breasts, and the availability of screening ultrasound as an adjunct to mammography, has led to new guidelines and legal requirements for reporting breast density in the United States. The Mammography Reporting Act (H.R. 1302) requires that every mammogram report &ldquo;contain information regarding the patient&rsquo;s breast density and language communicating that individuals with more dense breasts may benefit from supplemental screening tests &hellip;&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/120\">",
"     120",
"    </a>",
"    ]. Though not strictly enforced, some states (Connecticut, Texas, Virginia, California, and New York) have adopted this requirement as of 2012. However, with the exception of Connecticut, insurers are not required to cover the cost of the supplemental sonographic screening.",
"   </p>",
"   <p>",
"    Preliminary data demonstrate that US screening of women with dense breasts detects on average 0.8 to 10.0 additional cancers per 1000 women screened but has substantial false positives with the biopsy positivity rate being under 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/121,122\">",
"     121,122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance (MR) is not recommended for supplemental screening solely for breast density, because of a high false-positive rate leading to unnecessary biopsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/123\">",
"     123",
"    </a>",
"    ]. Widespread use of MR is also limited by the higher cost, lack of wide availability, potential adverse reactions to contrast medium, and lower tolerance by patients when compared to ultrasound. Thus, ultrasound is the adjunctive procedure of choice for women with dense breasts in whom additional imaging may be indicated. (See",
"    <a class=\"local\" href=\"#H16209629\">",
"     'As adjunct to mammography for screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Women with breast implants",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that there are more than two million breast implants in US women, for purposes of either cosmetic augmentation or reconstruction.",
"   </p>",
"   <p>",
"    There are many types of breast implants, with the majority consisting of an envelope filled with either silicone gel or saline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/124\">",
"     124",
"    </a>",
"    ]. Dual chamber silicone and saline implants are also available. The safety of silicone implants, available since 1962, has been extensively studied and the US Food and Drug Administration approved the use of silicone implants in women over the age of 22 years in November 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who have breast tissue augmented with implants require routine screening mammography to evaluate the native breast tissue. Women with reconstructed breasts and no remaining breast tissue do not typically undergo routine mammography, although there is at least one study that suggests earlier detection of recurrence with routine imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of implants makes mammography more difficult. The implant contents are radiopaque and can obscure small lesions. In addition the presence of the implant makes it harder to evaluate all parts of the breast and makes compression challenging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Standard imaging technique in women with breast implants involves four views, rather than the usual two views per breast. Positioning is important to include as much breast tissue as possible by pushing the implant out of view. Standard CC and MLO projections of each breast are obtained with the implant included (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58154 \" href=\"mobipreview.htm?3/20/3396\">",
"     image 15",
"    </a>",
"    ). These views permit evaluation of the implant as well as the deep breast tissues adjacent to the implant. The two views are repeated after the implant is displaced back against the chest wall and the breast tissue is pulled forward [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type of implant, as well as its location (prepectoral or retroglandular versus retropectoral or subpectoral) plays a role in the ease of imaging. Breasts with implants placed behind the pectoralis muscle (retropectoral or subpectoral) are easier to position. If the implant cannot be displaced, then tangential views can be obtained.",
"   </p>",
"   <p>",
"    Mammograms can also help to identify implant-related complications, including whether the implant remains intact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/129,130\">",
"     129,130",
"    </a>",
"    ]. Common problems associated with implants are rupture of the implant capsule with or without leakage of contents and capsular contraction. However, implant-related complications are best evaluated with dedicated magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/131-133\">",
"     131-133",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23002?source=see_link\">",
"     \"MRI of the breast and emerging technologies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23002?source=see_link&amp;anchor=H633682#H633682\">",
"     \"MRI of the breast and emerging technologies\", section on 'Assessment of breast implants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347891836\">",
"    <span class=\"h2\">",
"     Women with prior breast biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast biopsies are performed in approximately 1 to 2 percent of mammographic screenings in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/134\">",
"     134",
"    </a>",
"    ], with lower rates in other countries. The effect of a history of a prior breast biopsy on subsequent mammographic interpretation performance was investigated in a review of data from the Breast Cancer Surveillance Consortium involving over 2 million mammograms in nearly 800,000 women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/135\">",
"     135",
"    </a>",
"    ]. A history of a prior breast biopsy for benign disease was associated with reduced specificity (OR 0.75, 95% CI 0.79-0.92) and a lower positive predictive value for a referral for breast biopsy (OR 0.85, 0.79-0.92) in subsequent screening mammograms, compared to women with no prior biopsy history. This may reflect characteristics of the breast tissue (eg, more fibrocystic) that led to the initial biopsy, tissue effects of the biopsy itself, or differing thresholds for mammographic interpretation when a prior biopsy history is provided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Women with breast reconstruction (post mastectomy)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammography is not routinely performed following mastectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/136,137\">",
"     136,137",
"    </a>",
"    ]. When no breast tissue is left behind, mammography provides no substantial added benefit to clinical examination in detecting recurrence.",
"   </p>",
"   <p>",
"    Several methods of reconstruction are available following mastectomy. When silicone implants are used, MRI evaluation for implant-related issues is more sensitive than mammography.",
"   </p>",
"   <p>",
"    Reconstruction can also be performed by transfer of tissue from other parts of the body, typically muscle to skin. A TRAM (transverse rectus abdominis myocutaneous) flap consists of muscle and fatty tissue from the abdominal wall that is moved up to the chest along with an intact blood supply to create the breast mound. Similar reconstruction can also be performed using the latissimus dorsi muscle. More commonly, DIEP (deep inferior epigastric perforator) flaps, which consist of abdominal fat with its native blood supply, are performed preferentially for breast reconstruction. Identifying breast cancer recurrences in the reconstructed flap is important as it has implications on treatment options.",
"   </p>",
"   <p>",
"    At present, physical examination is the method of choice in monitoring myocutaneous breast reconstructions. However, it is difficult to identify lesions that are deep, and can be difficult to distinguish a palpable area of fat necrosis from recurrent cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both mammography and ultrasound of a reconstructed breast are technically feasible. The mammographic appearance of recurrence is similar to that seen in a native breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/139,140\">",
"     139,140",
"    </a>",
"    ]. Specific features on mammography can help distinguish recurrence (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67990 \" href=\"mobipreview.htm?20/19/20790\">",
"     image 16",
"    </a>",
"    ) from benign post operative fat necrosis as a cause of a palpable lump (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62817 \" href=\"mobipreview.htm?18/36/19012\">",
"     image 17",
"    </a>",
"    ). Locating the lesion on ultrasound facilitates intervention. Ultrasound with ultrasound-guided fine needle aspiration or core biopsy has been shown to be valuable in identifying and in obtaining histopathological confirmation of recurrence in both clinically palpable as well as occult lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is contradictory evidence regarding routine imaging of asymptomatic women with TRAM flap. In one study, mammogram screening in 113 asymptomatic women with TRAM flap reconstruction over a period of 25 months reported a cancer detection rate of 1.9 percent and concluded that routine screening mammography of TRAM flap reconstructed breast depicts non palpable recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/126\">",
"     126",
"    </a>",
"    ]. Another study of 554 mammograms in asymptomatic women with TRAM flap reconstruction found no cancers; 1.4 percent of mammograms were felt to be suspicious, leading to biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pregnancy and lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening mammography is not routinely performed in pregnant women. The role of mammography in pregnancy is for diagnostic purposes: to evaluate suspected cancer, check the contralateral breast, and assess clinical findings not clarified with ultrasound.",
"   </p>",
"   <p>",
"    The breast undergoes considerable change during pregnancy and lactation. Most breast disorders encountered in this period are benign and secondary to hormonal changes. However, breast cancer in pregnancy represents up to 3 percent of all breast cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/142\">",
"     142",
"    </a>",
"    ]. Poor prognosis in pregnancy-associated breast cancer has been attributed, among other factors, to delay in diagnosis related to difficulties obtaining or interpreting mammograms and challenges with clinical examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hormonal changes in pregnant and lactating women may cause proliferation of ducts and lobules that result in increased density and nodularity of the breast parenchyma on mammography. These changes make it difficult to identify small nodules, asymmetries and architectural distortion, and thereby decrease the sensitivity of the examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/143-145\">",
"     143-145",
"    </a>",
"    ]. Not all women undergo these changes in breast density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/146\">",
"     146",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of radiation from mammography on the fetus is of some concern. The developing fetus is most susceptible to effects from radiation in the first few weeks of gestation. In general, radiation doses of more than 5 rads or 50 mGy are considered harmful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/147\">",
"     147",
"    </a>",
"    ]. A four view standard mammogram with abdominal shielding exposes the fetus to 0.4 rads or 4 mGy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/142,148\">",
"     142,148",
"    </a>",
"    ]. Imaging of a pregnant woman with a palpable finding begins with ultrasound and mammography is only performed if the sonographic findings are suspicious for malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Males",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male breast cancer, though uncommon, is increasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/149\">",
"     149",
"    </a>",
"    ]. The American Cancer Society estimated that 2190 men developed breast cancer with 410 breast cancer deaths in 2012, accounting for less than 1 percent of total breast cancer diagnoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/150\">",
"     150",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine screening mammography is not performed in men. Men are referred for imaging when clinical findings such as a mass, thickening or pain are present.",
"   </p>",
"   <p>",
"    The initial mammogram evaluation in a male includes standard bilateral CC and MLO views (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54355 \" href=\"mobipreview.htm?38/61/39888\">",
"     image 18",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70483 \" href=\"mobipreview.htm?32/5/32852\">",
"     image 19",
"    </a>",
"    ). Use of narrower paddles may facilitate compression depending on breast size. Similar to females, additional mammographic views and ultrasound may be indicated to characterize abnormalities and facilitate biopsy if indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SCREENING VERSUS DIAGNOSTIC MAMMOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammographic views and subsequent procedures may differ, depending on whether the examination is ordered for screening (asymptomatic women) or for diagnostic purposes (work-up of a breast complaint or abnormal finding).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Screening mammogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;A screening mammogram is performed in a woman with no clinical symptoms or complaints. The purpose of the study is to decrease morbidity and mortality by detection of early stage and therefore treatable breast cancer. Although earlier detection does not necessarily ensure cure, screening mammography is the best modality currently available to detect clinically occult breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/1,2,151-153\">",
"     1,2,151-153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two standard views are obtained for each breast. Additional views, such as anterior compression, cleavage view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57051 \" href=\"mobipreview.htm?23/22/23908\">",
"     image 20",
"    </a>",
"    ) or an exaggerated craniocaudal (XCCL) view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76637 \" href=\"mobipreview.htm?16/18/16676\">",
"     image 21",
"    </a>",
"    ) may be obtained to maximize imaging of all breast tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Diagnostic mammogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic mammography is performed in women or men who present with breast complaints or have an abnormal clinical examination, and in women who have abnormal screening mammography. Patients with specific breast symptoms, such as a palpable lump, nipple discharge, or focal pain should undergo diagnostic mammography.",
"   </p>",
"   <p>",
"    Abnormalities on screening mammography include masses, calcifications, architectural distortion, or asymmetry. The abnormality could be related to technical factors such as motion, improper positioning or artifacts (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66345 \" href=\"mobipreview.htm?7/22/7524\">",
"     image 10",
"    </a>",
"    ). Alternatively, the finding might represent benign or malignant breast disease. Even when the abnormality seen on a screening mammogram is very suspicious for malignancy, additional evaluation is usually indicated to determine the extent of the lesion and to assess for the presence of any additional findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/155\">",
"     155",
"    </a>",
"    ]. Availability of the abnormal screening mammogram at the time of diagnostic examination is crucial in ensuring the appropriate diagnostic work-up. This is particularly important when the screening mammogram is performed at a different institution or practice.",
"   </p>",
"   <p>",
"    The diagnostic examination is always supervised by a radiologist. The views obtained are tailored to evaluate a specific abnormality, with the adjunctive use of ultrasound if needed in order to make an accurate diagnosis. The radiologist interprets the images and conveys the findings and recommendations directly to the patient at the time of the examination.",
"   </p>",
"   <p>",
"    A focal spot compression view, one type of additional view, is performed by applying focal compression to the area of interest in the breast using a small compression paddle. This view is helpful to further evaluate an area of asymmetry or a mass seen on screening mammography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78340 \" href=\"mobipreview.htm?16/5/16469\">",
"     image 22",
"    </a>",
"    ). Spot compression and tangential views of a palpable area have been shown to detect additional cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/156\">",
"     156",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A magnification spot compression view is performed to further characterize the morphology of calcifications and shape of a mass. The size, distribution, and morphology of calcifications are seen best on magnification views (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80031 \" href=\"mobipreview.htm?5/1/5140\">",
"     image 23",
"    </a>",
"    ). In addition, magnification views can provide details regarding margins of masses.",
"   </p>",
"   <p>",
"    A 90 degree lateral view is a true lateral view of the breast. The x-ray beam can travel from either the medial (mediolateral) or from the lateral (lateromedial) side of the breast. This view is a direct orthogonal view to the CC (craniocaudal) projection and is useful in triangulating lesions. A delayed lateral view is often performed in evaluating calcifications. The breast is held in compression for up to two minutes and the image is obtained after the two minute \"delay.\" This view may help in confirming the presence of a benign pattern of calcifications, called milk of calcium deposition, associated with benign breast microcysts.",
"   </p>",
"   <p>",
"    Other views that may be obtained in a diagnostic work-up are tangential views, to further evaluate a palpable area or to confirm calcifications are dermal in etiology, and rolled CC views. Rolled views are helpful in confirming that a finding seen only on one of the conventional views represents a true or three-dimensional lesion. For the rolled view, the patient is positioned similar to the view that depicted the original lesion. The technologist places her hands on either side of the breast and \"rolls\" the breast tissue (medial and lateral for the CC view; superior and inferior for the MLO view). Compression is applied to keep the breast tissues rolled and the image is obtained. The direction of the roll (medial, lateral, superior, or inferior) is documented on the image. If the lesion is &ldquo;real,&rdquo; the radiologist can use these images to determine the location of the lesion thereby facilitating performance of a targeted ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Surveillance mammogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammograms are performed for surveillance in women who have a history of breast cancer. In many centers, at least for the five years following the diagnosis of breast cancer, such mammograms are performed similar to diagnostic mammograms, with a radiologist on-site who can interpret the study at the time of the evaluation and determine if further views or tests are indicated. If the patient does not develop recurrence within the first five years, the patient returns to routine screening for subsequent years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link&amp;anchor=H560048#H560048\">",
"     \"Approach to the long-term survivor of breast cancer\", section on 'Breast imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     ROLE OF ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the primary roles of ultrasound is in the diagnostic follow-up of an abnormal screening mammogram. Ultrasound is used to further evaluate masses or asymmetries and can differentiate a solid mass from a cyst (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54203 \" href=\"mobipreview.htm?43/10/44198\">",
"     image 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63321 \" href=\"mobipreview.htm?41/50/42785\">",
"     image 12",
"    </a>",
"    ). If available, color Doppler ultrasound can aid in the assessment of breast masses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/157\">",
"     157",
"    </a>",
"    ]. However, the absence of flow on Doppler does not exclude the possibility of malignancy.",
"   </p>",
"   <p>",
"    Ultrasonography is also used to provide guidance for biopsies and other interventions. Ultrasound is the first line of imaging in a woman who is pregnant or less than 30 years old with focal breast symptoms or findings. A retrospective review of ultrasounds performed in one center for evaluation of focal breast signs or symptoms in women less than 30 years found that both the sensitivity of ultrasound and negative predictive value for malignancy were 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound is useful in evaluating the local extent of breast cancer (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82348 \" href=\"mobipreview.htm?11/17/11544\">",
"     image 24",
"    </a>",
"    ). Ultrasound can identify additional tumor in the same breast and alter surgical management in up to 18 percent of women with mammographically detected breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/159-161\">",
"     159-161",
"    </a>",
"    ]. Evaluation of the axilla in the setting of a newly-diagnosed cancer or a suspicious finding on mammography provides a noninvasive method to identify axillary nodes suspicious for metastasis. If seen, the suspicious nodes can readily undergo image-guided biopsy (FNA or core) to confirm or exclude malignancy, as a positive lymph node would lead to full axillary node dissection rather than sentinel lymph node biopsy at the time of definitive surgical management.",
"   </p>",
"   <p>",
"    MRI is superior to ultrasound in evaluating silicone implants for rupture, but ultrasound is often more readily obtained. Ultrasound is appropriate in evaluating implants in a woman with contradictions to MRI or where MRI is not available. Ultrasound can be used to check the integrity of a silicone implant capsule. Leak of silicone to the surrounding breast tissue causes a typical \"snowstorm\" appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/162,163\">",
"     162,163",
"    </a>",
"    ]. Similarly, intracapsular rupture can be diagnosed on ultrasound by a characteristic \"stepladder\" appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/164\">",
"     164",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16209629\">",
"    <span class=\"h2\">",
"     As adjunct to mammography for screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of ultrasound as an adjunct to mammography in primary screening for breast cancer has been evaluated in many studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/121,165-167\">",
"     121,165-167",
"    </a>",
"    ]. The addition of ultrasonography to mammography increases sensitivity for small cancers but decreases specificity. A large prospective, multicenter trial conducted through the American College of Radiology Imaging Network (ACRIN Protocol 6666) evaluated the diagnostic yield of screening ultrasound in addition to mammography in high-risk women with at least heterogeneously dense breasts on mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/166\">",
"     166",
"    </a>",
"    ]. The study concluded that adding screening ultrasound to mammography will identify an additional 4.3 cancers per 1000 women screened, but also increase the number of false-positive results (positive predictive value for mammogram alone 22.6 percent versus 11.2 percent for mammogram plus ultrasound). Other multicenter trials have reported similar findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/166,168-170\">",
"     166,168-170",
"    </a>",
"    ]. The majority of cancers found by ultrasound were node negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/171\">",
"     171",
"    </a>",
"    ]. For women with dense breasts as their only risk factor for breast cancer, the American College of Radiology states that &ldquo;the addition of ultrasound to screening mammography may be useful for incremental cancer detection&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/172\">",
"     172",
"    </a>",
"    ]. They also note that a decision not to offer ultrasound screening, due to issues of test reproducibility, high false-positive rates, operator dependency, and a low positive predictive value for biopsy recommendations, is acceptable within the standard of care.",
"   </p>",
"   <p>",
"    The US Food and Drug Administration approved an automated ultrasound device in September 2012 to be used as an adjunct to mammography for asymptomatic women with dense breasts and a negative mammogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/173\">",
"     173",
"    </a>",
"    ]. Approval was based upon data from an unpublished study indicating increased breast cancer detection when automated ultrasound images were viewed in conjunction with mammograms, compared to mammograms alone, for 200 women with dense breasts and negative mammograms. Concerns remain regarding the potential for high false-positive rates, potentially compounded by the ability of non-radiologists to use this device and interpret images, although approval requires that training and quality control measures be implemented. In the absence of published data from a screening trial using this device, we consider currently available evidence inadequate to support the use of this device.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     NEWER MAMMOGRAPHY TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission mammography (PEM) and breast specific gamma imaging (BSGI) are functional breast imaging techniques and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23002?source=see_link\">",
"     \"MRI of the breast and emerging technologies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Tomosynthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast tomosynthesis (also known as &ldquo;3-D mammography&rdquo;) has been approved by the US Food and Drug Administration for routine clinical use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/174\">",
"     174",
"    </a>",
"    ]. Tomosynthesis is a modification of digital mammography and uses a moving x-ray source and digital detector. A three dimensional volume of data is acquired and reconstructed using computer algorithms to generate thin sections of images.",
"   </p>",
"   <p>",
"    As a modification of digital mammography, tomosynthesis has all the advantages of a standard digital mammogram. In addition, thin slice reconstruction improves the delineation of a lesion in the slice by eliminating overlap from surrounding structures. In the screening setting, this helps to decrease recall rates by delineating true lesions from spurious lesions caused by overlapping structures seen on routine mammography. In the diagnostic setting, tomosynthesis improves lesion characterization, thereby decreasing the need for biopsy, leading to fewer false positive biopsies and higher rates of cancer detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/175-180\">",
"     175-180",
"    </a>",
"    ]. In one study two-view tomosynthesis performed better than digital mammography only for less-experienced radiologists, but the two techniques had equivalent performance when interpreted by more-experienced radiologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/181\">",
"     181",
"    </a>",
"    ]. Reading time required for tomosynthesis interpretation was nearly twice that needed for digital mammography. &nbsp;",
"   </p>",
"   <p>",
"    The examination has a slightly longer exposure time of 10 seconds per acquisition compared to standard digital mammography, which could increase the radiation dose per acquisition and increase the risk of motion artifacts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/35/39482/abstract/182,183\">",
"     182,183",
"    </a>",
"    ]. At present, tomosynthesis is approved only to be performed in conjunction with a conventional mammogram. Hence, when performed in the screening setting, the patient is exposed to approximately twice the usual radiation dose, which sometimes is greater if the patient had dense or thick breasts. This technique shows promise in screening women with dense breast tissue and with high risk for breast cancer, although there are no prospective large studies to justify its routine use at the present time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/59/19379?source=see_link\">",
"       \"Patient information: Breast cancer screening (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/56/6018?source=see_link\">",
"       \"Patient information: Common breast problems (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/40/36481?source=see_link\">",
"       \"Patient information: Breast cancer screening (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening mammography is the only breast imaging modality that consistently has been found to decrease breast cancer-related death. Routine evaluation includes obtaining two views (craniocaudal and mediolateral oblique) of each breast. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'The mammographic examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast compression improves image quality. Patient-controlled compression, oral or topical analgesics, and cushioned paddles may minimize discomfort. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Breast compression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effective radiation dose received from a routine screening mammogram is equivalent to the dose received from natural background radiation over three months. Women with BRCA1 or BRCA2 mutations may be at somewhat greater risk for radiation-induced cancer. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Radiation dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Full field digital mammography, compared to film mammography, can improve image quality and facilitate study interpretation, but is more costly and may not significantly impact overall cancer detection rates. Film mammography remains an acceptable screening modality for all women. Digital mammography, when available, may offer a small screening advantage in women younger than 50 years old. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Digital versus film screen mammogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Double-reading and computer-aided detection (CAD) may improve the sensitivity of mammogram screening to a limited extent, but have not been demonstrated to improve mortality rates from breast cancer screening. CAD may increase patient recall rates. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Double reading'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Computer aided detection (CAD)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic mammograms are performed to evaluate breast abnormalities (symptoms, clinical findings or follow-up of abnormal screening mammograms) and are distinguished from screening mammograms. Additional views are obtained with diagnostic mammograms and these are performed when a radiologist is immediately available for review of the study. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Screening versus diagnostic mammography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased breast density both increases the risk of breast cancer and decreases the sensitivity of mammography to detect small lesions. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'The dense breast'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who have breast tissue augmented with implants require routine screening mammography to evaluate the native breast tissue. Women with reconstructed breasts and no underlying breast tissue do not require regular mammography. Standard imaging technique in women with breast implants involves four views, rather than the usual two per breast. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Women with breast implants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Breast Imaging Reporting and Data System (BI-RADS) standardizes reporting for mammography and ultrasonography and helps guide decision making. It also serves as a useful tool in data collection and audit. The summary of a BI-RADS report specifies findings as incomplete or as one of six final assessment categories (",
"      <a class=\"graphic graphic_table graphicRef66601 \" href=\"mobipreview.htm?38/19/39227\">",
"       table 1",
"      </a>",
"      ). A negative mammogram should not deter further intervention if there is clinical suspicion for malignancy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Mammography quality control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound primarily has a diagnostic role in the further evaluation of abnormal mammograms, to distinguish solid and cystic lesions. It is first-line imaging in women who are pregnant or less than 30 years old with focal breast symptoms. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Role of ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/1\">",
"      Tab&aacute;r L, Vitak B, Chen HH, et al. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer 2001; 91:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/2\">",
"      Tabar L, Fagerberg G, Chen HH, et al. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer 1995; 75:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/3\">",
"      Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/4\">",
"      Tabar L, Duffy SW, Krusemo UB. Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. Eur J Cancer Clin Oncol 1987; 23:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/5\">",
"      Tab&agrave;r L, Fagerberg G, Duffy SW, et al. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am 1992; 30:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/6\">",
"      Gold RH, Bassett LW, Widoff BE. Highlights from the history of mammography. Radiographics 1990; 10:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/7\">",
"      Yaffe MJ. AAPM tutorial. Physics of mammography: image recording process. Radiographics 1990; 10:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/8\">",
"      Muir BB, Kirkpatrick AE, Roberts MM, Duffy SW. Oblique-view mammography: adequacy for screening. Work in progress. Radiology 1984; 151:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/9\">",
"      Wald NJ, Murphy P, Major P, et al. UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. BMJ 1995; 311:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/10\">",
"      Sickles EA, Weber WN, Galvin HB, et al. Baseline screening mammography: one vs two views per breast. AJR Am J Roentgenol 1986; 147:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/11\">",
"      Stomper PC, Kopans DB, Sadowsky NL, et al. Is mammography painful? A multicenter patient survey. Arch Intern Med 1988; 148:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/12\">",
"      Keefe FJ, Hauck ER, Egert J, et al. Mammography pain and discomfort: a cognitive-behavioral perspective. Pain 1994; 56:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/13\">",
"      Eklund GW. Mammographic compression: science or art? Radiology 1991; 181:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/14\">",
"      Kornguth PJ, Rimer BK, Conaway MR, et al. Impact of patient-controlled compression on the mammography experience. Radiology 1993; 186:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/15\">",
"      Markle L, Roux S, Sayre JW. Reduction of discomfort during mammography utilizing a radiolucent cushioning pad. Breast J 2004; 10:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/16\">",
"      Martin KE, Helvie MA, Zhou C, et al. Mammographic density measured with quantitative computer-aided method: comparison with radiologists' estimates and BI-RADS categories. Radiology 2006; 240:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/17\">",
"      Miller D, Livingstone V, Herbison P. Interventions for relieving the pain and discomfort of screening mammography. Cochrane Database Syst Rev 2008; :CD002942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/18\">",
"      Lambertz CK, Johnson CJ, Montgomery PG, Maxwell JR. Premedication to reduce discomfort during screening mammography. Radiology 2008; 248:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/19\">",
"      Dibble SL, Israel J, Nussey B, et al. Mammography with breast cushions. Womens Health Issues 2005; 15:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/20\">",
"      Tabar L, Lebovic GS, Hermann GD, et al. Clinical assessment of a radiolucent cushion for mammography. Acta Radiol 2004; 45:154.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Public Health Advisory. Potential hazards of skin products containing numbing ingredients for relieving pain from mammography and other medical tests and conditions. Available at: file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm110625.htm (Accessed on March 13, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/22\">",
"      Mettler FA, Upton AC, Kelsey CA, et al. Benefits versus risks from mammography: a critical reassessment. Cancer 1996; 77:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/23\">",
"      Berrington de Gonzalez A, Berg CD, Visvanathan K, Robson M. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst 2009; 101:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/24\">",
"      Kimme-Smith C, Bassett LW, Gold RH, et al. New mammography screen/film combinations: imaging characteristics and radiation dose. AJR Am J Roentgenol 1990; 154:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/25\">",
"      Haus AG, Yaffe MJ. Screen-film and digital mammography. Image quality and radiation dose considerations. Radiol Clin North Am 2000; 38:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/26\">",
"      Yaffe MJ, Mainprize JG, Jong RA. Technical developments in mammography. Health Phys 2008; 95:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/27\">",
"      Heddson B, R&ouml;nnow K, Olsson M, Miller D. Digital versus screen-film mammography: a retrospective comparison in a population-based screening program. Eur J Radiol 2007; 64:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/28\">",
"      Mor&aacute;n P, Chevalier M, Ten JI, et al. A survey of patient dose and clinical factors in a full-field digital mammography system. Radiat Prot Dosimetry 2005; 114:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/29\">",
"      Chevalier M, Mor&aacute;n P, Ten JI, et al. Patient dose in digital mammography. Med Phys 2004; 31:2471.",
"     </a>",
"    </li>",
"    <li>",
"     Bushberg JT, Seibert JA, Leidholdt EM Jr, Boone JM. The Essential Physics of Medical Imaging, 2nd, Lippincott Williams &amp; Wilkins, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/31\">",
"      Hendrick RE, Berns EA. Optimizing techniques in screen-film mammography. Radiol Clin North Am 2000; 38:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/32\">",
"      Mahesh M. AAPM/RSNA physics tutorial for residents: digital mammography: an overview. Radiographics 2004; 24:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/33\">",
"      Rowlands JA, Zhao W, Blevis IM, et al. Flat-panel digital radiology with amorphous selenium and active-matrix readout. Radiographics 1997; 17:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/34\">",
"      Pisano ED, Yaffe MJ. Digital mammography. Radiology 2005; 234:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/35\">",
"      Feig SA, Yaffe MJ. Digital mammography. Radiographics 1998; 18:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/36\">",
"      Pisano ED, Yaffe MJ, Hemminger BM, et al. Current status of full-field digital mammography. Acad Radiol 2000; 7:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/37\">",
"      Lewin JM, Hendrick RE, D'Orsi CJ, et al. Comparison of full-field digital mammography with screen-film mammography for cancer detection: results of 4,945 paired examinations. Radiology 2001; 218:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/38\">",
"      Skaane P, Young K, Skjennald A. Population-based mammography screening: comparison of screen-film and full-field digital mammography with soft-copy reading--Oslo I study. Radiology 2003; 229:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/39\">",
"      Skaane P, Skjennald A. Screen-film mammography versus full-field digital mammography with soft-copy reading: randomized trial in a population-based screening program--the Oslo II Study. Radiology 2004; 232:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/40\">",
"      Skaane P, Hofvind S, Skjennald A. Randomized trial of screen-film versus full-field digital mammography with soft-copy reading in population-based screening program: follow-up and final results of Oslo II study. Radiology 2007; 244:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/41\">",
"      Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005; 353:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/42\">",
"      Pisano ED, Hendrick RE, Yaffe MJ, et al. Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology 2008; 246:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/43\">",
"      Vinnicombe S, Pinto Pereira SM, McCormack VA, et al. Full-field digital versus screen-film mammography: comparison within the UK breast screening program and systematic review of published data. Radiology 2009; 251:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/44\">",
"      Sala M, Comas M, Maci&agrave; F, et al. Implementation of digital mammography in a population-based breast cancer screening program: effect of screening round on recall rate and cancer detection. Radiology 2009; 252:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/45\">",
"      Hambly NM, McNicholas MM, Phelan N, et al. Comparison of digital mammography and screen-film mammography in breast cancer screening: a review in the Irish breast screening program. AJR Am J Roentgenol 2009; 193:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/46\">",
"      Kerlikowske K, Hubbard RA, Miglioretti DL, et al. Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Ann Intern Med 2011; 155:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/47\">",
"      Hendrick RE, Cole EB, Pisano ED, et al. Accuracy of soft-copy digital mammography versus that of screen-film mammography according to digital manufacturer: ACRIN DMIST retrospective multireader study. Radiology 2008; 247:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/48\">",
"      Tosteson AN, Stout NK, Fryback DG, et al. Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med 2008; 148:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/49\">",
"      Bassett LW, Shayestehfar B, Hirbawi I. Obtaining previous mammograms for comparison: usefulness and costs. AJR Am J Roentgenol 1994; 163:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/50\">",
"      Sickles EA, Ominsky SH, Sollitto RA, et al. Medical audit of a rapid-throughput mammography screening practice: methodology and results of 27,114 examinations. Radiology 1990; 175:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/51\">",
"      White K, Berbaum K, Smith WL. The role of previous radiographs and reports in the interpretation of current radiographs. Invest Radiol 1994; 29:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/52\">",
"      Lindfors KK, O'Connor J, Parker RA. False-positive screening mammograms: effect of immediate versus later work-up on patient stress. Radiology 2001; 218:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/53\">",
"      Wilson TE, Wallace C, Roubidoux MA, et al. Patient satisfaction with screening mammography: online vs off-line interpretation. Acad Radiol 1998; 5:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/54\">",
"      Barton MB, Morley DS, Moore S, et al. Decreasing women's anxieties after abnormal mammograms: a controlled trial. J Natl Cancer Inst 2004; 96:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/55\">",
"      Raza S, Rosen MP, Chorny K, et al. Patient expectations and costs of immediate reporting of screening mammography: talk isn't cheap. AJR Am J Roentgenol 2001; 177:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/56\">",
"      Ghate SV, Soo MS, Baker JA, et al. Comparison of recall and cancer detection rates for immediate versus batch interpretation of screening mammograms. Radiology 2005; 235:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/57\">",
"      Thurfjell EL, Lernevall KA, Taube AA. Benefit of independent double reading in a population-based mammography screening program. Radiology 1994; 191:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/58\">",
"      Yankaskas BC, Klabunde CN, Ancelle-Park R, et al. International comparison of performance measures for screening mammography: can it be done? J Med Screen 2004; 11:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/59\">",
"      Ciatto S, Ambrogetti D, Risso G, et al. The role of arbitration of discordant reports at double reading of screening mammograms. J Med Screen 2005; 12:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/60\">",
"      Shaw CM, Flanagan FL, Fenlon HM, McNicholas MM. Consensus review of discordant findings maximizes cancer detection rate in double-reader screening mammography: Irish National Breast Screening Program experience. Radiology 2009; 250:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/61\">",
"      Hofvind S, Geller BM, Rosenberg RD, Skaane P. Screening-detected breast cancers: discordant independent double reading in a population-based screening program. Radiology 2009; 253:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/62\">",
"      Taylor P, Potts HW. Computer aids and human second reading as interventions in screening mammography: two systematic reviews to compare effects on cancer detection and recall rate. Eur J Cancer 2008; 44:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/63\">",
"      Hulka CA, Slanetz PJ, Halpern EF, et al. Patients' opinion of mammography screening services: immediate results versus delayed results due to interpretation by two observers. AJR Am J Roentgenol 1997; 168:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/64\">",
"      Slanetz PJ, Moore RH, Hulka CA, et al. Physicians' opinions on the delivery of mammographic screening services: immediate interpretation versus double reading. AJR Am J Roentgenol 1996; 167:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/65\">",
"      Chan HP, Doi K, Galhotra S, et al. Image feature analysis and computer-aided diagnosis in digital radiography. I. Automated detection of microcalcifications in mammography. Med Phys 1987; 14:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/66\">",
"      Chan HP, Doi K, Vyborny CJ, et al. Improvement in radiologists' detection of clustered microcalcifications on mammograms. The potential of computer-aided diagnosis. Invest Radiol 1990; 25:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/67\">",
"      Doi K, Giger ML, Nishikawa RM, Schmidt RA. Computer-Aided Diagnosis of Breast Cancer on Mammograms. Breast Cancer 1997; 4:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/68\">",
"      Kegelmeyer WP Jr, Pruneda JM, Bourland PD, et al. Computer-aided mammographic screening for spiculated lesions. Radiology 1994; 191:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/69\">",
"      Rao VM, Levin DC, Parker L, et al. How widely is computer-aided detection used in screening and diagnostic mammography? J Am Coll Radiol 2010; 7:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/70\">",
"      Birdwell RL. The preponderance of evidence supports computer-aided detection for screening mammography. Radiology 2009; 253:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/71\">",
"      Philpotts LE. Can computer-aided detection be detrimental to mammographic interpretation? Radiology 2009; 253:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/72\">",
"      Fenton JJ, Abraham L, Taplin SH, et al. Effectiveness of computer-aided detection in community mammography practice. J Natl Cancer Inst 2011; 103:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/73\">",
"      Jiang Y, Nishikawa RM, Schmidt RA, Metz CE. Comparison of independent double readings and computer-aided diagnosis (CAD) for the diagnosis of breast calcifications. Acad Radiol 2006; 13:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/74\">",
"      Brem RF, Schoonjans JM. Radiologist detection of microcalcifications with and without computer-aided detection: a comparative study. Clin Radiol 2001; 56:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/75\">",
"      Taplin SH, Rutter CM, Lehman CD. Testing the effect of computer-assisted detection on interpretive performance in screening mammography. AJR Am J Roentgenol 2006; 187:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/76\">",
"      Gromet M. Comparison of computer-aided detection to double reading of screening mammograms: review of 231,221 mammograms. AJR Am J Roentgenol 2008; 190:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/77\">",
"      Georgian-Smith D, Moore RH, Halpern E, et al. Blinded comparison of computer-aided detection with human second reading in screening mammography. AJR Am J Roentgenol 2007; 189:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/78\">",
"      Kim SJ, Moon WK, Cho N, et al. Computer-aided detection in full-field digital mammography: sensitivity and reproducibility in serial examinations. Radiology 2008; 246:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/79\">",
"      Kopans DB. Double reading. Radiol Clin North Am 2000; 38:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/80\">",
"      Brem RF. Blinded comparison of computer-aided detection with human second reading in screening mammography: the importance of the question and the critical numbers game. AJR Am J Roentgenol 2007; 189:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/81\">",
"      Gilbert FJ, Astley SM, Gillan MG, et al. Single reading with computer-aided detection for screening mammography. N Engl J Med 2008; 359:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/82\">",
"      Morton MJ, Whaley DH, Brandt KR, Amrami KK. Screening mammograms: interpretation with computer-aided detection--prospective evaluation. Radiology 2006; 239:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/83\">",
"      The JS, Schilling KJ, Hoffmeister JW, et al. Detection of breast cancer with full-field digital mammography and computer-aided detection. AJR Am J Roentgenol 2009; 192:337.",
"     </a>",
"    </li>",
"    <li>",
"     Stomper PC. Breast imaging. In: Atlas of Breast Cancer, Hayes DF (Ed), Mosby, Philadelphia 2000. p.54.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/85\">",
"      Liberman L, Abramson AF, Squires FB, et al. The breast imaging reporting and data system: positive predictive value of mammographic features and final assessment categories. AJR Am J Roentgenol 1998; 171:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/86\">",
"      Woods RW, Sisney GS, Salkowski LR, et al. The mammographic density of a mass is a significant predictor of breast cancer. Radiology 2011; 258:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/87\">",
"      Venkatesan A, Chu P, Kerlikowske K, et al. Positive predictive value of specific mammographic findings according to reader and patient variables. Radiology 2009; 250:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/88\">",
"      McLelland R, Hendrick RE, Zinninger MD, Wilcox PA. The American College of Radiology Mammography Accreditation Program. AJR Am J Roentgenol 1991; 157:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/89\">",
"      McLelland R, Pisano ED. The politics of mammography. Radiol Clin North Am 1992; 30:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/90\">",
"      Medicare program; Medicare coverage of screening mammography--HCFA. Final rule. Fed Regist 1994; 59:49826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/91\">",
"      Quality standards and certification requirements for mammography facilities--FDA. Interim rule; opportunity for public comment. Fed Regist 1994; 59:49808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/92\">",
"      Kivel M. FDA's mammography facility quality assurance program. Adm Radiol 1994; 13:43.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Radiology. American College of Radiology Breast Imaging Reporting and Data System BI-RADS, 4th ed, American Colege of Radiology, Reston, VA 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/94\">",
"      Sickles EA. Periodic mammographic follow-up of probably benign lesions: results in 3,184 consecutive cases. Radiology 1991; 179:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/95\">",
"      Sickles EA. Probably benign breast lesions: when should follow-up be recommended and what is the optimal follow-up protocol? Radiology 1999; 213:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/96\">",
"      Varas X, Leborgne F, Leborgne JH. Nonpalpable, probably benign lesions: role of follow-up mammography. Radiology 1992; 184:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/97\">",
"      Soo MS, Rosen EL, Baker JA, et al. Negative predictive value of sonography with mammography in patients with palpable breast lesions. AJR Am J Roentgenol 2001; 177:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/98\">",
"      Moy L, Slanetz PJ, Moore R, et al. Specificity of mammography and US in the evaluation of a palpable abnormality: retrospective review. Radiology 2002; 225:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/99\">",
"      Swann CA, Kopans DB, McCarthy KA, et al. Mammographic density and physical assessment of the breast. AJR Am J Roentgenol 1987; 148:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/100\">",
"      Boren WL, Hunter TB, Bjelland JC, Hunt KR. Comparison of breast consistency at palpation with breast density at mammography. Invest Radiol 1990; 25:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/101\">",
"      Boyd NF, Dite GS, Stone J, et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 2002; 347:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/102\">",
"      Stomper PC, D'Souza DJ, DiNitto PA, Arredondo MA. Analysis of parenchymal density on mammograms in 1353 women 25-79 years old. AJR Am J Roentgenol 1996; 167:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/103\">",
"      Kelemen LE, Pankratz VS, Sellers TA, et al. Age-specific trends in mammographic density: the Minnesota Breast Cancer Family Study. Am J Epidemiol 2008; 167:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/104\">",
"      White E, Velentgas P, Mandelson MT, et al. Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst 1998; 90:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/105\">",
"      Baines CJ, Vidmar M, McKeown-Eyssen G, Tibshirani R. Impact of menstrual phase on false-negative mammograms in the Canadian National Breast Screening Study. Cancer 1997; 80:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/106\">",
"      van Duijnhoven FJ, Peeters PH, Warren RM, et al. Postmenopausal hormone therapy and changes in mammographic density. J Clin Oncol 2007; 25:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/107\">",
"      Buist DS, Anderson ML, Reed SD, et al. Short-term hormone therapy suspension and mammography recall: a randomized trial. Ann Intern Med 2009; 150:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/108\">",
"      McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/109\">",
"      Tab&aacute;r L, Dean PB. Mammographic parenchymal patterns. Risk indicator for breast cancer? JAMA 1982; 247:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/110\">",
"      Lander MR, Tab&aacute;r L. Automated 3-D breast ultrasound as a promising adjunctive screening tool for examining dense breast tissue. Semin Roentgenol 2011; 46:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/111\">",
"      Vachon CM, van Gils CH, Sellers TA, et al. Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res 2007; 9:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/112\">",
"      Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007; 356:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/113\">",
"      Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995; 87:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/114\">",
"      Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 2004; 230:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/115\">",
"      Mandelson MT, Oestreicher N, Porter PL, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 2000; 92:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/116\">",
"      Stavros AT, Thickman D, Rapp CL, et al. Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. Radiology 1995; 196:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/117\">",
"      Ciatto S, Houssami N, Apruzzese A, et al. Categorizing breast mammographic density: intra- and interobserver reproducibility of BI-RADS density categories. Breast 2005; 14:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/118\">",
"      Kerlikowske K. The mammogram that cried Wolfe. N Engl J Med 2007; 356:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/119\">",
"      Kopans DB. Basic physics and doubts about relationship between mammographically determined tissue density and breast cancer risk. Radiology 2008; 246:348.",
"     </a>",
"    </li>",
"    <li>",
"     H.R. 3102: Breast Density and Mammography Reporting Act of 2011. Available at: file://www.govtrack.us/congress/bills/112/hr3102 (Accessed on October 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/121\">",
"      Hooley RJ, Greenberg KL, Stackhouse RM, et al. Screening US in patients with mammographically dense breasts: initial experience with Connecticut Public Act 09-41. Radiology 2012; 265:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/122\">",
"      Giuliano V, Giuliano C. Improved breast cancer detection in asymptomatic women using 3D-automated breast ultrasound in mammographically dense breasts. Clin Imaging 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/123\">",
"      Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/124\">",
"      Middleton MS, McNamara MP Jr. Breast implant classification with MR imaging correlation: (CME available on RSNA link). Radiographics 2000; 20:E1.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Breast Implants. www.fda.gov/cdrh/breastimplants (Accessed on September 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/126\">",
"      Helvie MA, Bailey JE, Roubidoux MA, et al. Mammographic screening of TRAM flap breast reconstructions for detection of nonpalpable recurrent cancer. Radiology 2002; 224:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/127\">",
"      Fajardo LL, Harvey JA, McAleese KA, et al. Breast cancer diagnosis in women with subglandular silicone gel-filled augmentation implants. Radiology 1995; 194:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/128\">",
"      Eklund GW, Busby RC, Miller SH, Job JS. Improved imaging of the augmented breast. AJR Am J Roentgenol 1988; 151:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/129\">",
"      Berg WA, Caskey CI, Hamper UM, et al. Diagnosing breast implant rupture with MR imaging, US, and mammography. Radiographics 1993; 13:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/130\">",
"      Glynn C, Litherland J. Imaging breast augmentation and reconstruction. Br J Radiol 2008; 81:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/131\">",
"      Brem RF, Tempany CM, Zerhouni EA. MR detection of breast implant rupture. J Comput Assist Tomogr 1992; 16:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/132\">",
"      H&ouml;lmich LR, Fryzek JP, Kj&oslash;ller K, et al. The diagnosis of silicone breast-implant rupture: clinical findings compared with findings at magnetic resonance imaging. Ann Plast Surg 2005; 54:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/133\">",
"      Kuhl CK. Current status of breast MR imaging. Part 2. Clinical applications. Radiology 2007; 244:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/134\">",
"      Taplin SH, Ichikawa LE, Kerlikowske K, et al. Concordance of breast imaging reporting and data system assessments and management recommendations in screening mammography. Radiology 2002; 222:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/135\">",
"      Taplin SH, Abraham L, Geller BM, et al. Effect of previous benign breast biopsy on the interpretive performance of subsequent screening mammography. J Natl Cancer Inst 2010; 102:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/136\">",
"      Fajardo LL, Roberts CC, Hunt KR. Mammographic surveillance of breast cancer patients: should the mastectomy site be imaged? AJR Am J Roentgenol 1993; 161:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/137\">",
"      Propeck PA, Scanlan KA. Utility of axillary views in postmastectomy patients. Radiology 1993; 187:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/138\">",
"      Noone RB, Frazier TG, Noone GC, et al. Recurrence of breast carcinoma following immediate reconstruction: a 13-year review. Plast Reconstr Surg 1994; 93:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/139\">",
"      Edeiken BS, Fornage BD, Bedi DG, et al. Recurrence in autogenous myocutaneous flap reconstruction after mastectomy for primary breast cancer: US diagnosis. Radiology 2003; 227:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/140\">",
"      Eidelman Y, Liebling RW, Buchbinder S, et al. Mammography in the evaluation of masses in breasts reconstructed with TRAM flaps. Ann Plast Surg 1998; 41:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/141\">",
"      Lee JM, Georgian-Smith D, Gazelle GS, et al. Detecting nonpalpable recurrent breast cancer: the role of routine mammographic screening of transverse rectus abdominis myocutaneous flap reconstructions. Radiology 2008; 248:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/142\">",
"      Sabate JM, Clotet M, Torrubia S, et al. Radiologic evaluation of breast disorders related to pregnancy and lactation. Radiographics 2007; 27 Suppl 1:S101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/143\">",
"      Yang WT, Dryden MJ, Gwyn K, et al. Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy. Radiology 2006; 239:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/144\">",
"      Ahn BY, Kim HH, Moon WK, et al. Pregnancy- and lactation-associated breast cancer: mammographic and sonographic findings. J Ultrasound Med 2003; 22:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/145\">",
"      Liberman L, Giess CS, Dershaw DD, et al. Imaging of pregnancy-associated breast cancer. Radiology 1994; 191:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/146\">",
"      Swinford AE, Adler DD, Garver KA. Mammographic appearance of the breasts during pregnancy and lactation: false assumptions. Acad Radiol 1998; 5:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/147\">",
"      Greskovich JF Jr, Macklis RM. Radiation therapy in pregnancy: risk calculation and risk minimization. Semin Oncol 2000; 27:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/148\">",
"      Behrman RH, Homer MJ, Yang WT, Whitman GJ. Mammography and fetal dose. Radiology 2007; 243:605; author reply 605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/149\">",
"      Giordano SH, Cohen DS, Buzdar AU, et al. Breast carcinoma in men: a population-based study. Cancer 2004; 101:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/150\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/151\">",
"      Bassett LW, Liu TH, Giuliano AE, Gold RH. The prevalence of carcinoma in palpable vs impalpable, mammographically detected lesions. AJR Am J Roentgenol 1991; 157:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/152\">",
"      Kopans DB. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer 2002; 94:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/153\">",
"      Michaelson JS, Silverstein M, Wyatt J, et al. Predicting the survival of patients with breast carcinoma using tumor size. Cancer 2002; 95:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/154\">",
"      Eklund GW, Cardenosa G. The art of mammographic positioning. Radiol Clin North Am 1992; 30:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/155\">",
"      Kopans DB. Breast imaging and the standard of care for the symptomatic patient. Radiology 1993; 187:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/156\">",
"      Faulk RM, Sickles EA. Efficacy of spot compression-magnification and tangential views in mammographic evaluation of palpable breast masses. Radiology 1992; 185:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/157\">",
"      Catalano O, Raso MM, D'Aiuto M, et al. Additional role of colour Doppler ultrasound imaging in intracystic breast tumours. Radiol Med 2009; 114:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/158\">",
"      Loving VA, DeMartini WB, Eby PR, et al. Targeted ultrasound in women younger than 30 years with focal breast signs or symptoms: outcomes analyses and management implications. AJR Am J Roentgenol 2010; 195:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/159\">",
"      Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 2004; 233:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/160\">",
"      Moon WK, Noh DY, Im JG. Multifocal, multicentric, and contralateral breast cancers: bilateral whole-breast US in the preoperative evaluation of patients. Radiology 2002; 224:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/161\">",
"      Berg WA, Gilbreath PL. Multicentric and multifocal cancer: whole-breast US in preoperative evaluation. Radiology 2000; 214:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/162\">",
"      Harris KM, Ganott MA, Shestak KC, et al. Silicone implant rupture: detection with US. Radiology 1993; 187:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/163\">",
"      Rosculet KA, Ikeda DM, Forrest ME, et al. Ruptured gel-filled silicone breast implants: sonographic findings in 19 cases. AJR Am J Roentgenol 1992; 159:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/164\">",
"      DeBruhl ND, Gorczyca DP, Ahn CY, et al. Silicone breast implants: US evaluation. Radiology 1993; 189:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/165\">",
"      Corsetti V, Houssami N, Ferrari A, et al. Breast screening with ultrasound in women with mammography-negative dense breasts: evidence on incremental cancer detection and false positives, and associated cost. Eur J Cancer 2008; 44:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/166\">",
"      Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 2008; 299:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/167\">",
"      Buchberger W, Niehoff A, Obrist P, et al. Clinically and mammographically occult breast lesions: detection and classification with high-resolution sonography. Semin Ultrasound CT MR 2000; 21:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/168\">",
"      Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA 2012; 307:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/169\">",
"      Corsetti V, Ferrari A, Ghirardi M, et al. Role of ultrasonography in detecting mammographically occult breast carcinoma in women with dense breasts. Radiol Med 2006; 111:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/170\">",
"      Tohno E, Ueno E, Watanabe H. Ultrasound screening of breast cancer. Breast Cancer 2009; 16:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/171\">",
"      Berg WA. Supplemental screening sonography in dense breasts. Radiol Clin North Am 2004; 42:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/172\">",
"      Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol 2010; 7:18.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm319867.htm (Accessed on September 19, 2012).",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/cdrh_docs/pdf8/p080003a.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/175\">",
"      Chan HP, Wei J, Sahiner B, et al. Computer-aided detection system for breast masses on digital tomosynthesis mammograms: preliminary experience. Radiology 2005; 237:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/176\">",
"      Smith A. Full-field breast tomosynthesis. Radiol Manage 2005; 27:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/177\">",
"      Andersson I, Ikeda DM, Zackrisson S, et al. Breast tomosynthesis and digital mammography: a comparison of breast cancer visibility and BIRADS classification in a population of cancers with subtle mammographic findings. Eur Radiol 2008; 18:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/178\">",
"      Gur D, Abrams GS, Chough DM, et al. Digital breast tomosynthesis: observer performance study. AJR Am J Roentgenol 2009; 193:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/179\">",
"      Gennaro G, Toledano A, di Maggio C, et al. Digital breast tomosynthesis versus digital mammography: a clinical performance study. Eur Radiol 2010; 20:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/180\">",
"      Hakim CM, Chough DM, Ganott MA, et al. Digital breast tomosynthesis in the diagnostic environment: A subjective side-by-side review. AJR Am J Roentgenol 2010; 195:W172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/181\">",
"      Wallis MG, Moa E, Zanca F, et al. Two-view and single-view tomosynthesis versus full-field digital mammography: high-resolution X-ray imaging observer study. Radiology 2012; 262:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/182\">",
"      Poplack SP, Tosteson TD, Kogel CA, Nagy HM. Digital breast tomosynthesis: initial experience in 98 women with abnormal digital screening mammography. AJR Am J Roentgenol 2007; 189:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/35/39482/abstract/183\">",
"      Ma AK, Darambara DG, Stewart A, et al. Mean glandular dose estimation using MCNPX for a digital breast tomosynthesis system with tungsten/aluminum and tungsten/aluminum+silver x-ray anode-filter combinations. Med Phys 2008; 35:5278.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7561 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-519069B3B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_35_39482=[""].join("\n");
var outline_f38_35_39482=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MAMMOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THE MAMMOGRAPHIC EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Breast compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Radiation dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Film screen mammography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Full field digital mammography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Digital versus film screen mammogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Online versus offline reading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Double reading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Computer aided detection (CAD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ABNORMALITIES ON MAMMOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MAMMOGRAPHY QUALITY CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      The mammography report",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      The BI-RADS categories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical decision making",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - A positive mammography report",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - A negative mammography report",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SPECIAL PATIENT POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      The dense breast",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H280971309\">",
"      - Supplemental screening in women with dense breasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Women with breast implants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H347891836\">",
"      Women with prior breast biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Women with breast reconstruction (post mastectomy)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SCREENING VERSUS DIAGNOSTIC MAMMOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Screening mammogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Diagnostic mammogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Surveillance mammogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      ROLE OF ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16209629\">",
"      As adjunct to mammography for screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      NEWER MAMMOGRAPHY TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Tomosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7561\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7561|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/58/6054\" title=\"diagnostic image 1\">",
"      Normal cc views",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/59/11191\" title=\"diagnostic image 2\">",
"      Normal MLO view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/35/26161\" title=\"diagnostic image 3\">",
"      Importance correct position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/38/14947\" title=\"diagnostic image 4\">",
"      Importance breast compress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/59/36799\" title=\"diagnostic image 5\">",
"      Spic mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/41/23188\" title=\"diagnostic image 6\">",
"      Suspicious calcifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/47/13045\" title=\"diagnostic image 7\">",
"      Benign patterns calcifica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/6/42094\" title=\"diagnostic image 8\">",
"      Round cals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/55/30580\" title=\"diagnostic image 9\">",
"      Breast density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/22/7524\" title=\"diagnostic image 10\">",
"      Tech factors add imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/10/44198\" title=\"diagnostic image 11\">",
"      Benign solid nodule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/50/42785\" title=\"diagnostic image 12\">",
"      Benign breast cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/29/25040\" title=\"diagnostic image 13\">",
"      Parenchymal asymmetry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/4/40004\" title=\"diagnostic image 14\">",
"      Mammographic occult breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?3/20/3396\" title=\"diagnostic image 15\">",
"      Normal saline implants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/19/20790\" title=\"diagnostic image 16\">",
"      Recurrent bc postmastectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/36/19012\" title=\"diagnostic image 17\">",
"      Postop fat necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/61/39888\" title=\"diagnostic image 18\">",
"      Normal male breast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/5/32852\" title=\"diagnostic image 19\">",
"      Male palpable lump",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/22/23908\" title=\"diagnostic image 20\">",
"      Cleavage view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/18/16676\" title=\"diagnostic image 21\">",
"      Exaggerated CCL view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/5/16469\" title=\"diagnostic image 22\">",
"      Value spot compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/1/5140\" title=\"diagnostic image 23\">",
"      Magnification view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/17/11544\" title=\"diagnostic image 24\">",
"      Role of ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7561|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/50/40737\" title=\"figure 1\">",
"      Schematic diagram mammogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/26/32175\" title=\"figure 2\">",
"      Lesion location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/14/26862\" title=\"figure 3\">",
"      Breast quadrants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/49/13087\" title=\"figure 4\">",
"      Clock locating lesion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7561|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/9/29845\" title=\"picture 1\">",
"      Suspicious mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/17/6423\" title=\"picture 2\">",
"      Pleomorphic calcifications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7561|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/19/39227\" title=\"table 1\">",
"      BIRADS mammography categories",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=related_link\">",
"      Approach to the long-term survivor of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/33/6680?source=related_link\">",
"      Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10009?source=related_link\">",
"      Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24138?source=related_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37561?source=related_link\">",
"      Ductal carcinoma in situ: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23002?source=related_link\">",
"      MRI of the breast and emerging technologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/14998?source=related_link\">",
"      Microinvasive breast carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/40/36481?source=related_link\">",
"      Patient information: Breast cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/59/19379?source=related_link\">",
"      Patient information: Breast cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/56/6018?source=related_link\">",
"      Patient information: Common breast problems (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_35_39483="Causes of ST segment elevation";
var content_f38_35_39483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of ST segment elevation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Myocardial ischemia or infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Noninfarction, transmural ischemia (Prinzmetal's angina pattern or acute takotsubo syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute myocardial infarction (MI) usually due to coronary atherosclerosis or occasionally to other causes (eg, acute takotsubo syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Post-MI (ventricular aneurysm pattern)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal early repolarization syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal variants (including benign early repolarization)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start_left\">",
"        Left ventricular hypertrophy or left bundle branch block (V1-V2 or V3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Myocarditis (may look like MI or pericarditis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Massive pulmonary embolism (leads V1-V2 in occasional cases)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Brugada-type patterns (V1-V3 with right bundle branch block-appearing morphology)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Myocardial tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Myocardial trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hyperkalemia (only leads V1 and V2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypothermia (J wave/Osborn wave)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypercalcemia (rarely)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Post-DC cardioversion (rarely)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_35_39483=[""].join("\n");
var outline_f38_35_39483=null;
var title_f38_35_39484="Decision tree";
var content_f38_35_39484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70214%7EOBGYN%2F63874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70214%7EOBGYN%2F63874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Decision tree - Save tissue for the following potential special studies. Consultation with a clinical geneticist can be helpful in all of these cases.",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Skeletal dysplasia/Craniosynostosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Freeze long bone (at 4 degrees Celsius)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Obtain tissue for DNA studies (skeletal muscle, skin)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Karyotype",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Renal anomalies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Karyotype",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Urinalysis for protein and crystals",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Freeze skin or renal tissue (at 4 degrees Celsius) for possible future genetic testing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Inborn error of metabolism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Freeze bile (at 4 degrees Celsius)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Save tissue for biochemical analysis (skin, brain, skeletal muscle, liver), consult with laboratory specialists as to how to obtain and preserve",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Hydrops fetalis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Blood smear (if not autolyzed) for morphologic evaluation of cells (eg, congenital dyserythropoetic anemia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hematocrit",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Karyotype",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Viral cultures if suggested by clinical findings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Blood typing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Arthrogryposes (any type)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Karyotype",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neuropathology consultation for muscle biopsy, spinal cord",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Freeze skin or skeletal muscle (at 4 degrees Celsius) for possible future genetic testing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Dysmorphic features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Karyotype",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Decision tree - Indications for sending tissue for cytogenetics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Clinician request",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Third loss, does not need to be consecutive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-immune hydrops fetalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe growth restriction (&lt;3rd percentile by best estimate of gestational age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One anomaly in 1st trimester loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two anomalies for all other losses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Single, \"specific\", anomaly (eg, complete common AV canal defect)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Known maternal or paternal balanced translocation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Verification of abnormal amniotic fluid-based karyotype",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_35_39484=[""].join("\n");
var outline_f38_35_39484=null;
var title_f38_35_39485="Treatment of microsporidiosis";
var content_f38_35_39485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of microsporidiosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"16%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"28%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adult dosage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pediatric dosage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\" colspan=\"4\">",
"        <strong>",
"         Ocular",
"        </strong>",
"        (",
"        <em>",
"         Encephalitozoon hellem",
"        </em>",
"        ,",
"        <em>",
"         E. cuniculi",
"        </em>",
"        ,",
"        <em>",
"         Vittaforma [Nosema] corneae",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Fumagillin (Fumidil-B) in saline equivalent to fumagillin 70 mcg/mL eye drops*",
"       </td>",
"       <td>",
"        2 drops every 2 hours for 4 days, then 2 drops 4 times per day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <strong>",
"         PLUS for management of systemic infection",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albendazole",
"        <sup>",
"         &bull;&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg orally twice per day",
"       </td>",
"       <td>",
"        15 mg/kg per day in 2 divided doses (max 400 mg/dose)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist_other_start\" colspan=\"4\">",
"        <strong>",
"         Intestinal",
"        </strong>",
"        (",
"        <em>",
"         E. bieneusi",
"        </em>",
"        ,",
"        <em>",
"         E. [Septata] intestinalis",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         E. bieneusi",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Fumagillin",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        20 mg orally three times per day for 14 days",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        <em>",
"         E. intestinalis",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Drug of choice:",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         &bull;&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg orally twice per day for 21 days",
"       </td>",
"       <td>",
"        15 mg/kg per day in 2 divided doses (max 400 mg/dose)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist_other_start\" colspan=\"4\">",
"        <strong>",
"         Disseminated",
"        </strong>",
"        (",
"        <em>",
"         E. hellem",
"        </em>",
"        ,",
"        <em>",
"         E. cuniculi",
"        </em>",
"        ,",
"        <em>",
"         E. intestinalis",
"        </em>",
"        ,",
"        <em>",
"         Pleistophora sp.",
"        </em>",
"        ,",
"        <em>",
"         Trachipleistophora sp.",
"        </em>",
"        , and",
"        <em>",
"         Anncaliia [Brachiola] vesicularum",
"        </em>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug of choice:",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        Albendazole",
"        <sup>",
"         &bull;&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Immunocompromised: 400 mg orally twice per day for 14 to 28 days. Continue treatment until CD4+ count &gt;200 cells/microL for &gt;6 months after initiation of potent antiretroviral therapy (ART).",
"        </p>",
"        Immunocompetent: 400 mg orally twice per day for 7 to 14 days. Symptoms may resolve with no therapy. (see 'Microsporidiosis')",
"       </td>",
"       <td>",
"        15 mg/kg per day in 2 divided doses (max 400 mg/dose)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The mainstay of treatment of microsporidiosis in HIV infected patients with severe immunosuppression is successful ART for immune restoration of CD4+ counts to greater than 100 cells/microL which is associated with resolution of symptoms of enteric microsporidiosis, including that caused by",
"    <em>",
"     E. bieneusi",
"    </em>",
"    .",
"    <div class=\"footnotes\">",
"     * Available as an investigational agent (non FDA approved) in US from Leiter's Park Avenue Pharmacy (a custom compounding pharmacy), San Jose, CA; 800-292-6773;",
"     <a href=\"file://www.leiterrx.com\" target=\"_blank\">",
"      www.leiterrx.com",
"     </a>",
"     . Ocular lesions due to",
"     <em>",
"      E. hellem",
"     </em>",
"     in HIV-infected patients have responded to fumagillin eyedrops prepared from",
"     <em>",
"      Fumidil-B",
"     </em>",
"     (bicyclohexyl ammonium fumagillin) used to control a microsporidial disease of honey bees (Chan et al, Ophtalmology 2003; 110:1420 and MJ Garvey et al, Ann Pharmacother 1995; 29:872). For lesions due to",
"     <em>",
"      V. corneae",
"     </em>",
"     , topical therapy is generally not effective and keratoplasty may be required (RM Davis et al, Ophthalmology 1990; 97:953).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Not US FDA-approved for this indication.",
"     <br/>",
"     &Delta; Albendazole must be taken with food; a fatty meal increases oral bioavailability.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Oral fumagillin (Flisint&mdash;Sanofi-Aventis, France) is not available in US. It has been effective in treating",
"     <em>",
"      E. bieneusi",
"     </em>",
"     in patients with HIV or solid organ transplants (J-M Molina et al, N Engl J Med 2002; 346:1963; F Lanternier et al, Transpl Infect Dis 2009; 11:83), but has been associated with thrombocytopenia and neutropenia. Potent antiretroviral therapy (ART) may lead to microbiologic and clinical response in HIV-infected patients with microsporidial diarrhea. Octreotide (",
"     <em>",
"      Sandostatin",
"     </em>",
"     ) has provided symptomatic relief in some patients with large-volume diarrhea.",
"     <br/>",
"     &sect; J-M Molina et al, J Infect Dis 1995; 171:245. There is no established treatment for",
"     <em>",
"      Pleistophora",
"     </em>",
"     . For disseminated disease due to",
"     <em>",
"      Trachipleistophora",
"     </em>",
"     or",
"     <em>",
"      Anncallia",
"     </em>",
"     , itraconazole 400 mg orally once per day plus albendazole may also be tried (CM Coyle et al, N Engl J Med 2004; 351:42).",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with special permission from: Treatment of microsporidiosis. In: Drugs for parasitic infections, 2nd Ed. New Rochelle, NY: The Medical Letter, Inc; 2010:44-45. www.medicalletter.org.",
"     <br/>",
"     Additional content from: Centers for Disease Control. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 2009; 58(RR-4):1-207. Available at:",
"     <a href=\"file://www.cdc.gov/mmwr/PDF/rr/rr5804.pdf\" target=\"_blank\">",
"      file://www.cdc.gov/mmwr/PDF/rr/rr5804.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_35_39485=[""].join("\n");
var outline_f38_35_39485=null;
var title_f38_35_39486="Eccentric exercise for elbow epicondylitis";
var content_f38_35_39486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eccentric exercise for elbow epicondylitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph demonstrates an eccentric exercise for the wrist extensor muscles. Eccentric exercise involves the application of a load during the lengthening of a muscle and may assist with healing of a tendinopathy. Here the wrist extensors are contracting eccentrically against the resistance of an exercise band.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Neeru Jayanthi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_35_39486=[""].join("\n");
var outline_f38_35_39486=null;
var title_f38_35_39487="Solitary pulmonary granuloma";
var content_f38_35_39487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lamellated calcification in pulmonary nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Benign pattern of calcification in a solitary pulmonary granuloma with lamellation at the periphery of the nodule. The digital computer printout of the same nodule shows a circular agglomeration of positive values above 200 Hounsfield Units surrounded peripherally and centrally by more negative values.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_35_39487=[""].join("\n");
var outline_f38_35_39487=null;
